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ABSTRACT 
Endogenous anti-inflammatory mediators form a complex network triggered in the host 
to dampen cell activation and promote resolution of inflammation. The glucocorticoid-
regulated 37-kDa protein Annexin A1 is one such endogenous checkpoint effector, 
acting on human neutrophils via a specific GPCR termed FPR like-1 (FPRL1). FPRL1 
belongs to the family of formyl-peptide receptors, of which FPR (the receptor for 
formylated peptides) is the prototype. However, very little information is available on 
the mechanisms governing the export of this protein from activated cells, hence the 
machinery required to activate the counter-regulatory circuit centred on Annexin A1. 
Furthermore, little data is available describing the status of Annexin A1 and the FPR 
receptor family in human disease conditions. These questions have been addressed in 
my thesis. 
 
The analysis of PMNs and monocytes from both Wegener granulomatosis and Giant 
cell arthritis (GCA) patients provided strong evidence for a deregulation in the Annexin 
A1 pathway as I observed an increased expression of both FPRL-1 and FPR, along with 
an elevated cell surface Annexin A1 expression. Moreover, Western blotting against 
Annexin A1 membrane expression also evidenced elevated protein cleavage suggesting 
that this is potentially the mechanism responsible for the reported hyper-activated status 
of the PMNs in these pathologies, a feature I could confirm also in the flow chamber 
assay, where marked adhesion to endothelial cell monlayers was measured. 
Significantly, pharmacological manipulation of the Annexin A1 axis could correct cell 
behaviour, further supporting the notion of a deregulated Annexin A1 system in these 
conditions. Interestingly, very little difference was observed at the mRNA levels for 
both the FPRL-1 and Annexin A1 genes in samples analysed from patients suffering 
from Wegener granulomatosis whilst there was a significant increase in expression of 
both these genes in the GCA samples when compared to aged matched healthy 
volunteers. An observation, which suggests that the underlying mechanisms governing 
the regulation in these two conditions, and their potential impact on the Annexin A1 
pathway, might be different.  
 
Annexin A1 lacks a signal peptide but nonetheless is abundantly released from 
activated PMNs; our understanding of the route that is employed for its release is still 
modest. The analysis of PMN derived microparticles confirmed the presence of the 
Annexin A1 protein in these microstructures; I was then able to demonstrate that this 
protein was responsible for microparticle-induced inhibition of PMN recruitment to an 
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activated endothelium in vitro and into the airpouch in vivo. Furthermore, when 
monitoring levels of Annexin A1 positive microparticles in plasma samples from a 
number of human inflammatory disease, I could observe that both these microparticle 
subsets were altered when compared to those found in healthy age matched controls, 
with higher extent of PMN-derived microparticles (CD62L positive) and Annexin A1 
positive microparticles. I had the opportunity to monitor these microparticles 
longitudinally in RA patients treated with prednisolone over a 2-week period: both 
CD62L and Annexin A1 positive microparticles were restored back to the values (as 
percentage and median fluorescence intensity) of healthy volunteers. This result 
occurred in parallel to an amelioration of the clinical symptoms. 
 
The final part of my project involved assessing the anti-inflammatory properties of 5 
novel Annexin A1 N-terminal derived peptides developed in collaboration with 
Unigene (Fairfield, NJ), that are modification of peptide Ac2-26 (which conserves the 
natural amino acid sequence). In vitro analyses of these peptides identified two peptides 
as the ones with the highest anti-inflammatory capabilities. In radioligand binding 
assays, I observed these peptides possessed similar binding affinities to the FPRL-1 as 
the natural peptide. More in detail, peptide 57 did not bind to FPR in a dose dependent 
faishon as opposed to peptide 84, even though when assessing p-ERK activity it was 
noted that both peptides equally activated ERK. When tested in vivo it was observed 
that both peptides were able to inhibit PMN recruitment into an inflamed mouse 
airpouch, with peptide 84 showing the highest potency.  
 
The findings of this thesis provided evidence for a deregulated Annexin A1 system in 
the human inflammatory pathologies under observation, hence vasculitis and RA. 
Treatment of patients with an acute glucocorticoid regimen modulated the Annexin A1 
pathway suggesting that the re-establishment of this effector of anti-inflammation, 
likely to occur also at the functional level, could contribute – at least partly – to the 
positive clinical effect of glucocorticoids in RA patients. Captivatingly, this acute 
glucocorticoid treatment was also observed to restore the plasma Annexin A1 positive 
microparticle levels to those observed in healthy age-matched volunteers, suggesting 
that these microstructures can potentially be used both as biomarkers of disease and 
also a measure of treatment effectiveness. Finally I have provided evidence for the anti-
inflammatory properties of two novel Annexin A1 N-terminal derived peptides that 
may serve as guidance for the development of novel treatments for inflammatory 
disorders, depicted on the biology of this intriguing protein that is Annexin A1. 
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1. Introduction 
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1.1. Inflammation 
Inflammation (Latin, inflamatio, to set on fire) is a complex biological response 
of vascular tissues to harmful stimuli, such as irritants, pathogens or damage. 
This is a process initiated by the organism as a response to tissue injury or 
infection in an attempt to remove the invading pathogens as well as initiate the 
healing process. Inflammation can be classified as either acute or chronic. Acute 
inflammation is the initial response of the body to harmful stimuli and is 
achieved by the increased movement of plasma and leukocytes from the blood 
into the injured tissues. A cascade of biochemical events propagates and 
matures the inflammatory response, involving the local vascular system, the 
immune system, and various cells within the injured tissue. Acute inflammation 
is a short-term process, usually appearing in a few minutes or hours and ceasing 
once the injurious stimulus has been removed. It is characterised by five 
cardinal signs: loss of function, increased temperature, redness, swelling, and 
pain. Cells already present in all tissues initiate the process of acute 
inflammation, mainly tissue macrophages called dendritic cells, endothelial 
cells and mastocytes. Once activated by an insult (infection, burn, etc.), they 
undergo activation and release inflammatory mediators responsible for the signs 
of inflammation. In acute inflammation, removal of the stimulus halts the 
recruitment of monocytes into the inflamed tissue, and existing macrophages 
exit the tissue via lymphatics. 
 
If the inflammatory insult is not cleared within the short term it leads to chronic 
inflammation. This is a pathological condition characterised by concurrent 
active inflammation, tissue destruction, and attempts at repair. This condition is 
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not characterised by the classic signs of acute inflammation listed above. 
Instead, chronically inflamed tissue is characterised by the infiltration of 
mononuclear immune cells including monocytes, macrophages, lymphocytes, 
and plasma cells; tissue destruction and attempts at healing, which include 
angiogenesis and fibrosis. Unlike in acute inflammation, in chronically inflamed 
tissue the stimulus is persistent, and therefore recruitment of monocytes is 
maintained, existing macrophages are tethered in place, and proliferation of 
macrophages is stimulated.  
 
1.2. Immunity  
The term immunity describes a state of having sufficient biological defences to 
avoid infection, disease, or other unwanted biological invasion. Immunity 
involves both specific and non-specific components. The non-specific 
components, or the innate branch of the immune response, play a role in 
preventing the infection by eliminating a wide range of pathogens irrespective 
of antigenic specificity. It involves local cells in the affected tissue, such as 
macrophages and mast cells that act as “alarm systems” and triggers leading to 
the co-activation of the ensuing events. 
 
Adaptive immunity conveys a pathogen-specific response to each new 
assault/pathogen encountered and is subdivided into two major subtypes 
depending on how the response was induced. Naturally acquired immunity 
results from contact with a disease-causing agent, when the contact was not 
deliberate, whereas artificially acquired immunity develops only through 
deliberate actions such as vaccination. Both naturally and artificially acquired 
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immunity can be further subdivided depending on whether immunity is induced 
in the host or passively transferred from an immune host. Passive immunity is 
acquired through transfer of antibodies or activated T-cells from an immune 
host, and is short lived, usually lasting only a few months, whereas active 
immunity is induced in the host itself by antigen, and lasts much longer, 
sometimes life-long. 
 
Once leukocytes arrive at a site of infection or inflammation, they release 
mediators that control the later accumulation and activation of other cells. 
However, in inflammatory reactions initiated by the immune system, the antigen 
itself exerts the ultimate control. 
 
Inflammatory mediators are soluble, diffusible molecules that act locally at the 
site of tissue damage and infection, and at more distant sites. They can be 
divided into exogenous and endogenous mediators. Bacterial products and 
toxins can act as exogenous mediators of inflammation. Notable among these is 
endotoxin, or lipopolysaccharide (LPS) of Gram-negative bacteria. The immune 
system of higher organisms has probably evolved around in a veritable sea of 
endotoxin, so it is perhaps not surprising that this substance evokes powerful 
responses. In fact endotoxin can trigger complement activation, resulting in the 
formation of anaphylatoxins C3a and C5a, which cause vasodilatation and 
increase vascular permeability. Endotoxin also activates the Hageman factor, 
leading to activation of the coagulation and fibrinolytic pathways as well as the 
kinin system. In addition, endotoxins elicit T cell proliferation, and have been 
described as superantigen for T cells. 
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Endogenous mediators of inflammation are produced from within the (innate 
and adaptive) immune system itself, as well as other systems. For example, they 
can be derived from molecules that are normally present in the plasma in an 
inactive form, such as peptide fragments of some components of complement, 
coagulation, and kinin system(s) components. Mediators of inflammatory 
responses are also released at the site of injury by a number of cell types. 
 
Thus the modulation of inflammation through the inhibition of an immune 
response can provide beneficial effects in chronic inflammatory responses 
where the inflammatory insult is self-propagating, in this context 
glucocorticoids are currently the most potent immunomodulators available. 
Glucocorticoids, first used therapeutically in 1950 (Hench 1950), regulate the 
immune system by modulating the expression of pro-inflammatory genes and 
the expression of transcription factors.  
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1.3. Annexin A1, a Glucocorticoid inducible anti-inflammatory 
protein. 
1.3.1. The discovery 
In the early 1980’s data generated from different laboratories showed that 
glucocorticoid inhibition of arachidonic acid production was dependent on the 
synthesis and release of inhibitory proteins which down-regulated 
phospholipase A2 (PLA2) activity. This in turn repressed the prostaglandin [PG] 
generation from perfused lungs and activated macrophages. Glucocorticoid 
treatment resulted in the production of a factor that mimicked the inhibitory 
action of the steroid itself. The factor was then identified as a protein of 37 kDa 
and named ‘lipocortin’ (nowadays referred to as Annexin A1 (Flower 1988)). 
 
Annexin A1 (ANXA1) was the first characterized member of the annexin 
superfamily of proteins, so called since their main property is to bind (i.e. to 
annex) to cellular membranes in a Ca2+-dependent manner (Crumpton and 
Dedman 1990).  
 
The 13 members of this family show a high degree of structural homology, with 
each possessing four (or 8 in the case of Annexin A6) repeated units of 
approximately 70 amino acids within the core and C-terminal regions. These 
units are believed to confer their Ca2+ and phospholipid binding properties. The 
N-terminal region of each family member is, however, unique and is considered 
to confer the biological specificity of the individual proteins. The basic structure 
of ANXA1 is shown in Figure 1-3. Crystallographic studies indicate that the 
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four repeated sequences are arranged around a pore, giving the protein a 
“doughnut” appearance.  
 
 
 
 
Figure 1-1: Molecular structure of Annexin-A1. Ribbon diagram of (A) Annexin A1, 
showing the N-terminal domain (yellow) and the protein core, consisting of four annexin 
repeats (1-4). (B) In response to calcium binding (indicated by the orange spheres), the 
N-terminal domain. Adapted from (Rosengarth and Luecke 2003). 
 
Furthermore, the N-terminal 26 amino acid residues form two α-helices with a 
bend at amino acid 16 that causes the first residues to insert within the protein 
core. This N-terminal domain is embedded within the pore at low Ca2+ 
concentrations, but elevations in Ca2+ levels expose this region and may thereby 
influence the biological activity of the protein. In this context studies have 
highlighted the fact that the Glu-255, which is present on the D-helix of repeat 3 
is essential for calcium binding to take place (Rosengarth and Luecke 2003). 
 
Annexin A1 expression and localization within the cell varies between cell 
types. In human neutrophils Annexin A1 is predominantly localised in 
gelatinase granules (Perretti, Christian et al. 2000) on the other hand in mast 
cells Annexin A1 is found in the α-granules (Oliani, Christian et al. 2000). This 
confined distribution does not seem to be a common trend however since in 
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macrophages and most of other cell types investigated, Annexin A1 was 
observed to be either in the cytoplasm, attached to the plasma membrane or in 
the nucleus depending upon the state of activation. Under resting conditions a 
large proportion of the protein is found intracellularly (Peers, Smillie et al. 
1993) however following a short stimulation, such as exposure (10 min) to 
glucocorticoid (Solito, Kamal et al. 2003) or LPS (Solito, Christian et al. 2006), 
Annexin A1 translocates from the cytoplasm to the cell surface where it is 
retained in a Ca2+-dependent manner (Solito, Christian et al. 2006). Longer 
stimulations, such as a 1-h glucocorticoid exposure, has been shown to enhance 
the translocation of Annexin A1 both in vivo and in vitro from the cytoplasm to 
the nucleus with an induction of Annexin A1 de novo synthesis (Buckingham 
1996). 
 
1.3.2. Annexin A1 and its receptor (s) 
Initial studies have outlined that Annexin A1 binds to human monocytes in a 
saturable and trypsin-sensitive manner suggesting that this protein could be 
binding to a specific protein site and not merely to membrane anionic 
phospholipids. Further studies highlighted that in fact Annexin A1 binding is 
also sensitive to collagenase, cathepsin G and elastase, where treatment of the 
cells with any of these enzymes lead to an almost complete loss of Annexin A1 
binding capacity to monocytes (Goulding, Pan et al. 1996). Analysis of surface 
radioiodinated human monocytes by SDS PAGE and autoradiography 
demonstrated that recombinant Annexin A1, in conjunction with a monoclonal 
antibody directed against Annexin A1 (clone 1B), immunoprecipitated two 
molecules with molecular masses of 15 kDa and 18 kDa respectively however 
no data is available on the nature of these two proteins (Goulding, Pan et al. 
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1996). 
 
Other later studies have demonstrated that Annexin A1 and/or the N-terminal 
peptides derived from this protein (Annexin A1 peptido-mimetics) bind to 
various extents all three members of the Formyl Peptide Receptor (FPR) family 
(as will be discussed further in subsequent sections). Moreover, recent data has 
showed that this protein and its peptides exert the majority of their anti-
inflammatory action through the FPR-Like 1 (FPRL1) receptor (Hayhoe, Kamal 
et al. 2006; Kamal, Hayhoe et al. 2006). In fact, it was demonstrated through the 
use of competitive binding assays, that both the Annexin A1-derived peptide 
Acetly (Ac) 2-26 (corresponding to amino acids 2-26 of the N-terminal portion 
of Annexin A1) and a shorter peptide denoted Ac2-12 (Ac- AMVSEFLKQAW) 
competed for specific [3H]LXA4 binding with similar affinities (50% inhibitory 
concentration; IC50 ~0.3 µM) in HEK 293 cells transfected with the FPRL1 
receptor. This point was further highlighted by the co-incubation of [125I-Tyr] 
Ac2- 26 peptide with the HEK293 transfected with the recombinant FPRL1 
receptor; which gave a specific and saturable binding with a Kd value of 
  ~0.9 µΜ (Hayhoe, Kamal et al. 2006). Furthermore, the full-length Annexin 
A1 protein also competed for [125I-Tyr] Ac2-26 binding with similar affinity, 
whereas the Ac2-12 peptide gave an IC50 of ~20 µM. A scrambled sequence 
peptide Ac2-26 did not compete for specific [125I-Tyr] Ac2-26 binding (Perretti, 
Chiang et al. 2002; Hayhoe, Kamal et al. 2006) 
 
The direct interaction between Annexin A1 and FPRL1 was further 
substantiated via immunoprecipitation of both the proteins from activated 
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human polymorphonuclear (PMN) cell lysates. Activation of PMNs with either 
PMA or fMLF induces adhesion and mobilization of Annexin A1 on to the cell 
surface. Following lysis proteins were co-immunoprecipitated (IP) from this 
soup using an anti-Annexin A1 specific antibody. Analysis of the IP by SDS-
PAGE revealed a band of approximately 70kDa, which was immunoreactive to 
the FPRL1 specific antibody in a western blot analysis. Furthermore, 
immunoreactive bands of ~36 kDa, consistent with molecular mass of Annexin 
A1, were obtained by co-immunoprecipitation with anti-FPRL1 antibody 
(Perretti, Chiang et al. 2002), thus confirming the interaction between Annexin 
A1 and the FPRL1 in human cells.  
 
1.3.3. Proposed mechanisms of action 
Low affinity FPR (or FPRL) ligands play a very important role in leukocyte 
recruitment toward the focus of inflammation where high concentrations of 
chemo-attractant are met and in which high affinity ligand-receptor interactions 
result in receptor saturation, desensitization and/or sequestration. This scenario 
requires high (micromolar) extracellular Annexin A1 concentrations in close 
proximity to the focus of inflammation; concentrations that are higher than the 
Annexin A1 levels reported in normal serum. However, a number of 
mechanisms have been proposed which could lead to the localized increase of 
extracellular Annexin A1 levels including: glucocorticoid administration 
(Flower 1988), inflammatory and infectious diseases (Goulding, Jefferiss et al. 
1992; Cuzzocrea, Tailor et al. 1997) and tissue or cell damage (Rescher, 
Goebeler et al. 2006). In such cases the released Annexin A1 is proteolytically 
cleaved generating the active N-terminal peptides. A substantial degree of N-
terminal Annexin A1 proteolysis also occurs within cells, e.g., in neutrophils 
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upon extravasation into the sub-endothelium (Perretti, Croxtall et al. 1996). 
Thus, suggesting that the N-terminal Annexin A1 peptides are the 
physiologically active entity released from cells or generated extracellularly at 
sites of inflammation.  
 
Apart from a role in inflammation Annexin A1 has also been shown to have a 
role in the control of cardiovascular function. Studies conducted by Wu and 
colleagues have demonstrated Annexin A1 has beneficial haemodynamic effects 
through inhibition of inducible nitric oxide synthase (iNOS) expression when 
rats suffering from septic shock were treated with dexamethasone (Wu, Croxtall 
et al. 1995). In addition, dexamethasone and the N-terminal fragment of 
Annexin A1 inhibited the induction of cyclooxygenase-2 (COX-2) and 
interleukin (IL)-12 mRNA, as well as the release of PGE2, in a dose-dependent 
manner, whilst augmenting the release of IL-10 in a number of macrophage cell 
lines activated with LPS. Furthermore, suppression of nitric oxide and PGE2 
release could also be important in the neuroprotective properties described for 
Annexin A1, since inflammatory metabolites may participate in the 
establishment of neurone and oligodendrocyte damage in ischaemic and 
neurodegenerative disorders (Merrill, Ignarro et al. 1993; Ferlazzo, D'Agostino 
et al. 2003). 
 
1.3.4. Annexin A1 and its effect on adhesion molecules 
The leukocyte adhesion process is very important in the context of 
inflammation, playing an integral part in the extravasation of inflammatory cells 
from the microvasculature to the sites of insult. A number of recently published 
reports conducted both in vivo and in vitro have shown that exogenous and 
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endogenous Annexin A1 strongly inhibit this process (Perretti, Getting et al. 
2001; Hayhoe, Kamal et al. 2006). 
 
A mechanism that has been put forward to explain the observed regulation of 
cell migration is the interference of Annexin A1 with adhesion molecules that 
mediate leukocyte-endothelium interactions. In support of this theory is the 
observation that Annexin A1 colocalizes with the α4β1 integrin on the surface of 
monocytic cells. It is known that α4β1 integrin interacts with vascular cell 
adhesion molecule (VCAM)-1 expressed by endothelial cells to mediate several 
neutrophil functions such as tethering, rolling and firm adhesion (Meerschaert 
and Furie 1995); a process that could be reversed by the extracellular domain of 
VCAM-1. Moreover, co-immunoprecipitation experiments demonstrated that 
Annexin A1 and VCAM-1 competed for binding to the α4β1  integrin in a pro-
monocytic cell line (Solito, Romero et al. 2000) (Figure 1-2). 
 
Another adhesion molecule, which seems to be under the regulation of Annexin 
A1 is L-selectin, whereby this protein promotes L-selectin shedding 
(Strausbaugh and Rosen 2001). A process which has recently been confirmed 
by de Coupade et al. (de Coupade, Solito et al. 2003) who have proposed that 
endogenous Annexin A1, externalized on the cell surface of monocytic cells by 
treatment with glucocorticoids, could facilitate CD62L shedding through a 
calcium-dependent interaction the adhesion molecule. However, the details of 
the mechanism governing this process are still elusive. 
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Work conducted by Lim and colleagues along with that done by Das and 
colleagues suggests that Annexin A1 also has an influence on CD11b 
expression. It was in fact observed that CD11b protein expression but not 
mRNA levels in eosinophils were altered in a number of in vivo models upon 
post glucocorticoid treatment (Lim, Flower et al. 2000), an effect that was, at 
least in part, mediated by Annexin A1 (Das, Lim et al. 1997).  
 
 
 
 
 
 
 
 
Figure 1-2: Sites of action of the Annexin A1 system in the leukocyte adhesion 
cascade. 
 
 
1.3.5. Mechanisms of Annexin A1 Externalization. 
As previously described this protein’s main site of action appears to be at the 
cell surface, at least with respect to its actions on inflammatory cells, thus 
understanding the mechanisms responsible for its externalization is of great 
importance.  
 
Initial studies have shown that Annexin A1 does not possess a signal sequence, 
a property it shares with other proteins such as IL-1 and galectin-1, as opposed 
to most pre-secretory proteins that have a sequence of about 13 to 30 
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hydrophobic amino acids, which allow transport across the membrane of the 
endoplasmic reticulum. This will then lead to the direction of the protein to the 
endoplasmic reticulum-Golgi system and hence permits vesicular packaging for 
release by exocytosis (Milstein, Brownlee et al. 1972) Furthermore, its gene 
does not include a nucleotide sequence which would encode for an appropriate 
amino acid sequence (Raynal and Pollard 1994) 
 
The specific localization of Annexin A1 within the neutrophil gelatinase 
granules was thought for some time to be the only pathway by which this 
protein is externalized from this cell type, as these granules and their contents 
can be exported to the cell surface by a process of exocytosis, similar to that 
described by Borregaard and colleagues (Sengelov, Follin et al. 1995; 
Borregaard and Cowland 1997). 
 
However, only neutrophils contain these gelatinase granules, thus limiting the 
functionality of this mechanism to this cell type, leaving the question on the 
mechanism/s governing the transport of Annexin A1 to the cell membrane in 
other cell types unanswered. It thus seems likely that Annexin A1 can also be 
exported via an alternative pathway at least in other cell types. This hypothesis 
was confirmed when it was show that brefeldin A, monensin and nocodazole, 
three drugs which block the classical pathway of protein secretion had no effect 
on the capacity of dexamethasone to induce the cellular exportation of Annexin 
A1 in brain (cortex, hippocampus, hypothalamus), anterior pituitary tissue and 
peritoneal macrophages (Philip, Flower et al. 1998).  
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Recent data have started to shed some light into one possible mechanism of 
Annexin A1 exportation, at least in folliculo-stellate cells.  In these cells, 
Annexin A1 is secreted through a non-classical pathway that is dependent on 
the ABCA1 transporter. This was shown by the pharmacological blockade of 
the ABCA1-transporter with geranyl-geranyl pyrophosphate and 
sulfobromophthalein, which in turn lead to a significant reduction Annexin A1 
externalization. Partial silencing of ABCA1 expression in TtT/GF cells by 
siRNA also significantly decreased the amount of cell surface Annexin A1. 
Further information can be obtained by looking into the secretory pathways 
described for other annexin family members, where for example Annexin A2 
secretion in human umbilical endothelial cells is dependent on S100A10 protein 
expression (Omer, Meredith et al. 2006). 
 
 
1.3.6. The role of Annexin A1 in human neutrophils 
Annexin A1 is expressed in relatively large amounts (between 2% and 4%) in 
the cytosol of human neutrophils (Francis, Balazovich et al. 1992; Rosales and 
Ernst 1997). The pattern of expression appears to be punctuate with patches of 
immunoreactivity seen throughout the cell within a specific subset of neutrophil 
organelles. Other studies conducted with human resting neutrophils in vitro 
(Perretti, Christian et al. 2000) and with rat neutrophils within an inflamed 
vascular bed in vivo (Oliani, Paul-Clark et al. 2001) found that a majority 
(~50%) of intracellular Annexin A1 colocalized with gelatinase granules, 
whereas a much smaller proportion was detected on the plasma membrane 
(Figure 1-3). 
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In parallel studies, it was demonstrated that treatment with glucocorticoids 
increased Annexin A1 content in circulating leucocytes in man (Goulding, 
Godolphin et al. 1990) and rodents (Perretti and Flower 1996). As cytosolic 
Annexin A1 is actively mobilized when the neutrophil adheres to the 
endothelium, glucocorticoid-dependent increase in cellular Annexin A1 content 
would increase the amount of the protein externalized on the cell surface once 
the leukocyte adheres to the inflamed vascular endothelium. A survey of human 
donors indicated that between 50% and 70% of total Annexin A1 is externalized 
onto the neutrophil surface upon adhesion to endothelial cell monolayers 
(Perretti 1997). It is likely that the Annexin A1 system in the neutrophil can be 
finely regulated by post-translational mechanisms. The Annexin A1 N-terminal 
region, which is unique to this member of the family, contains several putative 
phosphorylation sites. For instance, epidermal growth factor receptor activation 
leads to Annexin A1 phosphorylation on tyrosine 21 (Hollenberg, Valentine-
Braun et al. 1988). More recently, protein kinase C (PKC)-dependent 
serine/threonine phosphorylation has been reported in a pituitary cell line, and 
this event was essential to externalization of the protein (John, Cover et al. 
2002). 
Recent data indicates the existence of a phenylmethylsulfonyl fluoride-sensitive 
enzymatic activity responsible for Annexin A1 cleavage (Rescher, Goebeler et 
al. 2006). However, a metalloprotease has also been proposed to cleave the first 
seven amino acid of the Annexin A1 N-terminus (Movitz, Sjolin et al. 1999). A 
more recent publication has showed that proteinase 3 is another enzyme, which 
can cleave Annexin A1 in a similar way to that observed in vivo (Vong, 
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D'Acquisto et al. 2007). Whereas this aspect warrants further analysis, it is 
already conceivable that Annexin A1 cleavage might be of clinical relevance. 
 
 
 
 
 
 
 
 
Figure 1-3: Neutrophil extravasation and Annexin A1 externalization. Neutrophil 
adhesion to the post capillary venule leads to the externalization and cleavage of the 
Annexin A1 protein on the neutrophil cell membrane along with the transfer of this 
protein to the endothelium (Adapted from Perretti 2002). 
 
In fact, bronchoalveolar lavage fluids obtained from patients suffering from 
cystic fibrosis and other lung pathologies display a marked degree of Annexin 
A1 proteolysis (Tsao, Meyer et al. 1998). These studies proposed a role for 
elastase as the proteolytic Annexin A1-cleavage enzyme. In line with the data 
just discussed, Annexin A1 (intact and cleaved) is often recovered from 
inflammatory exudates, and inflamed tissues, in correspondence to the peak of 
neutrophilia (Vergnolle, Comera et al. 1997). 
 
1.3.7. The Annexin A1 peptides 
A number of peptides mainly derived from the unique N-terminal portion of the 
Annexin A1 protein have been shown to possess anti-inflammatory properties. 
The first peptide to be synthesized is that derived from the first 188 amino acid 
sequence of the Annexin A1 protein. This was in the first instance shown to 
Lumen 
Tissue 
Annexin A1 
Cleaved Annexin A1 
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inhibit Thromboxane A2 production in perfused guinea pig lungs when 
stimulated with fMLF (Cirino, Flower et al. 1987). Its anti-inflammatory 
properties were then highlighted in various models of inflammation where the 
administration of this peptide was shown to reduce PMN recruitment following 
ischaemia reperfusion injury in the rat brain (Relton, Strijbos et al. 1991) and 
into an inflamed airpouch (Perretti, Ahluwalia et al. 1993). Apart from its anti-
inflammatory effects, the Ac1-188 fragment has also been shown to display 
antipyretic properties when administered into the rat brain stimulated with INF-
γ and IL1-β . Interestingly, this antipyretic effect was not observed in the same 
model when the brain was stimulated with PGE2, indicating that its effects are 
probably exerted on cytokine synthesis upstream prostaglandin synthesis 
(Carey, Forder et al. 1990). 
 
One of the most extensively studied Annexin A1 peptides is peptide Ac2-26, 
which mimics the 2nd to the 26th amino acids of the 54-aa N-terminal region, and 
like the Ac1-188 fragment (and the native protein) has an N-terminal acetylation 
to increase its stability, and possibly its half-life. When employed in an in vitro 
model of leukocyte/endothelium interaction, the flow chamber model, it was 
observed that this peptide was able to reduce the number of rolling neutrophils 
on to the activated endothelial cells. Interestingly, no effect was observed on the 
number of adherent cells suggesting that this peptide selectively inhibits one 
portion of the leukocyte recruitment cascade. Furthermore, apart from reducing 
the rolling on neutrophils this peptide was also able to increase the clearance 
rate of apoptotic neutrophils by human macrophages in vitro (Maderna, Yona et 
al. 2005), suggesting that the Ac2-26 peptide also has pro-resolving properties. 
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In vivo the Ac2-26 peptide has been shown to exert an anti-inflammatory effect 
in models of myocardial ischaemia reperfusion (I/R) (La, D'Amico et al. 2001), 
mesentery I/R (Gavins, Yona et al. 2003), glycogen peritonitis (Teixeira, Das et 
al. 1998) and IL1β airpouch (Perretti, Ahluwalia et al. 1993), where it was 
reported to significantly reduce the recruitment of neutrophils to the site of 
injury/inflammation (Perretti and Flower 1993). In other more complex acute 
models such as zymosan peritonitis apart from a reduction in PMN recruitment 
at an early time point (4h) a reduction of monocyte recruitment into the 
peritoneal cavity after 24h was also reported (Getting, Flower et al. 1997). 
Furthermore, in models of tissue injury such as glacial acetic acid induced 
gastric ulcers (Martin, Perretti et al. 2008), contusive spinal chord injury (Liu, 
Zhang et al. 2007), septic shock (Ritchie, Sun et al. 2003) and mouse skin 
oedema (Perretti, Ahluwalia et al. 1993) the administration of the Ac2-26 
peptide has been shown to partially - and in some cases completely - reverse the 
damaged. This effect is, at least in part, mediated through down regulation of 
pro-inflammatory factors such as TNF-α, IL1β and Cox2. However, the anti-
inflammatory properties of this peptide are not just restricted to acute models of 
inflammation. In a number of chronic models, including, the carrageean induced 
arthritis, intra-articular administration of the Ac2-26 peptide was shown to 
reduce disease severity through a reduction in neutrophil recruitment (Yang, 
Leech et al. 1997). 
  
Shorter versions of the Ac2-26 peptide, the Ac2-12 and the Ac2-6 peptides, 
have also been shown to produce some degree of anti-inflammatory effects in 
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vivo in acute models of inflammation. The administration of peptide Ac2-12 in 
models of inflamed mouse dorsal airpouch (Perretti, Chiang et al. 2002), 
myocardial I/R (La, D'Amico et al. 2001) and inflamed mesenteric 
microvasculature reduced PMN recruitment (La, D'Amico et al. 2001), infarct 
size and the number of adherent PMN to the inflamed vascular endothelium 
respectively. On the other hand, the latter peptide has only been reported to 
exert anti-inflammatory properties in the mouse inflamed airpouch model where 
it reduced PMN recruitment into the airpouch (Perretti, Chiang et al. 2002). 
Thus, although not as potent as the longer peptide Ac2-26, these shorter 
mimetics still retain some of the anti-inflammatory properties characteristic of 
the parent protein, further highlighting the importance of this region in the 
resolution of inflammation.  
 
Work conducted by a number of laboratories has shown that a peptide derived 
from a region completely independent of the N-terminal of the Annexin A1 
protein, more precisely amino acids 247-253 – in the third repeat of the core 
region of the protein - referred to as antiflammin-2 (AF2), also possesses anti-
inflammatory properties. Of interest this region is also the portion of the 
Annexin A1 protein that is of highest sequence similarity to uteroglobin (Miele, 
Cordella-Miele et al. 1988). In fact this sequence corresponds to the amino acids 
40-46 on the uteroglobin monomer a region that corresponds to the C-terminal 
part of the third α−helix (Vostal, Mukherjee et al. 1989). This peptide has been 
shown to reduce the number of rolling cells but not the number of adherent cells 
in the flow chamber model, as was observed for the Ac2-26 peptide, thus 
suggesting that it might be acting through a similar pathway as the N-terminal 
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derived peptide (Kamal, Hayhoe et al. 2006). Furthermore, AF2 was effective in 
inhibiting Leukotrine C4 and Thromboxane B2 production in unsensitized and 
ovalbumin-sensitized guinea pig lungs in vitro, whilst it had no effect in 
histamine or bradykinin sensitized lungs, pointing to a stimulus specific 
response by the AF2 peptide (Sautebin, Cirino et al. 1992). On the other hand, 
in vivo, this nona-peptide has been shown to inhibit eosinophil recruitment in a 
model of allergic conjuvitis (Sohn, Kim et al. 2003). AF2 has also been shown 
to suppress endotoxin-induced uvitis in rats and murine allergic conjuvitis with 
potencies similar to those observed for glucocorticoids (Chan, Ni et al. 1991). 
Moreover, this peptide is effective in reducing vascular permeability and PMN 
infiltration in a model of carrageenan-induced rat footpad oedema (Camussi, 
Tetta et al. 1990). 
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1.4. The Formyl Peptide Receptor Family  
1.4.1. The Discovery of the Formyl Peptide Receptors 
Chemoattractant receptors comprise a single 350–370 amino acid polypeptide 
chain, which spans the cell membrane seven times (Figure. 1-4). The N-
terminus and three loops, believed to be essential for interaction with the ligand, 
are exposed extracellularly, and the carboxyl terminus and three additional 
loops of importance for intracellular signalling, are facing the cytosolic side of 
the membrane (Murphy 1994; Murphy 1997). Neutrophil chemoattractant 
GPCRs all share sequence similarities in some of the transmembrane domains 
as well as in the cytosolic signalling domains. In contrast, the surface-exposed 
regions which confer the ligand specificity of the GPCRs show a lower degree 
of sequence similarity (Miller and Falke 2004). 
 
 
 
 
 
 
 
 
 
Figure 1-4: Figure outlining the typical organization of the FPR receptor family 
 
The N-formylated peptides, derived from Gram-negative bacteria and human 
cell mitochondria, were initially identified as chemoattractants for human 
phagocytes (Chen, Bernstein et al. 1995; Su, Gong et al. 1999; Gavins, Yona et 
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al. 2003; Bellner, Thoren et al. 2005). Ligand binding and chemical cross-
linking allowed the identification of distinct high-affinity cell surface binding 
proteins for fMLF, which migrated as a broad band on SDS-PAGE with an 
apparent molecular mass between 55 and 70 kDa (Walther, Riehemann et al. 
2000; Perretti, Chiang et al. 2002). Boulay and co-workers isolated two human 
cDNAs encoding a 350 amino acid protein from a cDNA library prepared from 
differentiated HL-60 cells (Boulay, Tardif et al. 1990; Boulay, Tardif et al. 
1990). These two cDNAs differ in the organization of their 5' and 3' flanking 
regions as well as by two nucleotides in the coding sequence, yet both encode a 
functional protein that belongs to the G protein-coupled receptor family. This 
receptor, termed FPR by its high affinity interaction with the bacterial formyl 
peptide, is encoded by a 6 kb single copy gene (Perez, Holmes et al. 1992; 
Haviland, Borel et al. 1993; Murphy, Tiffany et al. 1993). The open reading 
frame is intronless, but the 5' untranslated region resides on three exons. The 
FPR gene contains three Alu repeats, one in each intron, and a third in the 3' 
flanking region, indicating that the different cDNA clones originally isolated 
may be derived by alternative polyadenylation (Haviland, Borel et al. 1993). 
The proposed promoter contains a non-consensus TATA box and an inverted 
CCAAT element. Two mRNAs are produced in HL-60 myeloid cells and 
human monocytes by alternative splicing of exon 2 (Murphy, Tiffany et al. 
1993). The presence of this exon permits the potential formation of stem-loop 
structures that could affect mRNA stability (Boulay, Tardif et al. 1990; Murphy 
and McDermott 1991). 
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Sequence analysis of cDNA clones isolated from different sources revealed 
amino acid differences that do not alter the pharmacological profile (Boulay, 
Tardif et al. 1990; Perez, Holmes et al. 1992), suggesting that there are allelic 
forms of FPR and a polymorphism of the FPR gene. FPR binds and is activated 
by picomole to low nanomole concentrations (Kd <1 nM) of fMLF, and was 
thus defined as the high-affinity fMLP receptor.  
 
The cellular distribution of FPR is not restricted to neutrophils and monocytes, 
as previously thought. It is also expressed in hepatocytes, dendritic cells, 
astrocytes, microglia cells, and the tunica media of coronary arteries (Lacy, 
Jones et al. 1995; McCoy, Haviland et al. 1995), More recently, by using an 
antiserum directed against the carboxyl terminus of human FPR receptor, it was 
shown that the FPR receptor, or an antigenically similar receptor, is widely 
localized in different human tissues and organs, including thyroid, adrenals, 
liver, and the nervous system. It is therefore speculated that FPR may have 
broader functions than host defence against bacterial infection (Becker, 
Forouhar et al. 1998).  
 
Two additional human genes, designated FPRL1 (FPR-like 1) and FPRL2 
(FPR-like 2), were subsequently isolated by low-stringency hybridization using 
FPR cDNA as a probe (Klein, Paul et al. 1998; Le, Gong et al. 1999; Hu, Le et 
al. 2001; Tiffany, Lavigne et al. 2001) and shown to cluster with FPR on human 
chromosome 19q13.3 (Le, Gong et al. 1999; Tiffany, Lavigne et al. 2001). 
FPRL1 is defined as a low-affinity fMLP receptor, based on its activation only 
by high concentrations of fMLP (µM range) in vitro (Gao, Lee et al. 1999; Le, 
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Murphy et al. 2002). However, it is unclear whether such concentrations of 
fMLP could be generated at sites of bacterial infection or tissue injury. 
Therefore, the role of FPRL1 as another bona fide functional fMLP receptor in 
vivo remains to be determined. This receptor exhibits an amino acid sequence 
similarity of 69% to FPR (Fig. 1), but the degree of identity differs in different 
regions of the receptors. A high degree of identity is found in the three cytosolic 
loops of the receptors, whereas the carboxyl tail and the extracellular domains 
have lower degrees of identity. Taken together, this suggests that the ligand-
binding epitopes as well as the signalling properties might differ between the 
two receptors.  
 
The FPRL2 gene has a 56% sequence identity to human FPR and 83% sequence 
identity to FPRL1. The expression profile of this gene is different to that of 
FPRL1, in fact it is expressed in monocytes, mature and immature dendritic 
cells but not in neutrophils (Durstin, Gao et al. 1994). Furthermore very little is 
known about its function and only a few ligands most of which are synthetic 
have been identified for this receptor. To date, the only endogenous ligand 
described for this receptor is the F2L ligand, which is an acetylated amino-
terminal peptide derived from the cleavage of the human haeme-binding protein 
(Migeotte, Riboldi et al. 2005). This peptide binds and activates the receptor in 
the low nanomolar range, triggering a cascade of events through the Gi class of 
heteromeric G proteins leading to intracellular Ca2+ release and cAMP 
accumulation. Peptide Ac2-26, activates FPRL2 mediated chemotaxis in cells 
transfected with the receptor (Ernst, Lange et al. 2004). In contrast, the 
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expression of the FPRL2 in Xenopus oocytes did not result in any functional 
responses to fMLP (Durstin, Gao et al. 1994). 
 
1.4.2. The FPR family its agonists and the functional domains responsible 
for their signalling 
Due to the limited knowledge on the FPLR2 receptor the remainder of my 
summary will concentrate on FPR and FPRL1; furthermore, the latter receptors 
are co-expressed in neutrophils, the cell type of interest in this study, thus unless 
otherwise stated the term FPR family will refer to FPR and FPRL1. 
 
The FPR is a high-affinity pattern recognition receptor with the ability to 
recognize a number of N-formylated peptides, formed as part of prokaryotic 
protein synthesis (Fu, Dahlgren et al. 2003; Rabiet, Huet et al. 2005), supporting 
the idea that this receptor evolved to mediate trafficking of phagocytes to sites 
of bacterial invasion or tissue damage. The receptor also binds formylated 
peptides of mitochondrial origin (Fu, Dahlgren et al. 2003), and based on 
studies with free amino, desamino, and acetylated derivatives of the potent 
model peptide fMLP, it was believed that the formyl group was of utmost 
importance for the binding affinity and function of the chemoattractant. 
However, recent work reveals that FPR also recognizes nonformylated peptides 
as well as peptides with several other modifications, which all bind with high 
affinity and activate the receptor (Gao, Becker et al. 1994; Chen, Bernstein et al. 
1995). In addition, FPRL-1 recognizes and is activated by peptides that lack all 
sequence similarities with the peptides originally isolated from bacteria. 
Important examples of such proteins and peptides are, the GP-41 envelope 
protein of the human immunodeficiency virus type 1 (Le, Jiang et al. 2000), a 
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member of the annexin family of calcium-regulated proteins (Perretti, Chiang et 
al. 2002; Gavins, Yona et al. 2003) and proteins linked to the onset of 
Alzheimer’s (Table 1-1)  (De, Chen et al. 2000).  
 
Although no defined structure has been identified as the determinant for FPR 
binding and activation, the close relationship between structural variation and 
function is illustrated by the fact that substitution of the carboxyterminal D-
methionine in W-peptide (WKYMVm), which is a hexa- peptide that uses both 
FPR and FPRL1, for the L-isomer generates a peptide that loses most of the 
FPR-binding affinity (Freer, Day et al. 1980; Christophe, Karlsson et al. 2001), 
and replacement of the formyl group in fMLP by a tert-Boc (tBoc) group 
generates a receptor-specific antagonist with low receptor affinity (Freer, Day et 
al. 1980).  
 
Functional domains on the FPR receptor have been extensively analyzed using 
receptor chimeras and site-directed mutations. Chimeric receptors constructed 
between C5aR and FPR suggested the involvement of multiple FPR domains in 
recognition of the agonist fMLP, including the first, second, and third 
extracellular loops. The transmembrane domains in FPR are also implicated in 
contributing to the formation of a ligand binding structure (Mills, Miettinen et 
al. 2000). Studies with chimeric receptors composed of segments from FPR and 
FPRL1 suggested that the first and third extracellular loops with adjacent 
transmembrane domains in FPR were essential for its high-affinity binding for 
fMLP (Le, Ye et al. 2005). 
Table 1-1 Summary of the agonists and antagonists for the FPR family members. 
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Expressing Cell Types Ligands Receptor Antagonist (s) 
Cortical Cells of the 
adrenal, As, DC, EC, H, 
LC, M, N, NB, NS 
fMLP and other formly peptides from 
bacteria and mitochondria, 
WKYMVm, WKGMVm, 
WKRMVm, Annexin 11-26, Annexin 
19-23, T20 (DP176), fMIVIL, 
fMIVTFL, gG-2p20  
FPR BOC-PLPLPL, Boc-MLF, 
Several N-Ureido peptides, 
cyclosporine H, CHIPS 
As, iDC, L, M, Mi, N, T, 
Ep, NB, SF, spleen, testis 
fMLP and other formly peptides from 
bacteria and mitochondria, 
WKYMVM WKYMVm, Annexin A1 
and related peptides, SAA, Hp(2-20), 
LL-37, Ab42, HIV envelope protein 
fragments -T20, T21 (DP107), F 
peptide, V3 peptide,- N36, LXA4, 
MMK1, D2D3[x]-247, PrP106-126, MHC 
binding peptide, Compound 43, 
sCKb8-1, fMIVIL, fMIVTFL, 
PACAP27 
FPRL1 WRWWWW, FLIPr, 
PBP10, BOC-PLPLPL, 
Boc-MLF 
M, iDC, DC Annexin 1-25, F2L, WKYMVM, Hp(2-
20) 
FPRL2  
 
Cell abbreviations: As, Astrocytes; DC, dendritic cell; EC, endothelial cell; Ep, epithelial cells; H, 
hepatocytes; iDC, immature DC; L, lung; LC, lung carcinoma cell; M, monocyte; Mi, microglia; N, 
neutrophil; NB, neutroblastoma; NS, nervous system; SF, synovial fibroblasts; T, T cells. 
Agonist abbreviations: Ab, amyloid b; fMLF, formylmethionyl-leucyl-phenylalanine; F2l, FPL2 
Ligand; LXA4, lipoxin A4; MHC, major histocompatibility complex; SAA, serum amyloid A; 
WKYMVm, Trp-Lys-Tyr-Met-Val-D-Met; WKYMVM, Trp-Lys-Tyr-Met-Val-L-Met, CHIPS, 
chemotaxis inhibitory protein secreted by Staphylococcus aureus; FLIPr 105-AA protein isolated 
from S. aureus; fMIVIL, fMIVTFL, putative degradation fragments from Listeria monocytogenes 
components, PACAP27 pituitary adenylate cyclase-activating polypeptide 27for FPR, FPRL1, 
and FPRL2.   
 
In addition, three noncontiguous clusters of amino acid residues in the first 
extracellular loop and the adjacent transmembrane domains in FPR are 
important for its high-affinity interaction with fMLP (Quehenberger, Pan et al. 
1997). Consistent with these results, in a study where HEK293 cells were 
transfected with a number of chimaeric receptors in which one or more of the 
transmembrane domains of FPR were replaced by the sequences from FPRL1, 
the cells either did not migrate or showed greatly reduced efficacy in response 
to fMLP (Le, Ye et al. 2005).  
 
On the other hand, an intriguing observation was obtained when these cells were 
incubated with the W-peptide to stimulate phagocytes with a certain degree of 
preference for FPRL1 (Le, Gong et al. 1999; Dahlgren, Christophe et al. 2000). 
In fact, in this case the peptide induced migration of the HEK293 cells 
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expressing all chimeric receptors, including those chimeras that had failed to 
show any chemotactic response to fMLP. These results further highlight the 
possibility that different peptides can exploit different, possibly unrelated 
domains of the receptor to activate it.  
  
A recent search for new FPR antagonists, using a ligand-based virtual screening 
technique, identified 30 different FPR antagonistic compounds belonging to 
nine distinct chemical families (Edwards, Bologa et al. 2005), suggesting that 
there will be an increasing number of antagonists also identified for FPRL1. The 
only FPRL1-specific antagonist described so far is the recently identified 
hexapeptide, WRWWWW. This peptide has no effect on FPR signalling but 
blocks activation by most (but not all) FPRL1 agonists (Bae, Lee et al. 2004). 
The WRWWWW peptide also affects cellular activities mediated by FPRL2, 
the FPR family member expressed selectively in cells of the monocytic lineage 
(Shin, Lee et al. 2006). 
 
LXA4 was the first high-affinity ligand described for FPRL1, where initially it 
was shown to activate monocytes through FPRL1, to induce adherence and 
migration. However, its most prominent activity was then shown to be 
inhibition of neutrophil functions using the same receptor (Serhan 2002; Levy 
and Serhan 2003). The dichotomy in responses elicited by this lipid and the 
fMLP peptide upon activation of the FPRL1 receptor has been linked to a 
differential activation of the receptor. In fact, some data suggest that LXA4 
competes with activating agonists for binding to FPRL1, and that the binding of 
LXA4 switches the function of FPRL1 towards the generation of an inhibitory 
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signal suggested to involve a novel polyisoprenyl phosphate signalling pathway 
(Levy, Fokin et al. 1999; Chiang, Fierro et al. 2000; Fierro, Colgan et al. 
2003;Levy, 1999). Furthermore, it has been shown that whereas N-
glycosylation of the receptor is essential for its recognition of peptide sequences 
this is not true for LXA4 where recognition is independent of glycosylation. 
Moreover, more recent data has shown that the seventh transmembrane and 
adjacent regions are essential for LXA4 recognition (Le, Ye et al. 2005), in 
contrast to signalling by other peptide agonists where their high affinity 
recognition and signalling has been shown to be independent of these regions. 
 
Recently, a number of novel peptide agonists of diverse origin and distinct 
chemical entities have been identified that selectively activates FPRL1. 
Amongst these agonists one finds the peptide domains derived from the 
envelope proteins of human immunodeficiency virus type 1 (HIV-1) (Miller and 
Falke 2004) and at least three amyloidogenic polypeptides, SAA (Rabiet, Huet 
et al. 2005), Ab42 (Murphy 1994) and a 21 amino acid fragment of human prion 
(PrP 106–126) (Dalpiaz, Pecoraro et al. 1999) (Table 1-1 on page 45). 
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1.5. Mechanisms governing the signalling processes of the FPR 
family 
1.5.1. Activation similarities and the role of intracellular Ca2+ 
The biology of FPR and the downstream signalling pathways it activates have 
been studied extensively as a model system in GPCR research. In contrast, little 
is known about signalling from FPRL1, however it is reasonable to assume that 
this receptor uses similar signalling pathways as the FPR, since, apart from 
these two receptors being structurally similar, the cellular responses they induce 
are almost identical. Receptor signalling upon chemoattractant stimulation 
through FPR and FPRL1 starts with a rapid, conformational change of the 
occupied receptor followed by a dissociation of G proteins into two parts: Gβγ 
and Gα subunits, which then mediate the activation of phospholipase Cβ  
(PLCβ) and phosphoinositide 3-kinase (PI3K) (Le, Li et al. 2000; Le, 
Oppenheim et al. 2001). The dissociated protein subunits activate multiple 
downstream second messengers, including various phospholipases and protein 
kinases (Figure 1-5) (Rane, Carrithers et al. 1997; Miller and Falke 2004). 
 
An immediate consequence of the production of inositol 1,4,5-trisphosphate 
(IP3) upon cleavage of membrane phosphatidylinositol 4,5 bisphosphate (PIP2) 
by phospholipase C (PLC) is the transient elevation of intracellular Ca2+, 
characterized by a release of Ca2+ from intracellular Ca2+ storage organelles 
exposing IP3 receptors (Ptasznik, Traynor-Kaplan et al. 1995). In resting cells, 
the cytosolic Ca2+ concentration is kept at low levels (~100 nM) as compared 
with the level outside of the cells. However, the cytosolic concentration can rise 
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up to µM levels upon chemoattractant stimulation and then return to basal levels 
quite rapidly. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5: Schematic signalling pathways of an activated formyl-peptide 
receptor.  Adapted from (Le, Li et al. 2000) 
 
Such a transient rise in Ca2+ has long been considered essential for various 
neutrophil functions; however, recent evidence indicates that an elevation of 
Ca2+ alone is neither sufficient nor required for certain FPR family mediated 
responses. In fact, although cytoskeletal remodelling protein activity has been 
shown to be Ca2+ dependent (Janmey 1994), cytoskeleton-dependent cellular 
processes such as neutrophil polarization, membrane ruffling, chemotaxis, and 
phagocytosis can also occur in Ca2+-depleted cells (Zaffran, Lepidi et al. 1993). 
Furthermore in the activation of processes such as the superoxide-generating 
system, an increase of intracellular Ca2+ alone is not sufficient (Dahlgren 1987), 
and can occur independently of cytosolic Ca2+ elevation (Bylund, Bjorstad et al. 
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2003; Bylund, Pellme et al. 2004; Fu, Bylund et al. 2004).  
 
Another process elicited by the FPR family of receptors, which has been shown 
to be Ca2+ mediated, is the exocytosis of neutrophil secretory vesicles induced 
by fMLF or LTB4 that occurs to the same extent even in a Ca2+ free buffer 
(Sengelov, Kjeldsen et al. 1993). Moreover, a transient elevation of Ca2+ alone 
is not sufficient for the low level of neutrophil azurophilic granule mobilization 
induced during fMLP stimulation; a second synergistic signal is required 
(Hattori, Komoda et al. 1998). 
 
1.5.1.1. Receptor desensitization and internalization 
When neutrophils encounter increasing concentrations of a chemoattractant, 
they gradually become nonresponsive to further stimulation by the same 
agonist. This process, known as homologous desensitization (Ali, Richardson et 
al. 1999), is also important to limit or terminate the response to higher 
concentrations of an attractant, avoiding prolonged activation and thereby a 
continuation of an inflammatory event. Cells desensitized to FPR or FPRL1 
agonists are also desensitized to a second stimulation with the GPCR agonists 
IL-8 or PAF, suggesting the existence of a hierarchical receptor cross-talk 
within the GPCR receptor family (Heit, Tavener et al. 2002; Fu, Bylund et al. 
2004). This type of hierarchy may be of importance in guiding the neutrophils 
to the site of bacterial infections when facing multiple gradients of different 
chemoattractants.  
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Cross-desensitization experiments with specific FPR and FPRL1 agonists have 
suggested that these receptors are hierarchically, equally strong. The 
phosphorylation of occupied GPCRs by specific GPCR kinases, β-arrestin 
binding, phosphorylation of nonoccupied GPCR by second messengers, and 
physical GPCR coupling to the cytoskeleton are proposed mechanisms by 
which these receptors are desensitized (Klotz and Jesaitis 1994; Miller and 
Falke 2004). 
  
In the context of receptor recycling very little work has been done on the 
FPRL1 receptor and thus I will concentrate on the FPR receptor, however until 
further data becomes available one can hypothesize that due to the high 
structural homogeneity found between these two receptors, some of these 
processes might be similar.  
 
Unlike other extensively investigated GPCRs such as the β2 adrenergic and 
angiotensin 1A receptors, FPR internalization occurs in an arrestin-, dynamin-, 
and clathrin-independent manner, despite the fact that the FPR forms stable 
endosomal complexes with arrestin (Dalpiaz, Ferretti et al. 2002). FPR 
internalization is, however, dependent upon receptor phosphorylation (Dalpiaz, 
Pecoraro et al. 1999) and as opposed to internalization, receptor recycling to the 
surface is dependent on arrestin binding (Bae, Lee et al. 2004). Recent studies 
have shown that the eight residues located between and including Ser328 and 
Thr339, at the C-terminal end of the receptor, are critical for internalization and 
desensitization of the receptor (Dalpiaz, Pecoraro et al. 1999). These eight 
residues are arranged as two clusters of four serines or threonines with acidic 
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residues preceding each cluster, which are characteristic of G protein-coupled 
receptor kinase (GRK)-mediated phosphorylation sites (Miller and Falke 2004).  
1.5.1.2. Distinct differences between FPR and FPRL1 
signalling 
The plasma membranes of many cells, including neutrophils, contain lipid rafts 
which are liquid-ordered microdomains enriched in cholesterol and suggested to 
be of prime importance in the outside-in signalling, leading to priming or a 
direct cellular activation (Lambert, Barlow et al. 1998). Treatment of cells with 
cholesterol-depleting reagents disrupts the integrity of the rafts, and such an 
approach has been used to determine the importance of the microdomains in 
signalling through FPR and FPRL1. Cholesterol depletion had little effect on 
the neutrophil response to high concentrations of an FPR agonist, whereas the 
response induced by a FPRL1 agonist wasgreatly impaired. The exact 
mechanism involved is yet to be determined, but the proposed hypothesis 
suggests a difference between the two receptors in their ability to couple to the 
signalling G protein, a process affected by the disruption of the lipid rafts 
(Pachter 1997). 
 
Furthermore, in attempts to investigate the role of the cytoskeletal protein 
gelsolin in neutrophil activation, there was an up to 50% inhibition of reactive 
oxygen species production and granule mobilization triggered by the FPRL1-
specific agonist WKYMVM and the more general agonist fMLP by PBP10, a 
selective inhibitor of the PIP2 binding region of gelsolin. Treatment of 
neutrophils with PBP10 prior to WKYMVM stimulation did not alter the Ca2+ 
response, suggesting that the PBP10-mediated, inhibitory effect on the FPRL1 
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response is independent of PLC and affects a signal generated in a PLC-
independent signalling pathway. On the other hand, PBP10 was without effect 
when another FPR-specific agonist replaced fMLP. Apparently, this PBP10-
sensitive pathway is essential and selective for FPRL1-mediated responses in 
human neutrophils (Fu, Bylund et al. 2004). 
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1.6. Microparticles and their potential biological roles 
The first report of microparticles (MP), also referred to as microvesicles, is from 
1967, when Wolf described the presence of fragments derived from platelets in 
human plasma (Wolf 1967). Analysis of these fragments demonstrated that they 
were small membrane-coated vesicles. At that time, these vesicles were 
considered to be a residue or by-product of platelet activation and were 
therefore named “platelet dust.” Subsequent studies have demonstrated that 
these particles, like the cells from which they arise, have potent activities in 
clotting and are not inert (Combes, Simon et al. 1999).  Since the first report by 
Wolf it has been shown that MP can be released from multiple cell types, 
including macrophages, monocytes, B and T cells, neutrophils, erythrocytes, 
endothelial cells, vascular smooth muscle cells, epithelial cells, and tumour cell 
lines.   
 
MP are a heterogeneous population of small, membrane-coated vesicles with a 
size varying between 0.1 and 1.5 µm, that represent subcellular elements for cell 
signalling and intercellular communication in inflammation, bearing on their 
surfaces at least some of the antigenic markers distinctive of the parent cell. 
Several circumstances occurring in many disease states are known to stimulate 
their release such as (i) activation or apoptosis induced by numerous agents, (ii) 
partial or complete lysis by for example complement, (iii) oxidative injury, or 
(iv) other insults such as high shear stress (Miyazaki, Nomura et al. 1996) 
(Figure 1-6). 
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Stimuli that trigger the release of MP increase the intracellular calcium levels, 
leading to a rearrangement of the cytoskeleton and the budding of MP from the 
plasma membrane (Wiedmer and Sims 1991). 
 
Studies in a variety of in vitro systems have demonstrated that MP are 
potentially important mediators of cellular interactions. Thus, these subcellular 
structures can transfer bioactive molecules between cells as well as regulate 
diverse processes, such as inflammation, coagulation, vascular function, 
apoptosis, and cell proliferation. In view of these activities, MP play a role in 
the pathogenesis of rheumatologic diseases such as rheumatoid arthritis (RA) 
(Berckmans, Nieuwland et al. 2005), systemic vasculitis (Daniel, Fakhouri et al. 
2006), and antiphospholipid syndrome (Joseph, Harrison et al. 2001). 
Figure 1-6: A schematic outlining the production of MP, outlining the segregation 
of cell specific antigens upon activation and the release of different antigens 
depending on the stimulus being provided (VanWijk, VanBavel et al. 2003).  
 
Although arising during apoptosis, MP are distinct from apoptotic bodies. After 
the induction of apoptosis, the cell shrinks and shows chromatin condensation 
and cellular rearrangement, leading to formation of blebs. Eventually, the 
apoptotic cell collapses and fragments, which leads to the formation of 
Activation/ 
Apoptosis 
Stimulus A 
Stimulus B 
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membrane-coated structures, the so-called apoptotic bodies. In contrast to MP, 
which are released early during apoptosis, apoptotic bodies form in the final 
stages of programmed cell death. In addition to the kinetics of their generation, 
MP and apoptotic bodies differ in composition and size, with apoptotic bodies 
being many times larger in diameter and volume (Hristov, Erl et al. 2004). 
 
MP also differ from exosomes, another type of vesicle released from eukaryotic 
cells either spontaneously or during activation. Unlike MP, exosomes are 
preformed vesicles. Exosomes are stored intracellularly in multivesicular bodies 
and are secreted when the multivesicular bodies fuse with the cell membrane 
(Gasser, Hess et al. 2003). Although they arise from the inside of cells, 
exosomes, nevertheless can be functionally active. For example, exosomes 
derived from B lymphocytes can bind to follicular dendritic cells and function 
in antigen presentation (Denzer, Kleijmeer et al. 2000), while exosomes from 
cytotoxic T cells may mediate target cell killing (Monleon, Martinez-Lorenzo et 
al. 2001). As shown in morphologic studies, exosomes range in size from 50 to 
100 nm and are coated by a lipid bilayer. Exosomes also display certain surface 
receptors of the parental cell (Stein and Luzio 1991). 
 
Another term used to characterize vesicles released from cell membranes is 
ectosomes. Stein and Luzio coined the expression “ectocytosis” for the process 
of releasing vesicles with a “right-side-out” orientation (Stein and Luzio 1991). 
Most MP that are released by monocytes, neutrophils, platelets, and fibroblasts 
correspond to the definition of ectosomes. While the terms MP and ectosomes 
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may not be synonymous, there is evidence for a structural and functional 
similarity of these structures. 
 
It had been known for a long time that many, if not all, proteins of the plasma 
membrane exhibit a high degree of lateral mobility (White 1993), manifested in 
such phenomena as receptor clustering, dimerization and capping of leukocytes 
(Nurden 1997). Recently, the concept of lipid rafts has emerged, in part to 
account for aspects of this mobility being floating islands of distinctive lipid 
composition bearing restricted sets of proteins (such as GPI-anchored proteins), 
and are studied by their differential solubility in detergents (Simons and Ikonen 
1997; Czech 2000). Erythrocytes (RBC) have been good models for study and 
their rafts assisted in understanding earlier findings amongst which the selective 
shedding of RBC MP enriched in acetyl cholinesterase (Butikofer, Kuypers et 
al. 1989). It was also observed that in some cells the clustering (capping) of 
platelet endothelial cell adhesion molecule (PECAM)-1 occurs as a prelude to 
the shedding of MP enriched in it (Jy, Jimenez et al. 2002), suggesting that 
specific kinds of rafts are preferentially shed as MP. This could also explain 
another finding, that of endothelial MP with multiple phenotypes (Jimenez, Jy et 
al. 2003), since it would mean that the same cell could be the origin of 
distinctive raft species the content of which depend on stimulus and 
environment.  
 
Yet another interesting observation was the fact that the shedding of endothelial 
MP in vivo is highly sensitive to the blood lipid profile, consistent with the fact 
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that the composition and stability of rafts are very sensitive to levels and 
compositions of particular plasma lipid particles and transfer proteins.  
 
 
1.6.1. Composition of microparticle plasma membranes 
MP expose membrane antigens that are specific for the ‘parent cell’ they 
originate from. These identification antigens are always present on the surface, 
irrespective of the activation or apoptosis status of the parent cell, and enable 
the determination of their cellular source, e.g., CD62L for neutrophil derived 
MP (Gasser, Hess et al. 2003). MP however, can differ in the expression of cell 
surface molecules from their parental cells. This phenomenon has been analyzed 
in the most detail for RBCs. MP derived from erythrocytes upon treatment with 
calcium and ionophore A23187 are enriched for glycosyl phosphatidylinositol–
anchored proteins, such as acetylcholinesterase and decay accelerating factor 
(Butikofer, Kuypers et al. 1989). Erythrocyte-derived MP are also enriched for 
the membrane protein stomatin and for the proteins synexin and sorcin, which 
translocate from the cytosol to the plasma membrane upon calcium binding 
(Salzer, Hinterdorfer et al. 2002). 
 
Furthermore, the expression of surface molecules on MP may vary with parent 
cell activation state, with levels of PECAM-1 and E-selectin significantly higher 
on MP from activated endothelial cells than on those from resting cells (Abid 
Hussein, Meesters et al. 2003) and cellular origin. 
 
 59 
The microparticle composition is also agonist dependent. T-cells produce MP 
that are enriched in CD3ε- and ζ-chains only upon activation of the T-cell 
antigen receptor and not upon activation by ionomycin plus p-
methoxyamphetamine hydrochloride (Blanchard, Lankar et al. 2002). MP from 
thrombin- or collagen-activated platelets expose glycoprotein IIb–IIIa 
complexes that bind fibrinogen, in contrast to MP produced by platelets 
incubated with C5b-9, which do not bind fibrinogen (Martinez, Tesse et al. 
2005). Finally, even MP released by one cell type in response to a single agonist 
still can form a heterogeneous population. For instance, MP released from 
platelets after stimulation with serum from patients with heparin-induced 
thrombocytopenia are heterogeneous in size and in exposure of glycoprotein 
IIb–IIIa (Hughes, Hayward et al. 2000). 
 
1.6.2. Microparticle cytoplasmic content  
In contrast to the characterization of surface molecules, little is known about the 
intracellular contents of MP. Thery and colleagues demonstrated that MP from 
dendritic cells contain histones (Thery, Boussac et al. 2001), whilst MP released 
by THP-1 monocytic cells upon activation of the ATP receptor P2X7 contain 
IL-1β (MacKenzie, Wilson et al. 2001). 
 
Based on the mechanism of microparticle release, it is possible that cytosolic 
and even nuclear proteins from the parental cells are present within the MP. 
These internal molecules could contribute to biological activity of the particles, 
although this has not been investigated extensively. 
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1.6.3. MP as intercellular transporters 
MP may have various (patho-) physiological functions, namely transport of 
membrane components from the parent cell to other cells and (in-)direct 
activation of inflammation, coagulation or vascular function. 
 
Among their pro-inflammatory activities, MP can transport biologically active 
compounds such as lipid mediators and cell surface receptors between different 
cells. Barry and coworkers demonstrated that MP can alter cellular functions 
through transcellular lipid metabolism (Barry, Pratico et al. 1997; Barry, 
Kazanietz et al. 1999). 
 
Recently, it has also been shown that MP can mediate the intercellular transfer 
of cell surface receptors. The transferred receptors can be integrated into the 
plasma membrane of the acceptor cells rendering them responsive to new 
stimuli. Horizontal transfer of proteins via MP could also play a role in the 
pathogenesis of human immunodeficiency virus (HIV) infection. While receptor 
transfer provides a novel regulatory mechanism, the integration of receptors 
from MP into the plasma membrane of the acceptor cells may not lead to new 
function. One example is that although when MP containing the chemokine (C-
C motif) receptor (CCR)-5 were incubated with T-cells and the receptor was 
observed to be incorporated into the cell membranes, the incubation with a 
CCR5 agonist was not observed to lead to down stream signalling by this 
receptor. This finding suggests that the functional integration of chemokine 
receptors may be limited to certain cell types. In addition, the transfer of cell 
surface molecules by MP has been demonstrated only for chemokine receptors. 
It remains unknown whether other cell surface proteins can be exchanged 
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between different cells through this mechanism (Mack, Kleinschmidt et al. 
2000). 
 
1.6.4. MP and their role in inflammation 
As shown in a few in vitro studies, MP can display a variety of proinflammatory 
activities that could contribute to the pathogenesis of rheumatic disease. Thus, 
these particles can promote adhesion and rolling of leukocytes, contain 
proinflammatory cytokines, and trigger the release of MP from various cell 
types in vitro (Mesri and Altieri 1998). Further evidence for a potential role in 
disease pathogenesis comes from observations of increased numbers of MP 
during inflammatory states in vivo (Nieuwland, Berckmans et al. 2000; Knijff-
Dutmer, Koerts et al. 2002; Amabile, Guerin et al. 2005). 
 
Similar to the events promoted by damaged cells, MP can trigger inflammation 
by activating the complement cascade. In fact, C1q bound to MP can activate 
the classical complement pathway, as demonstrated by deposition of C3 and C4 
on the surface of MP (Nauta, Trouw et al. 2002). 
 
In their interactions with cells, platelet-derived MP can enhance the binding of 
neutrophils to other neutrophils prebound to the surface of a flow chamber. In 
these experiments, even when L-selectin is blocked, platelet-derived MP allow 
neutrophils to aggregate and adhere to prebound cells. In this model, the 
interaction between P-selectin on platelet-derived MP and P-selectin–
glycoprotein ligand 1 (PSGL1) on neutrophils has been suggested to be 
responsible for this interaction. Furthermore, platelet-derived MP can promote 
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cell–cell contact by inducing adhesion molecules expression on recipient cells 
(Forlow, McEver et al. 2000). 
 
Interestingly, a recent study suggests that MP can, under certain circumstances, 
exert anti-inflammatory effects. In these experiments, MP derived from fMLP-
stimulated polymononuclear cells up-regulated the expression of the anti-
inflammatory cytokine transforming growth factor β1 (TGF β1) in 
macrophages. In contrast, the release of the proinflammatory cytokines TNF α, 
IL-8, and IL-10 induced by zymosan and lipopolysaccharide was reduced by 
these MP in a dose-dependent manner (Gasser and Schifferli 2004).  MP may 
also exert anti-inflammatory effects by the induction of apoptosis in 
immunocompetent cells. Jodo and colleagues showed that cells were able to 
release MP that bear Fas ligand (FasL) on their surface. Unlike soluble FasL, 
which is a relatively poor mediator of cytotoxicity, the efficacy of 
microparticle-associated FasL was similar to that of cellular FasL in killing B 
and T cell lines (Jodo, Xiao et al. 2001). In similar experiments, it was 
demonstrated that T cell MP can induce apoptosis in RAW 264.7 macrophages, 
thereby triggering the release of MP from dying macrophages (Distler, Huber et 
al. 2005).  
 
MP appear to play an important role in the pathogenesis of coronary artery 
disease. Endothelial cell– and platelet-derived MP are significantly increased in 
coronary artery disease, especially in patients with acute events, whilst MP 
derived from monocytes and lymphocytes are found in atherosclerotic plaques 
(Figure 1.6) (Distler, Pisetsky et al. 2005).  
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These structures have also been implicated to play a role in rheumatic diseases, 
were in a number of studies it was observed that there was an elevated number 
of MP in plasma samples from patients suffering from these diseases (Figure 
1.7). Consequently it was suggested that MP could function in disease 
pathogenesis by acting systemically on the vasculature as well as locally in the 
joint.  Since cell death and activation are ubiquitous events at sites of 
inflammation, microparticle release could be a common occurrence, with these 
structures further stimulating inflammation (e.g., T cell activation leading to 
fibroblast activation via transferred particles) (Knijff-Dutmer, Koerts et al. 
2002).  
 
Figure 1-7: Schematic outlining the roles played by MP in the pathogenesis of 
some the rheumatic diseases. In the synovium MP from various sources primarily T-
cells and macrophages activate the fibroblasts leading to the release of 
proinflammatory cytokines, which attract more cells into the synovium. These cytokines 
in turn also activate the newly attracted cells leading to a further activation of the 
synovial fibroblasts. In the vessels, MP are involved in the formation of atherosclerotic 
plaques (Distler, Pisetsky et al. 2005). 
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1.7. Rheumatic diseases  
Rheumatic diseases may cause pain, stiffness, and swelling in the joints and 
other supporting body structures, such as muscles, tendons, ligaments, and 
bones, however, other areas of the body, including internal organs may also be 
affected. Some rheumatic diseases involve connective tissues (called connective 
tissue diseases), while others may be caused by an autoimmune disorder. 
Rheumatic diseases can affect anyone, at any age, or of any race. However, 
certain diseases are more common in specific populations, some examples are: 
osteoarthritis in the elderly; rheumatoid arthritis in women; ankylosing 
spondylitis and gout in men; scleroderma and lupus in women. 
 
The cause of most types of rheumatic diseases remains unknown and, in many 
cases, it may vary depending on the type of rheumatic disease. However, it is 
believed that some if not all of the following factors may play a role in the 
development or aggravation of one or more types of rheumatic diseases: genetic 
predisposition and family history (i.e., inherited cartilage weakness); lifestyle 
choices (such as being overweight); trauma; infection; neurogenic disturbances; 
metabolic disturbances; excessive wear and tear along with stress on a joint(s); 
environmental trigger and the influence of certain hormones on the body. 
Increasing evidence is highlighting the role of auto-antibodies in the 
propagation of at least a subset of these diseases, where they can have either 
organ-specific or generalized autoreactivity. 
 
There are a number of symptoms reported for rheumatic disease with some of 
the most common being: pain, swelling, early morning stiffness, chronic pain, 
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tenderness, warmth, redness and limited movement in the joints and fatigue. 
However, each individual may experience symptoms differently, and different 
types of rheumatic diseases present different symptoms.  
 
1.7.1. Rheumatoid Arthritis- a brief overview 
The first recognized description of rheumatoid arthritis (RA) was made in 1800 
by Dr Augustin Jacob Landré-Beauvais (1772-1840) of Paris. The name is 
based on the term "rheumatic fever", an illness which includes joint pain and is 
derived from the Greek word rheumatos ("flowing"). The suffix -oid 
("resembling") gives the translation as joint inflammation that resembles 
rheumatic fever.  
 
RA is a chronic, systemic autoimmune disorder that most commonly causes 
inflammation and tissue damage in joints (arthritis) and tendon sheaths, together 
with anaemia. It can also produce diffuse inflammation in the lungs, 
pericardium, pleura, the sclera of the eye, and also nodular lesions most 
common in subcutaneous tissue under the skin. Extra-articular manifestations 
other than anaemia (which is very common) are clinically evident in about 15-
25% of individuals with rheumatoid arthritis (Gabriel, Crowson et al. 2003; 
Turesson, O'Fallon et al. 2003). It can be difficult to determine whether disease 
manifestations are directly caused by the rheumatoid process itself, or from side 
effects of the medications commonly used to treat it for example methotrexate 
has been limited to lung fibrosis and corticosteroids to osteoporosis (Guler-
Yuksel, Bijsterbosch et al. 2008).  
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1.7.2. Current Treatments for RA 
A number of treatments have been developed using an array of medications. 
The first subset is referred to as non-pharmacological treatment, which includes 
physical therapy and occupational therapy. Pharmacologically, analgesics and 
anti-inflammatory drugs, as well as steroids, are used to suppress the symptoms 
with the former only being effective in reducing pain and stiffness without 
effecting joint damage or disease progression. Disease-modifying anti-
rheumatic drugs (DMARDs) are often required to inhibit or halt the underlying 
immune process and prevent long-term damage. The DMARDs originally 
meant a drug that affects biological measures such as erythrocyte sedimentation 
rate (ESR), haemoglobin and autoantibody levels. However nowadays this 
definition has been expanded to also encompass those drugs that reduce the rate 
of damage to bone and cartilage. DMARDs have been found to produce both 
durable symptomatic remissions and to delay or halt progression of the disease. 
 
Among the chemically synthesised DMARDs one finds: azathioprine, 
cyclosporin (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, 
leflunomide and methotrexate (MTX). 
 
The most important and most common adverse events of these drugs relate to 
liver and bone marrow toxicity (MTX, SSZ, leflunomide, azathioprine, gold 
compounds, D-penicillamine), renal toxicity (cyclosporine A, parenteral gold 
salts, D-penicillamine), pneumonitis (MTX), allergic skin reactions (gold 
compounds, SSZ), autoimmunity (D-penicillamine, SSZ, minocycline) and 
infections (azathioprine, cyclosporine A). Hydroxychloroquine may cause 
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ocular toxicity, although this is rare, and because hydroxychloroquine does not 
affect the bone marrow or liver it is often considered to be the DMARD with the 
least toxicity. Unfortunately hydroxychloroquine is not very potent, and is 
usually insufficient to control symptoms on its own and is normally used as part 
of a combination therapy with other DMRADs such as methotrexate and 
sulfasalazine (Weaver, Lautzenheiser et al. 2006; Walker-Bone and Farrow 
2007). 
In late 1980 it was suggested that TNF-α was a pivotal cytokine in the 
development of RA and a number of companies amongst which Centocor, Inc. 
started working on the development of anti-bodies to block this cytokine. 
Subseqent work lead to the development of an anti-TNF Receptor (TNFR) – Ig 
fusion protein and the starting of clinical trials in the US, where by the late 1990 
this was approved as method of therapy for RA in both the US and Europe. The 
development of this novel therapy represented a tremendous advance in the 
management of RA. Furthermore their use meant that those patients whose 
disease was previously resistant to conventional DMARDs could usually be 
satisfactorily controlled, and remission of disease became an increasingly 
realistic aim. However, these therapies are expensive in comparison with 
conventional DMARDs and, in countries with socialized healthcare, their 
unrestricted use would be unaffordable (Ledingham J, Deighton C. et al 2001). 
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1.7.3. Wegener’s Granulomatosis- a brief overview 
Small-vessel vasculitides are defined as selective inflammation of the arterioles, 
venules, and capillaries (Figure 1-8). 
 
 
 
 
 
 
 
 
Figure 1-8: Size of vessels as defined at the Chapel Hill consensus 
conference and associated rheumatic diseases. (Taken from  (Jennette et al 
1994). 
 
The identification of anti-neutrophil cytoplasmic antibodies (ANCA) about two 
decades ago in patients with pauci immune small-vessel vasculitis proved a 
breakthrough in the classification, diagnosis, monitoring, and understanding of 
the vasculitides. ANCA were found to be associated with four vasculitides: 
microscopic polyangiitis, Wegener granulomatosis, Churge-Strauss syndrome, 
and necrotizing crescentic glomerulonephritis. The incidence of ANCA-
associated vasculitides is rising; it has been estimated at more than 20/106 
population, with a peak between 65 and 75 years of age (Seo and Stone 2004). 
 
Scottish otolaryngologist Peter McBride first described the condition in 1897, 
Heinz Karl and Ernst Klinger would add information on the anatomical 
pathology, but the full picture was presented by Friedrich Wegener, a German 
pathologist, in two reports in 1936 and 1939. 
 69 
 
The upper and lower respiratory tract and the kidneys are the main targets of 
Wegener granulomatosis. About 90% of patients experience otolaryngological 
involvement that may manifest as episodes of rhinitis, sinusitis, epistaxis or 
nasal crusting. The pathology of Wegener granulomatosis combines vasculitis 
of the small vessels or, less often, the medium-sized vessels; irregularly 
contoured foci of ischaemic necrosis with the development of sterile abscesses; 
and formation of granulomas composed of neutrophils, lymphocytes, and giant 
multinuclear cells. ANCA against PR3 are found in 80-90% of patients with 
systemic Wegener granulomatosis, of whom only 10% have anti-MPO ANCA 
(Gross, Schmitt et al. 1993). 
 
Histology may show granulomatous airway inflammation in addition to small 
vessel vasculitis. Only 60% of these patients have detectable titers of ANCA, 
specifically cytoplasmic (c) ANCA, in contrast to perinuclear (p) ANCA 
(normally targeted against MPO). The presence of these antibodies leads to the 
activation of neutrophils, an increase in their adherence to endothelium leading 
to degranulation. This causes extensive damage to the vessel wall, particularly 
of arterioles. The exact cause for the production of ANCAs is unknown, 
although some drugs have been implicated in secondary forms of Wegener's 
granulomatosis (Csernok, Lamprecht et al. 2006; Jennette, Xiao et al. 2006).  
1.7.3.1. Current treatment for Vasculitides 
Before steroid treatment became available, mortality within one year was over 
90%, with average survival being 5 months. Since the introduction of 
glucocorticoids and immunosuppressants to treat ANCA-associated 
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vasculitides, 5-year survival has exceeded 80%. The introduction of 
cyclophosphamide (CYC) in the 1970s was a major breakthrough. However, 
early mortality due to alveolar haemorrhage or severe renal failure remains 
common, most notably in older patients. Infection is also a major cause of early 
death. Despite the improved survival, some patients fail to achieve long-term 
remissions where about 50% of patients experience one or more relapses within 
the first 4-5 years. Relapses are more common in Wegener granulomatosis than 
in the other ANCA-associated vasculitides. They may be related to the presence 
of granulomas and to colonization of the airways by pathogens such as 
Staphylococcus aureus. As relapses occur in more than 50% of patients with 
Wegener granulomatosis, prolonged immunosuppressant therapy is often 
required, at the cost of frequent and severe adverse events. With regimens 
involving long-term oral cyclophosphamide therapy, a risk increase of 33-fold 
occurred for urinary bladder carcinoma, 11-fold for lymphoma, and 2.4-fold for 
solid tumours. Although relapses are often less severe than the initial 
presentation, they may add to the burden of sequelae thereby worsening the 
functional impairment (Stegeman, Tervaert et al. 1994; Cruz, Ramanoelina et al. 
2003; Jayne 2003). 
 
1.7.4. Giant Cell Arteritis  
Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown 
aetiology occurring in the elderly. It affects the cranial branches of the arteries 
originating from the aortic arch including the temporal artery and the ocular 
nerve where is usually associated with markedly elevated acute-phase reactants.  
This disease is more commonly found in females by a 3:1 ratio. The mean age 
of onset is about 70 years and is rare in those less then 50 years of age. Patients 
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present with a number of symptoms amongst which: fever, headache, tenderness 
and sensitivity on the scalp, jaw claudication (pain in jaw when chewing), 
tongue claudication (pain in tongue when chewing), reduced visual acuity and 
acute visual loss (Wang, Hu et al. 2008). 
 
GCA of large- and medium-sized peripheral arteries typically leads to long 
tapering and occlusion of the arterial lumen due to concentric intimal 
thickening, sometimes accompanied by spontaneous dissection (Devauchelle-
Pensec, Jousse et al. 2008). Depending on the extent of the arterial obliteration 
and on the anatomy of the involved arterial segment, this may result in severe 
ischaemia of the limbs during the acute phase of the disease. GCA of the aorta 
usually remains asymptomatic for many years, and leads to a markedly 
increased risk of aneurysms and dissections, particularly of the thoracic aorta. In 
76% of cases involving the eye, the inflammatory condition effects the 
ophthalmic artery causing anterior ischemic optic neuropathy. Loss of vision in 
both eyes may occur very abruptly and this disease is therefore a medical 
emergency (Devauchelle-Pensec, Jousse et al. 2008; Tato and Hoffmann 2008; 
Wang, Hu et al. 2008). 
 
The diagnosis is relatively straightforward in the presence of cranial 
manifestations, but it may be challenging in the case of a normal erythrocyte 
sedimentation rate that may occult the disease or in patients with isolated extra-
cranial features. Temporal artery biopsy still represents the gold standard for 
diagnosis, while the role of ultrasonography, high-resolution magnetic 
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resonance imaging and positron emission tomography should be better 
addressed (Devauchelle-Pensec, Jousse et al. 2008). 
 
1.7.4.1. GCA Treatment 
Treatment of this condition involves corticosteroids, typically high-dose 
prednisone (40-60mg bd), which must be started as soon as the diagnosis is 
suspected (even before the diagnosis is confirmed by biopsy) to prevent 
irreversible blindness secondary to ophthalmic artery occlusion. Steroids do not 
prevent the diagnosis from later being confirmed by biopsy, although certain 
changes in the histology may be observed towards the end of the first week of 
treatment and are more difficult to identify after a couple of months (Moutray, 
Williams et al. 2008). The dose of prednisone is lowered after a few days, 
although treatment may continue for up to two years.  
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1.8. Aims of the thesis 
In previously conducted studies it was shown that MP derived from human 
neutrophils might produce anti-inflammatory effects on human monocyte-
derived macrophages in vivo. Furthermore it was also described that primed 
PMN export Annexin A1 to their cell surface thus it was deemed important to 
determine what role Annexin A1 is playing in the inhibitory effect described 
above: 
 
Thus I set out to determine the presence of Annexin A1 on PMN derived MP. 
 In order to fulfil this aim I propose to produce PMN derived MP by 
stimulation of PMNs with fMLP and determine their presence by using the 
flow-cytometry, and subsequently I intend establishing the presence of 
Annexin A1 in these microstructures by flow cytometry, Western Blotting 
and Q-Tof LC/MS/MS 
 
After determining the presence of Annexin A1 on these MP it is important to 
determine if this Annexin A1 is playing a role in the observed anti-
inflammatory effects.  
 In order to fulfil this aim I intend incubating the PMN derived MP with 
PMN and then flowing these cells over and activated endothelial cell 
monolayer. Then blocking either the Annexin A1 protein or its specific 
receptor to further elucidate the anti-inflammatory role of Annexin A1. 
Furthermore I intend extracting PMN MP from Annexin A1 -/- and WT 
mice to further outline the role of microparticle Annexin A1 in and in vivo 
model of inflammation.    
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Upon determining the role of Annexin A1 in MP the next step is to understand 
the clinical importance of these Annexin A1 positive MP and their potential use 
as biomarkers: 
 In order to achieve this I intend analyzing MP obtained from the plasma 
of patients suffering from rheumatic diseases mainly, MPO and PR3 
ANCA positive, GCA and RA patients to determine if there is any 
alteration in levels of the Annexin A1 - FPRL1 axis on these MP. 
Further more in order to further validate the robustness of using Annexin 
A1 and FPRL1 positive MP as biomarkers, I intend analyzing the levels 
of these two proteins on plasma samples obtained from RA patients pre, 
during and post steroidal treatment.  
 
The third area of my research involves the development of novel Ac2-26 
derived peptides as potential anti-inflammatory drugs. A panel of peptides has 
been synthesized based on previously published data in our lab highlighting 
PR3 cleavage sites on the N-terminal portion of the Annexin A1. Two of these 
amino acids, amino acid 11 and 22, of the Ac2-26 peptide were substituted with 
5 different amino acids resulting in 5 distinct peptides.  
 In order to achieve this aim, a screening process will be conducted 
where first the ability of each of the peptides to activate ERK 1/2 
through the FPRL1 receptor will be assessed by western blotting.  
 The next step will be to determine the ability of each of these peptides to 
inhibit neutrophil recruitment to an activate HUVEC monolayer. Based 
upon the data obtained from this set of experiment and the ERK 1/2 
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activation 2 peptides showing properties similar to the parent peptide 
will be chosen for further analysis. 
 After identifying the two peptides to take forward, the binding affinity to 
the FPR and FPRL1 receptors will be assessed using transfected HEK 
cell lines expressing the two receptors. Furthermore their ability to 
activate the MAPK pathway will be further assessed by conducting a 
dose response curve on the activation of ERK 1/2 along with their ability 
to reduce neutrophil recruitment to an activated HUVEC monolayer. 
 Finally the anti-inflammatory propertied of the two peptides will be 
assessed in a pre-clinical model of inflammation where the ability of 
these peptides to inhibit neutrophil recruitment into an airpouch 
inflamed using IL-1β will be investigated. 
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2. Materials & Methods 
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2.1. Materials List 
 
Distributor Material 
Serotec Star9b 
 IgG1 Isotype 
 Anti-CD62P 
(clone:Psel.KO.2.12) 
 Anti-CD62L (clone: FMC64) 
 Anti-CD14 (TUK14) 
 IgG2b Isotype 
 Anti-CD11b (clone:MCA551) 
Oxoid PBS 
Astra-Zeneca Anti-FPRL1 (clone:6C7-3-A) 
In-house Anti-Annexin A1 (clone:1b) 
 hr-Annexin A1 
CRB Ac2-26 peptide 
 W-peptide 
 Anti-Flammin 2 
Pierce BCA-protein assay kit 
Sigma Penicillin 
 Streptomycin 
 Fugizone 
 L-Glutamine 
 Meidum 199 
 Trypsin 
 Gelatin 
 HEPES buffered saline 
 EDTA solution 
 RPMI 1640 medium 
 Histopaque 1077 
 Histopaque 1119 
 Sodium Chloride 
 Sodium Citrate 
 TNF-α 
 HBSS 
 Human γ-Globulins 
 Bovine serum albumin 
 DDT 
 Sodium orthovanadate 
 Sodium fluoride 
 PMSF 
 Tris-HCl 
 SDS 
 Glycerol 
 Bromophenol blue 
 Pepstatin 
 β-glycerolphosphate 
 Leupeptin 
 Triton-X 100 
 DMSO 
 Ammonium persulphate 
 TEMED 
 Tris-Base 
 Tween 20 
 p-Coumaric acid 
 Luminol 
 Hydrogen peroxide 
 DEPC water 
 fMLP 
 Ethanol 
 Coomassie Blue 
 Lucigenin 
 DCFDA 
 PMA 
 IL1β 
BD Pharmingen Anti-mouse CD102 (clone 3C4) 
 Anti-FPR (clone: 5F1) 
Cell Signalling 
Tech 
Anti-total ERK ½ (clone: E10) 
 Anti-phospho-ERK ½ (clone: 
137F5) 
DakoCytomation Anti-mouse-HRP conj. 
 Anti-rabbit-HRP conj. 
Amersham Hyperfilm ECL 
 Percoll 
Qiagen  18s Quantitec Primer Assay   GAPDH Quantitec Primer Assay   FPRL1 Quantitec Primer Assay   AnxA1 Quantitec Primer Assay 
 RNA mini-kit 
Phoenix-Pharma W-peptide I125 
Bioline dNTP 
Invitrogen Foetal Calf serum 
 Trizol 
 Oligo-dt20 
 Superscript III 
 RNAse OUT 
 Ham’s F-12 media 
 Collaginase type IS 
 Collaginase type II 
  
Ambion Turbo DNase I 
ABi bioscience POWET SYBR Green  
Calbiochem Lipoxin A4 
Gift Anti-PR3 (clone:CLB-12.8) 
VWR Acetic Acid 
eBioscience Anti-Gr1-PE (clone rb6-8c5) 
 Ig2a Isotype-PE 
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2.2. Isolation and culture of primary HUVEC. 
Primary HUVEC cells were employed for the studies conducted during my 
PhD, these were isolated from umbilical cords as will be detailed below. Human 
cells were prepared according to a protocol approved by the local Research 
Ethics Committee (P/00/029 ELCHA).  
 
Umbilical cords were kindly supplied by the midwifery staff of the Maternity 
Unit, Royal London Hospital. Cords were placed in cord buffer (PBS containing 
penicillin (100U) streptomycin (100mg/ml) and fungizone (2.5µg/ml)] and 
stored at 4°C until endothelial isolation. Endothelial cells were isolated from 
umbilical cords by collagenase digestion of the interior umbilical vein (Jaffe, 
Nachman et al. 1973). The veins were perfused with approximately 50 ml of 
cord buffer using a sterile syringe, to wash out the residual blood. The other end 
of the cord was then clamped and approximately 20ml of 0.1% collagenase type 
II in serum free medium 199 containing penicillin (100U), streptomycin 
(100mg/ml), fungizone (2.5µg/ml) and L-glutamine (2mM) was added. Another 
clamp was then placed at the top end of the cord and the vein was incubated in a 
humidified chamber in 5% CO2 at 37°C for 15min. Following incubation, the 
collagenase solution was collected into a 50ml centrifuge tube and the vein was 
flushed with 30ml of cord buffer, and once with air to remove endothelial cells. 
The cells were centrifuged at 560g for 5min, supernatant removed, and the 
pellet was re-suspended in 15ml of complete medium (M199 containing 20% 
human serum (FCS), penicillin (100U), streptomycin (100mg/ml), fungizone 
(2.5µg/ml) and L-glutamine (2mM)) and transferred to a T75 flask. Typically 
the yield from this procedure was in the range of 0.5-1.5x106 cells per cord. 
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Cells were seeded into T75 flasks and 35mm plates precoated in 0.5% bovine 
gelatine prior to use. Gelatine (2%) was diluted 1:4 with PBS and tissue culture 
plastics were coated with the 0.5% solution for 20min. Following the coating 
procedure, gelatine was aspirated before seeding. The cells or dishes were 
incubated in a humidified chamber in 5% CO2 at 37°C, medium was replaced 
after 24h and changed every 48h thereafter. When the cells cultured in the flask 
had reached approximately 80% confluency, they were rinsed once with HEPES 
buffered saline solution (BSS) and subcultured using room temperature (RT) 
0.025% trypsin/0.01% EDTA solution (4ml for a 75cm2 flask). When 90% of 
the cells had rounded and started to detach, the flask was tapped firmly on the 
side to release the cells and an equal volume of trypsin neutralizing solution 
(TNS) was added. Cells were transferred to a 15ml centrifuge tube, flasks rinsed 
with HEPES-BSS added to tube, and spun at 220xg for 5min to pellet the cells. 
The HUVEC were never cultured beyond passage 3. 
 
2.3. Human blood leukocyte isolation. 
Experiments with healthy volunteers were approved by the local research 
committee, and informed consent was provided according to the Declaration of 
Helsinki.  
 
Blood was collected from healthy volunteers with a 21-gauge needle and 
transferred to a 50ml centrifuge tube containing 1/10 volume of 3.2% sodium 
citrate. Blood was first diluted 1:1 with warm Roswell Park Memorial Institute 
(RPMI) 1640 medium before addition to a double density gradient. The double 
gradient is formed by layering an equal volume (3ml) of Histopaque 1077 over 
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Histopaque 1119. This was prepared immediately before use to avoid any 
diffusion occurring between the two layers. Pre-diluted blood was carefully 
added to the top layer using a sterile Pasteur pipette and centrifuged at 400g for 
30min at room temperature.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Neutrophil isolation from human blood using histopaque double 
density centrifugation. 
 
Two distinct layers of leukocytes can be seen after centrifugation, with red 
blood cells (RBCs) pelleted to the bottom of the centrifuge tube. 
Polymorphonuclear cells (PMNs) are found above the RBCs whereas peripheral 
blood mononuclear cells (PBMCs) are found at the plasma/histopaque 
interphase (Figure 2-1). In order to reduce cross contamination between the two 
cell populations the PBMC layer was isolated first and the cells discarded. Then 
the PMNs were removed and placed in 6ml aliquots in 15ml centrifuge tubes to 
which an equal volume of RPMI 1640 was added. Samples were centrifuged at 
300g for 15min, supernatant discarded and cells re-suspended gently with a 
Pasteur pipette in 7.5ml of ice-cold water and subsequently 2.5ml of 3.6% 
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0.1mm 
sodium chloride solution were added. The ice-cold water was employed to lyse 
any erythrocytes which were present along with the PMN pellet, whilst the 
sodium chloride was immediately added to preserve the PMNs. Cells were then 
centrifuged at 300xg for another 10 min and then resuspended in 3ml of RPMI 
medium supplemented with 10% heat inactivated foetal calf serum (FCS), L-
glutamine (2mM), penicillin (100U) and streptomycin (100mg/ml) (complete 
media) to count. Cells were counted in all four large squares outlined in red in 
Figure 2-2, and divided by 4 to obtain the average. The total number of cells per 
ml was calculated according to the formula below: 
 
 
Average cell count per square x dilution 
factor x 104 = Cell count per ml. 
 
 
 
Figure 2-2: Illustration of the counting grid on a Neubauer haemocytometer. Cells 
were counted in the four large squares highlighted and an average was obtained. 
 
 
2.4. In vitro flow chamber assay. 
HUVECs were seeded in 35mm2 coated-coated dishes at a density of 3x105 
cells in complete media, and used two days after plating, at confluence. 
Confluent monolayers were stimulated with TNF-α (10ng/ml; Sigma-Aldrich) 
for 4h to up-regulate adhesion molecules such as E-Selectin, ICAM-1 and 
VCAM-1Human PMNs were isolated as outlined in section 2.2, centrifuged at 
300g for 5min and resuspended to 1x107 cells/ml in Dulbecco phosphate 
 82 
buffered saline (DPBS) containing 0.1% bovine serum albumin (BSA) and kept 
on ice before use. Immediately prior to flow, 5x106 (0.5ml) PMNs were diluted 
to 5ml (1x106 cells/ml) in DPBS supplemented with Ca2+ and Mg2+ (as integrins 
on the PMNs require these divalent cations for their adhesive function). The 
PMNs were then incubated for 10min at 37°C following which the endothelium 
was rinsed with PBS prior to attachment to the parallel plate laminar flow 
chamber (GlycoTech) as shown in Figure 2-3 and the cells were flowed for 8 
min prior to recording.  
 
 
Figure 2-3: Assembly of the parallel plate flow chamber. The chamber was first 
covered in vacuum grease to hold the gasket in place, and residual grease was 
removed using an alcohol wipe. PBS was then added to the window in the gasket to 
cover both the inlet and outlet, ensuring no air bubbles are present. Finally, the HUVEC 
monolayer was added to the vacuum-sealed chamber, inverted and placed under a 
Nikon microscope.   
 
A shear stress of 1 dyne/cm2 was generated using an automated syringe pump 
(Harvard Apparatus, South Natick, MA). This was calculated according to an 
adaptation of Poiseuille’s law that states: 
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τw = 6µQ 
         a2b 
 
 
Wall shear stress (dyne/cm2) = Mean flow velocity (mm/s) x [8/tube diameter (mm)] x 
viscosity (Poise).  
This takes into account the flow rate through a cylindrical vessel; the equation 
relating wall shear stress to volumetric flow rate through the chamber is given 
by (Lawrence, McIntire et al. 1987):  
 
 
 
Where: 
τw = Wall shear stress (dynes/cm2) 
µ = Coefficient of viscosity (Poise) 
Q = Volumetric flow rate (ml/s) 
a = Channel height (i.e. gasket thickness, cm) 
b = Channel width (i.e. gasket width, cm) 
 
Experiments were performed at a constant volumetric flow rate of 0.00707ml/s. 
The coefficient of viscosity is determined by the fluid in which the PMNs are 
resuspended and the temperature of the solution. For PBS at a constant 
temperature of 37°C, the viscosity is 0.0076 Poise. The flow channel was a set 
size determined by the dimensions of the gasket; the channel height relates to 
the thickness of the gasket, which was of 0.0254cm and the channel width was 
of 0.5cm. These conditions create a wall shear stress of precisely 0.9994172 
dyne/cm2. 
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The entire flow chamber was placed under a Nikon Eclipse TE3000 microscope 
fitted with x10 and x20 phase contrast objectives (Nikon, Melville, NY). 
Neutrophils were perfused over HUVEC monolayers for a period of 8min, and 
six, 10s frames were chosen from random fields of view using a Q-imaging 
Retiga EXi digital video camera (Q-imaging) and recorded in Streampix capture 
software (Norpix) ready for off-line analysis. Sequences were loaded into 
ImagePro-Plus software (Media Cybernetics, Wokingham), PMNs were 
manually tagged and their migration monitored. Three measurements were 
made in the analysis: the total number of interacting cells were quantified as 
number of cells initially captured during the 10s frame, which were further 
classified as either rolling or firmly adherent (those which remain stationary for 
the 10s observation period) (Patel 1999). Experiments were repeated at least 
three times using various blood donors and various sources of HUVEC. The 
total number of interacting cells for each category (capture, rolling and 
adhesion) was converted to number of cells/mm2.  
 
In some experiments the PMNs were pre-incubated with either a monoclonal 
anti-FPRL1 (clone: 6C7-3-A, Kind gift of Dr. Duncan Anderson, Astra Zeneca) 
or microparticles previously generated from isolated PMN, as described in 
section 2.10, for 10min at 37°C prior to perfusion of the PMNs. Alternatively, 
the microparticles were pre-incubated with the monoclonal anti-Annexin A1 
(clone 1B) prior to the preincubation of these microparticles with the PMN and 
the perfusion over the HUVEC monolayer, with the pre-incubations being both 
conducted for 10min at 37°C. In a separate set of experiments the PMNs were 
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preincubated for 10mins at 37°C with microparticles generated from either 
unstimulated or adherent PMNs prior to flowing over the HUVEC monolayer.   
 
Additional experiments were performed in order to determine, initially, which 
of the novel Ac2-26 derived peptides (sequences illustrated in Table 1.3) 
possessed inhibitory properties similar to those observed for the parent Ac2-26 
peptide. In this case the PMNs were pre-incubated for 10 min at 37°C with 
10µM of peptide prior to flowing over the HUVEC monolayer. 
 
In a distinct set of experiments a dilution series was prepared for both Pep57 
and Pep84 (sequences illustrated in Table 1.3) ranging from 10µM down to 
0.01nM.  
These dilutions were then employed to determine the inhibitory potential of 
each of these peptides on PMN adhesion to an activated endothelial monolayer. 
To do so, each of the prepared dilution was pre-incubated with PMNs for 10min 
at 37°C with and then perfused over the activated HUVEC monolayer.  
 
In another separate set of experiments PMNs isolated from Wegner and GCA 
patients were flowed over an activated HUVEC monolayer in order to 
determine their level of activation when compared to healthy volunteers. In 
another set of experiments these PMNs were pre-incubation with 10nM hr 
Annexin A1 for 10 min (Hayhoe, Kamal et al. 2006) prior to perfusion in order 
ascertain the pharmacological effect of hr-Annexin A1 protein in this subset of 
rheumatic conditions. 
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2.5. Flow-cytometric analysis. 
Flow-cytometry is a versatile tool that allows various characteristics of a cell to 
be analyzed. Cell suspensions are aspirated in single file through a narrow 
chamber (the flow cell) and illuminated by a laser (incident beam). This light 
will either be scattered or absorbed when it hits the cell. Absorbed light of the 
appropriate wavelength may be re-emitted as fluorescence if the cell contains a 
naturally fluorescent substance (autofluorescence) or if fluorochrome-labelled 
antibodies are attached to the cell. Light scatter is dependent on the internal 
structure of the cell, its size and shape. The amount of light scattered at small 
angles (0.5-5°) or forward scattering (FSC) gives a rough measure of cell size, 
whereas the light scattered at large angles (15-150°) or side scattering (SSC) 
increases with the cells’ internal granularity. This data alone can be very useful 
as it discriminates between distinct cell types. This is demonstrated in the dot 
plot below, where larger cells with a big nucleus and granular cytoplasm 
(granulocytes) are gated in blue, small cells with a large nucleus (lymphocytes) 
are gated in green, and monocytes, which have intermediate properties are gated 
in red (Figure 2-4).  
 
These groups can be confirmed using antibodies specific for each of the cell 
types, CD11b, CD3 and CD14 respectively. To excite the fluorescence of a 
fluorochrome, an intense light source that provides the necessary excitation 
wavelengths is needed. Fluorescein isothiocyanate (FITC) for example, is 
stimulated by blue wavelengths of light around 490nm (therefore the blue 
Argon-ion laser is used which excites at 488nm) and re-emits light at a longer 
wavelength (emission spectra). 
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Figure 2-4: Representative dot 
plot of human blood 
leukocytes. Granulocytes 
(purple), lymphocytes (green) and 
monocytes (light blue) are gated 
according to size and granularity.  
 
 
 
 
 
FITC emits light over the range 475-700nm peaking at 525nm, which falls in 
the green spectrum, shown in the spectral diagram (Figure 2.5). Photo 
multiplier-based detectors placed in line or perpendicular to the axis of the laser 
beam collect the emitted or scattered light. Typically, 10,000 cells from each 
sample are analyzed for statistically valid results. Flow-cytometry data was 
acquired using a FACScan II analyser (Becton Dickinson, Cowley) and 
analyzed with CellQuest software (BD Biosciences).  
 
 
Figure 2-5: Light absorbance 
and light emission spectra of 
FITC.  
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2.5.1. Assessment of surface molecule expression on the HEK-FPR, HEK-
FPRL1 and HEK-CMV cells by flow cytometry 
Three human embryonic kidney (HEK) cell lines were thawed from the 
cryogenic stocks by placing the cryovial in a water bath at 37oC for 2mins, 
following which the cells were immediately re-suspended in 15ml Minimum 
Essential Medium Eagle (MEM) supplemented 10% heat inactivated foetal calf 
serum (FCS), L-glutamine (2mM), gentamycin (1µg.ml) and geneticin 
(200µg/ml). The medium was initially changed after 24h following which it was 
changed after 48h. Cells were cultured till 90% confluency after which they 
were trypsinized and counted, 1x105 cells were seeded per well in 96-well 
plates. Cells were incubated with blocking IgG (at a concentration of 16mg/ml) 
and purified mouse anti-human monoclonal antibodies (mAb) at 5µg/ml final 
concentration: FPRL1 (clone 6C7-3-A: kind gift Dr Duncan Anderson, Astra 
Zeneca), FPR (clone 5F1: BD Pharmingen) for 1h on ice. The cells were then 
washed twice with PBC (which is PBS + 0.15% BSA and 1mM CaCl2) prior to 
staining with fluorescein isothiocyanate (FITC)-conjugated F(ab’)2 rabbit anti-
mouse IgG (1:200; AbD Serotec). An IgG1 isotype and unstained controls were 
also prepared for accurate calibration of the FACS machine. Surface protein 
expression was recorded as Mean Fluorescence Index (MFI) units measured in 
the FL1 green channel. 
 
In a separate set of experiments HEK-FPRL cells were seeded in a 24 well plate 
and incubated with 1µM of either Pep84, Pep57 and Ac2-26 (sequences 
illustrated in Table 1.3) for the following time points 15, 30, 60 and 120 min. At 
the end of each time point a metabolic inhibitor cocktail containing 1mM 2-4 
dinitrophenol and 45mM 2-deoxy-D-glucose was added to each well to stop any 
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further receptor trafficking. This inhibitor cocktail interferes with mitochondrial 
function blocking respiration and this metabolic activity. The cells were 
incubated with this metabolic inhibitor cocktail for 10 min then washed twice 
with PBC counted and seeded at a concentration of 1x105 cells per well in 96-
well plates. Following which they stained using a mouse monoclonal anti-
human FPRL1 antibody and anti-mouse FITC conjugated secondary antibody as 
outlined above. An IgG1 isotype and unstained controls were also prepared for 
accurate calibration of the FACS machine. Surface protein expression was 
recorded as MFI units and percentage positive cells measured in the FL1 green 
channel. 
 
2.5.2. Assessment of surface molecule expression on PMNs derived 
microparticles by flow cytometry 
Microparticles derived from patients suffering from a number of rheumatic 
conditions, healthy volunteers and wild type (WT) and Annexin A1 knock out 
mice (Annexin A1 -/-) were produced as will be subsequently outlined in 
section 2.10. These were then re-suspended and counted using the forward and 
side scatter parameters on the flow-cytometer, which had been previously 
calibrated using 1µm size beads (Gasser, Hess et al. 2003). After counting the 
microparticles were seeded into 1.2 ml FACS tubes at a concentration of 4x104 
microparticles per tube. Subsequently, they were incubated with purified mouse 
anti-human monoclonal antibodies (mAb) at 5µg/ml final concentration: 
Annexin A1 (clone 1B), FPRL1 (Clone 6C7-3-A, Astra Zeneca), CD62L 
(Clone: FMC46, Serotec), CD62P (clone: Psel.KO.2.12, Serotec), CD14 
(TUK4, Serotec) for 1h on ice, and concomitantly they were stained with FITC-
conjugated F(ab’)2 rabbit anti-mouse IgG (1:200; AbD Serotec). Whilst the 
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mouse microparticles were co-incubated with rat anti-mouse anti bodies against 
CD62L (clone: MEL14, Serotec) along with an annexin-V FITC conjugated 
protein (also used for the human microparticles). IgG1, IgG2b isotypes and 
unstained controls were also prepared for accurate calibration of the FACS 
machine. Surface antigen expression was recorded as MFI units and percentage 
positive MP measured in the FL1 green channel. 
 
The FPRL1 and Annexin A1 levels in plasma microparticles derived from 
healthy volunteers, Wegner and GCA patients were assessed using flow-
cytometry. This was done by incubating 10µl of plasma to 10µl of primary 
antibody for 30 min at 4oC following which 2µl of secondary anti-mouse FITC 
conjugated antibody (1:200 final dilution) was added for a further 20 min. 
Finally 200 µl of PBC were added to the reaction mixture and the antigen 
expression was determined by flow-cytometry. 
 
In a further separate set of experiments the effect of a daily prednisolone (14mg 
oral) treatment on the Annexin A1 and FPRL1 levels in MPs was assessed. 
Blood was collected in collaboration with Dr. Stephen Kelly at the Mile End 
Rheumatology Clinic, the plasma separated as described in section 2.10 and 
stained as highlighted above. 
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2.5.3. Assessment of surface molecule expression on PMNs from Wegener 
granulomatosis, GCA patients and healthy volunteers by flow 
cytometry 
PMN’s from were isolated as detailed in section 2.2, after isolation and 
counting, 1x105 cells were seeded per well in 96-well plates. Cells were 
incubated with purified mouse anti-human monoclonal antibodies (mAb) at 
5µg/ml final concentration: Annexin A1 (clone 1B), FPRL1 (Clone 6C7-3-A, 
Astra Zeneca), FPR (clone 5F1: BD Pharmingen) CD62L (Clone: FMC46, 
Serotec), PR3 (clone CLB-12.8: kind gift Dr Valerie Witko-Sarsat) for 1h on 
ice, prior to staining with FITC-conjugated F(ab’)2 rabbit anti-mouse IgG 
(1:200; AbD Serotec) for a further 30min. IgG1, IgG2b isotypes and unstained 
controls were also prepared for accurate calibration of the flow-cytometer. 
Surface protein expression was recorded as MFI units and percentage positive 
cells measured in the FL1 green channel. 
 
2.5.4. Assessment of surface molecule expression on PMNs from RA 
patients by flow cytometry 
Monocytes and PBMC’s were isolated as detailed in section 2.2, from patients 
enrolled in a clinical study to determine the efficacy of an oral daily 
prednisolone(15mg) treatment on disease control in Rheumatoid Arthritis 
patients in collaboration with Dr Stephen Kelly, Rheumatology Clinic, Mile 
End. Blood was collected on days 0 (i.e. prior to commencement of 
glucocorticoid treatment) and after, at days 1, 3, 7 and 14. Where cells were 
isolated, counted and seeded at a concentration of 1x105 cells per well in 96-
well plates. Cells were incubated with purified mouse anti-human monoclonal 
antibodies (mAb) at 5µg/ml final concentration: Annexin A1 (clone 1B), FPRL1 
(Clone 6C7-3-A, Astra Zeneca), FPR (clone 5F1: BD Pharmingen) CD62L 
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(Clone: FMC46, Serotec) and CD11b (clone: MCA551 Serotec), for 1h on ice, 
prior to staining with FITC-conjugated F(ab’)2 rabbit anti-mouse IgG (1:200; 
AbD Serotec) for a further 30min. IgG1, IgG2b isotypes and unstained controls 
were also prepared for accurate calibration of the flow-cytometer. Surface 
protein expression was recorded as MFI units and percentage positive cells 
measured in the FL1 green channel. 
 
Staining of the synovial cells was also conducted, in this case the synovial fluids 
obtained from the patients at day 0 were centrifuged at 400xg for 10 min and the 
supernatant removed. The cells were then washed twice with HBSS and re-
suspended in PBC, after which the staining protocol outlined above was 
followed and the level of antigen expression observed on the synovial monocyte 
and neutrophil populations was determined. 
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2.6. Sodium Dodecyl Sulphate - Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) Western Blotting.  
In principle, electrophoresis separates molecules according to their molecular 
weight, shape and intrinsic charge using an electric field. Using SDS-PAGE 
proteins are resolved primarily by their size. The anionic detergent SDS 
denatures proteins by disrupting hydrogen bonds and also causes them to 
become negatively charged by covering the polypeptide backbone of the protein 
in its hydrophobic tail. SDS binds to most proteins at a constant ratio of 1.4g per 
gram of protein resulting in a negative uniform charge-to-mass ratio. 
Consequently, the charge of the protein becomes insignificant compared to the 
overall net negative charge of the bound SDS, and proteins migrate in the gel 
according to size, with the smallest proteins moving furthest through the gel.  
 
2.6.1. Sample Preparation 
Microparticles were extracted and washed, supernatants were aspirated and, for 
analysis of total cellular proteins, 50µl per ~6x104 microparticles of 1x hot 
Laemmlli sample buffer (50mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol) 
were added directly to the pellet. This solution was syringed twice with a 25G 
needle to fully lyse the microparticles. Protein concentration was determined 
using the BCA protein assay (Pierce) as described below and samples were 
equalized by dilution with sample buffer. The reducing agent, 100mM DTT was 
added to cleave disulphide bonds to completely unfold the protein structure, and 
0.01% bromophenol blue was added to identify the protein front as they migrate 
through the gel, prior to boiling the samples. 40µl of sample containing 20-30µg 
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of protein was boiled for 5 min before loading and running on a polyacrylamide 
gel.  
 
In a separate set of experiments microparticles were produced from PMNs and 
pelleted as will be subsequently highlighted and the supernatant collected. This 
supernatant was then concentrated 40x by loading on to the receiving part of a 
10kDa cut of concentration column (Millipore) and centrifugating for 45mins at 
13000xg. Subsequently, 8µl of lamelli buffer were added to 42µl of the 
concentrated sample this solution was boiled for 5mins loading and running on 
a polyacrylamide gel  
 
To determine the subcellular localization of Annexin A1 in PMNs derived from 
Wegner, and GCA patients along with healthy aged matched controls, 
membrane and cytoplasmic extracts were obtained using a protocol adapted 
from (Hilgenberg and Miles 1995). Cells were washed with ice cold PBS and 
100µl of Lysis Buffer (20mM Tris-HCL (pH7.5), and the following protease 
inhibitors: 10µM Leupeptin, 1µM Pepstatin A, 200µM Phenylmethyl-sulfonyl 
fluoride, 1mM Sodium Fluoride and 1mM β-glycerolphosphate) per 3x106 
PMNs and homogenized through a 25G needle 5 times. Homogenates were 
centrifuged at 300g for 2 min at 4°C to remove cell debris and the supernatants 
were transferred to a new eppendorf. These were centrifuged at 100, 000xg for 
45min at 4°C, and the new supernatants were collected as the cytosolic fraction. 
1% Triton X-100 was added to the lysis buffer and 100µl was added to the 
pellet, re-suspended and incubated on ice for 15min to obtain the membrane 
fraction.  
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In the quest to determine the affectivity of the Ac2-26 derived peptides, the 
HEK-FPR and FPRL1 cells were seeded in 12 well plates and grown to 90% 
confluency, following which 10µM of each of the five peptides, the parent 
peptide, W-peptide or DMSO was added to each well and the cells incubated in 
a humidified chamber at 37oC and 5% CO2 for 8 min. Subsequently, the 
supernatant was aspirated and the cells transferred to -80oC for 2 min. The plate 
was then taken out and then 100µl of lysis buffer containing the protease 
inhibitors described above was added following which, the cells were scraped 
off and transferred into eppendorfs where subsequently the protein content for 
each sample was determined using the BCA protein assay described in section 
2.5.2. 
 
Subsequently, a concentration range for Pep84 and Pep57 was prepared by 
diluting the original stock of each of these peptides 1:10 in DMSO for a final 
concentration range between 10µM and 0.1nM. The cells were incubated with 
various concentrations of these peptides and the proteins prepared for western 
blotting analysis as outlined above. 
  
Two types of buffer system can be used for protein electrophoresis, a 
continuous and a discontinuous system; the former uses only one buffer whereas 
the latter uses two buffers to make the gel. The discontinuous (Laemmli) buffer 
system, constructed of a low percentage (4%) stacking and a higher percentage 
(6-15%) resolving gel, allows proteins to concentrate prior to separation 
resulting in a far greater resolution. The percentage of the resolving gel depends 
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on the molecular weight of the protein of interest, the formulations of which are 
shown in Table 2.1.  The resolving and stacking gels were prepared by 
combining all reagents except for the polymerisation catalysts ammonium 
persulfate (APS) and TEMED, which were added immediately before pouring 
the gels. A gel cassette was assembled using a Bio-Rad casting frame, spacer 
plate and short plate, and was placed in a casting stand with pressure levers that 
seal the bottom of the cassette. 
 
 
Table 2-1: Formulations for SDS-PAGE resolving and stacking gels using 
National Diagnostic buffers. 
 
A 1.5mm spacer plate, and either a 10 or 15-well comb were used allowing a 
maximum of 66µl and 40µl of sample to be loaded respectively. The glass plate 
was marked 1cm below the teeth of the comb, the level to which the resolving 
gel was poured using a Pasteur pipette. This was overlaid with water and 
allowed to polymerise for 30min, after which the water was poured off and 
blotted with filter paper. The stacking gel was poured to the top of the short 
plate and the comb was carefully inserted to avoid bubbles forming. After 
polymerisation, the gel cassettes were placed into the electrode assembly, which 
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in turn was placed into the Mini Tank of the Hoefer Mini Blotting 
Electrophoresis System. Running buffer (25mM Tris base, 200mM glycine and 
0.1% SDS) was added to the inner chamber and approximately 200ml was 
added to the lower chamber of the tank. Combs were removed and samples as 
well as pre-stained protein markers (GE Healthcare) were added using gel 
loading tips. The lid was added and connected to a power supply, and the gel 
was run at 100 constant volts for approximately 90min until the dye front 
reached the bottom of the gel.   
 
Once electrophoresis was complete, gels were removed from between the 
plates, the stacking gel was discarded, and the resolving gel was placed in 
transfer buffer (25mM Tris base, 192mM glycine and 20% methanol). Protein 
was transferred onto Polyvinylidene Fluoride (PVDF) membrane (GE 
Healthcare) by wet transfer (Hoefer). A gel sandwich was made using 1 sheet of 
blotting paper, PVDF membrane, the gel and 1 sheet of blotting paper on top, all 
of which were first soaked in transfer buffer. The sample set was then placed in 
a transfer chamber filled with transfer buffer and was run at a constant voltage. 
For Annexin A1 and extracellular signal-regulated kinases (ERK) analysis, the 
transfer was conducted at a 110 constant volts for 90min, for other proteins. 
 
For western blotting, membranes were blocked overnight at 4°C on a plate 
rocker in either 5% non-fat dried milk solution (1g in 20ml) made up in Tris-
buffered saline (TBS) (150mM sodium chloride, 2mM Tris base, pH7.4) 
containing 0.1% Tween 20 (TBS-T). Membranes were then incubated for 1h at 
room temperature (RT) in TBS-T with the mouse monoclonal anti-Annexin A1 
 98 
Ab (clone 1B: 1:2,000 dilution, 10-µl in 20ml). Following three 5-min washes, 
with TBS-T, the membrane was incubated for 1h at RT with a horseradish 
peroxidase (HRP) conjugated goat anti-mouse IgG secondary Ab (1:2,000 
dilution) (DakoCytomation).  Membranes were washed three times for 5min and 
excess buffer drained prior to incubation with enhanced chemoluminescence 
(ECL) solution for protein detection. In principle, the HRP/ H2O2 oxidises the 
luminol within the ECL solution under alkaline conditions, resulting in an 
excited state, which then decays to its ground state by emitting light at a peak 
wavelength of 428nm that can be detected by autoradiography film. An equal 
volume of ECL solution 1 was mixed with ECL 2 according to the 
manufacturer’s instructions (Amersham Pharmacia Biotech), 4ml was poured 
onto each membrane and incubated for 90s at RT. Excess reagent was drained 
off and membranes were wrapped in SaranWrap, placed protein side up in an X-
ray film cassette, and transferred to the dark room. A sheet of Hyperfilm ECL 
(Amersham Pharmacia Biotech) was placed on top of the membrane, the 
cassette was closed and film was exposed for a minimum of 15s and up to 
15min in most instances. Films were placed in developer solution until bands 
were visible, rinsed with H2O, placed in fixer, rinsed again with H2O and left to 
dry.     
 
After determining presence of annexin A1 immunoreactivity in these samples, 
blots were stripped using 1mM glycene for 15 min and then thoroughly washed 
for 1 hour with TBS-T in order to ensure adequate removal of any glycene 
traces. Then the blot was incubated in the presence of an anti-β actin anti body 
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for 1hour at room temperature as outlined above. Then the anti-β actin content 
was determined as previously mentioned. 
  
In a separate set of experiments, where the ability to activate the Mitogen-
activated protein kinase (MAPK) pathway through either the FPRL1 or FPR 
receptors as a measure of activity for the Ac2-26 derived peptides was being 
assessed, the blot was blocked using a 3% BSA solution for 2h then probed first 
with an anti-phospho (p)-ERK, 1:2000 dilution in 3% BSA (clone: E10; Cell 
Signalling Technologies), overnight at 4oC. Subsequently the membrane was 
washed three times with TBS-T and incubated with a goat anti-mouse HRP 
conjugated anti-body for 1hour at room temperature, after which the p-ERK 
levels were assessed using ECL chemistry as outlined above. 
 
Following the determination of the p-ERK levels in each of these samples, the 
blot was stripped for 15mins with 1mM glycene following which the membrane 
was washed for 2 hours in T-BST. Subsequently the blot was then re-incubated 
for 1h with an anti-total ERK anti-body, 1:2000 dilution in 3% BSA (clone: 
137F5; Cell Signalling Technologies), which provided a positive control to the 
protein concentration loaded. The blot was the probed with an anti-rabbit 
 
2.6.2. BCA (Bicinchoninic acid) protein assay 
This assay is based on a colorimetric detection of protein reduction from Cu2+ to 
Cu+. Bicinchoninic acid is highly sensitive and specific for Cu+ and rapidly 
forms an intense purple colour complex.  
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A set of standards was prepared for each protein assay using a stock 
concentration of 2mg/ml BSA. Dilutions were made using the same diluent as 
the samples (lysis or sample buffer) ranging from 25-2000µg/ml (Table 2-2). 
10µl of each standard or unknown sample were pipetted in duplicate into a 96-
well plate. Working Reagent (WR) was prepared by mixing BCA Reagent A to 
B at a ratio of 50:1, and 200µl of WR was added to each well. The plate was 
incubated at 37°C for 30min and the absorbance was measured at 570nm on an 
optical plate reader. An average absorbance value of the blank standards was 
subtracted from all other absorbance measurements, a standard curve was 
plotted from each BSA standard versus its concentration, yielding a linear 
response curve (r2 > 0.95). This curve was used to interpolate the protein 
concentrations of the unknown samples. 
Table 2-2: Preparation of BSA standards for the BCA protein assay. 
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2.7. Description of novel Acetyl2-26 derived peptides. 
 The Acetyl 2-26 peptide is derived from peptides 2-26 of the n-terminal portion 
of Annexin A1, which has been acetylated on the n-terminal in order to increase 
its stability and thus its half-life (peptide sequence highlighted in Table 1.3). 
Modifications were made in the synthesis of this peptide with the aim to 
produce a more potent peptide with an extended half-life in vivo. This 
modification consisted of substituting amino acids 11 and 22 during the 
chemical synthesis process, by either two non charged amino acids labelled as 
α and ε corresponding to peptides 84 and 57. Two charged amino acids labelled 
as χ  and δ  corresponding to peptides 59 and 60 and an amino acid with a 
tertiary structure labelled as β corresponding to peptide 83. I cannot declare the 
real sequences of these novel peptides, as not provided by the Company that 
sponsored this work (Unigene Corp, Fairfield, New Jersey). These substitutions 
at the 3 dimensional level could possibly lead to the alterations of the peptide 
structure or otherwise depending on the charge and bulkiness of the amino acids 
being substituted. 
  
Table 2-3: Sequences, peptide contents and nomenclature for each of the novel 
ac2-26 derived peptides and the parent peptide. 
 
The peptides were received in a lyophilized form, following which they were 
reconstituted in DMSO at a concentration of 10mM. The volume of DMSO 
added to each individual vial was calculated taking into consideration the 
peptide content of each preparation in order to ensure a homogenous final 
Amino-Acid Sequence % pep content Reference 
   
acetyl-AMVSEFLKQAWFIENEEQEYVQTVK (CRB) 90.1 Ac2-26 CRB 
acetyl-AMVSEFLKQAWFIENEEQEYVQTVK (Uni) 83.1 Ac2-26 Uni 
acetyl-AMVSEFLKQαWFIENEEQEYαQTVK 88.1 Pep84 
acetyl-AMVSEFLKQβWFIENEEQEYβQTVK 86.1 Pep83 
acetyl-AMVSEFLKQχWFIENEEQEYχQTVK 50.7 Pep59 
acetyl-AMVSEFLKQδWFIENEEQEYδQTVK 64.8 Pep60 
acetyl-AMVSEFLKQεWFIENEEQEYεQTVK 73.3 Pep57 
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peptide concentration for each sequence. After reconstitution these peptide 
solution was aliquoted into 15µl volumes and stored at -80oC until required. 
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2.8. RadioLigand binding assay. 
The HEK-FPRL1 or HEK-FPR cells were grown in a T175 flask up to 
approximately 90% confluency in complete MEM as described in section 2.4.1. 
Upon reaching ~90% confluency, the cells were washed with PBS and then 
trypsinized using 3ml of 0.05% trypsin with EDTA for 5mins at 37oC. 
Subsequently, the flask was gently tapped to detach the cells and 10ml of 
complete MEM media was added to neutralize the trypsin.  The cell suspension 
was then transferred to a 15ml flacon from which a 100µl aliquot was taken for 
cell count, whilst the remaining cells were centrifuged at 400 x g for 5 min. The 
supernatant was then aspirated and the cells re-suspended in 1 ml of PBS 
containing Ca2+ and Mg2+. From this cell suspension 31x106 cells were taken, 
re-suspended at a concentration of 10x106 cells per ml in PBS containing Ca2+ 
and Mg2 and then placed on ice until needed, whereas the remaining cells were 
reseeded in a T175 flask.  
 
The tracer was prepared following manufacturer’s instructions, whereby it was 
re-suspended in 1ml of distilled water. The concentration was calculated using 
the specific activity (1507.17 Ci/mmol), quantity provided (10µCi) and the 
relative molecular mass of the peptide (856.11) and was determined to be of 
7ng/ml (82pM). With this information the following 1:10 serial dilutions were 
prepared from: 82pM down to 82fM. 
 
The cold peptide was also prepared by resuspension in distilled water to a final 
concentration of 1µM. Subsequently a 500µM working stock was prepared, this 
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was then employed to determine the extent of Non Specific Binding (NSB) buy 
the radio labelled tracer. 
 
Figure 2-6: Figure outlining the setup being employed for the binding assays (a) 
outlined the position of the G/FC filters employed to trap the cells along with any 
bound tracer (b) the setup as employed to wash off any unbound tracer. 
 
The first step in this protocol was to determine the optimal tracer concentration 
to be employed for the subsequent assays. The criteria employed to identify this 
concentration involved having a significant difference in the number of counts 
recorded on a gamma counter between the Total Binding (TB) and Non-Specific 
binding (NSB) group. In order to achieve this a concentration range of tracer 
was prepared which ranged from 82pM down to 82fM, whilst the concentration 
of cold peptide in the NSB group was maintained constant at 1µM.  
 
Following the preparation of the tracer dilutions the various experimental 
conditions (i.e. TB and NSB) were setup as follows in triplicate in 1.5ml 
eppendorfs: 
Total Binding (TB) - 800 µl PBS (with Ca2+ and Mg2+), 100 µl of one of the 
tracer dilutions previously prepared and 100 µl of the cell suspension 
a 
 
b 
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Non Specific Binding (NSB) - 700 µl PBS (with Ca2+ and Mg2+), 100 µl of one 
of the tracer dilutions previously prepared, 100ul of cold peptide at 1 µM (final 
concentration) and 100 µl of the cell suspension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7: Determining the optimal concentration of tracer to be employed in 
Radioligand Binding assay. Following the resuspension of the HEK-FPRL1 cells at a 
concentration of 1x106 cells were incubated with 10µM of cold peptide and various 
concentrations of tracer. The highest concentration of tracer is the one that shows a 
significant difference between Total and nonspecific binding (NSB). Data are mean ± 
SEM of 3 independent experiments. * = P<0.05 vs. CT group 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-8: Determining the optimal concentration of cold peptide to be 
employed in Radioligand Binding assay. Following the resuspension of the HEK-
FPRL1 cells at a concentration of 1x106 cells were incubated with 7pM of cold peptide 
and 10, 1 or 0.1µM of cold peptide. In this set of experiments the highest concentration 
of cold peptide was shown to be the most effective at displacing the tracer from the 
FPRL1 receptor. Data are mean ± SEM of 3 independent experiments * = P<0.05 vs. 
CT group. 
 
The reaction mixture was then incubated for 1 hour on ice after which it was 
transferred on to a vacuum filtration unit equipped with 25mm GF/C filter 
membranes on to which any cells and bound tracer would be retained. The 
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filters were then washed 3 times using 4ml aliquots of 10mM ice cold Tris-
HCL, to remove any unbound tracer (Figure 2-6). Following the wash step the 
filter paper was transferred into recipient tubes and the amount of bound tracer 
was determined using a γ−counter. This experiment was repeated 3 times in 
order to confirm the reproducibility of the results obtained.  
 
After identifying the optimal tracer concentration  (Figure 2.7), the next step 
was to determine the optimal cold peptide concentration that best displaces the 
tracer from its binding to the FPR and FPRL1. For this purpose 3 cold peptide 
dilutions were prepared at a final concentration of, 10µM, 1µM and 0.1µM 
(Figure 2.8). Then following the procedure outlined above and using the optimal 
tracer concentration previously determined of 82pM the optimal cold peptide 
concentration was determined; once again the experiment was repeated 3 times 
in order to ensure reproducibility of the results obtained. 
 
Subsequently, the binding affinities of Pep84 and Pep57 to both the FPRL1 and 
FPR receptors, using the HEK-FPRL1 and the HEK-FPR cell lines, were 
determined following the protocol outlined above and employing a dilution 
series ranging in concentration between 10µM and 0.1nM. Once again, 
experiments were repeated 3 times in order to ensure the reproducibility of the 
obtained results. 
 
 
 
 107 
2.9. Real-Time Reverse Transcription-PCR 
2.9.1. RNA extraction 
A number of RNA extraction protocols have been developed and in order to 
determine the optimal extraction method for my studies, I initially compared 
two of these techniques previously employed in the lab. The first technique 
employed a charged membrane that traps the RNA from the samples using 
electrostatic charges on the RNA molecule. This methodology allows for the 
purification of the RNA by sequential washes and then by reversing the charge 
of the solution and consequently of the RNA one can elute it off the membrane. 
The protocol followed was that supplied with the Quiagen RNA mini-kit. This 
RNA extraction protocol was then compared to a more classical phenol-
chloroform derived protocol whereby the sample is homogenised in a phenol-
guanidine isothiocyanaye containing solution, marketed under the name of 
TRIZOL®. Following the homogenisation step the RNA was extracted from the 
aqueous phase obtained upon centrifugation of the TRIZOL®-cell solution, 
following isopropanol was added to reversing the charge on the RNA molecules 
leading to the precipitation of the RNA. The RNA was pelleted by 
centrifugation and then washed in 75% ethanol in DEPC water (protocol 
outlined in further detail below). The resulting RNA was then assessed for 
integrity, purity and yield. The integrity was assessed by reverse transcribing the 
RNA using Oligo-dt, as described below, and the cDNA yield measured using a 
Nano-Drop spectrophotometer. The rationale behind this step was that the 
Oligo-dt binds to poly-A tails on the mRNA, which in turn is very susceptible to 
degradation. Thus by assessing the amount of cDNA produced a measure of the 
poly-A tail integrity and thus mRNA integrity is obtained. The purity and yield 
of the RNA were assessed using a Nano-Drop spectrophotometer; purity could 
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be assessed using the absorbance in 230, 260 and 280nm ranges. This is because 
the 230/260 ratio provides a measure of assessing the amount of phonetics 
present in the RNA solution whilst the 260/280 ratio provides a measure of 
protein contamination in the sample. Thus, after assessing all these parameters it 
was observed that the integrity and purity of for both protocol employed were 
comparable. However, the yield obtained using the TRIZOL® (Invitrogen) 
protocol was superior especially when extracting RNA from tissues. 
Furthermore, the cost per reaction was much less for this method over the 
Quigen kits, thus I decided to employ the TRIZOL® method for all the RNA 
extractions conducted during my PhD 
 
Using TRIZOL® reagent (Invitrogen) cells were rinsed with PBS and lysed 
directly by adding 1ml of reagent to every 5x106 cells, and pipetting several 
times to lyse the cells. At this point samples could be stored at -80°C until 
required. The homogenized samples were incubated for 5min at RT to allow 
complete dissociation of nucleoprotein complexes, and 0.2ml of chloroform (per 
ml of TRIZOL) was added. Tubes were shaken vigorously by hand for 15s, left 
at RT for 2-3min before centrifuging at 12,000xg for 15min at 4°C. This 
procedure separates the solution into a colourless aqueous phase containing the 
RNA, an interphase and a lower organic phase. The aqueous phase was 
transferred to a new tube and the RNA was precipitated with 0.5ml of isopropyl 
alcohol (per ml of TRIZOL). Samples were incubated for 10min at RT, 
centrifuged at 12,000xg for 10min at 4°C to pellet the RNA, supernatants 
carefully aspirated, and washed with 1ml of 75% ethanol (per ml of TRIZOL). 
Samples were vortexed, centrifuged at 7,500g for 5min at 4°C, supernatants 
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carefully aspirated and pellets briefly air-dried at 50°C. RNA was dissolved in 
20µl of RNase-free water, and stored at -20°C until further use.  
 
The first step when extracting RNA form the human cells using the RNeasy kits 
(Qiagen) was to pellet ~1x106 cells, by centrifuging for 5min at 300g, after 
which the supernatant was removed. The cell membranes were then disrupted 
by re-suspending the cell pellet in 350 µl RLT buffer. Subsequently, the cell 
pellet  was homogenised by passing the lysate 5 times thorough a blunt 20 
gauge needle fitted with an RNase free syringe. 350 µl of 70% ethanol were 
then added and the solution was mixed well. Following which the sample was 
transferred, including any precipitate that may have formed, to an RNeasy spin 
column placed in a 2 ml collection tube. The lid was then closed, and centrifuge 
for 15 s at 8000g. The flow-through was then discarded and 700 µl Buffer RW1 
was added to the RNeasy spin column once again the column was spun for 15 s 
at 8000g to wash the spin column membrane. The flow through was then 
discarded and the RNeasy spin column was then carefully removed from the 
collection tube so that the column does not contact the flow-through. 500 µl of 
the RPE Buffer were again added to the RNeasy spin column the lid gently 
closed, and the column centrifuge for 15 s at 8000g to wash the spin column 
membrane followed by another 500 µl Buffer RPE and 2 min at 8000g 
centrifugation to wash the spin column membrane. The longer centrifugation 
dries the spin column membrane, ensuring that no ethanol is carried over during 
RNA elution following which the RNeasy spin column was carefully removed 
ensuring that the membrane did not come in contact with the flow-through. This 
is due to that fact that residual ethanol may interfere with downstream reactions.  
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The RNeasy spin column was subsequently placed in a new 2 ml collection 
tube, the lid gently closed, and centrifuged at 13000g for 1 min. This step was 
performed in order to eliminate any possible carryover of Buffer RPE, or if 
residual flow-through remains on the outside of the RNeasy spin column. 
Subsequently the RNeasy spin column in a new 1.5 ml collection tube. 30–50 µl 
RNase-free water was then directly added to the spin column membrane that 
was then centrifuge for 1 min at 8000g to elute the RNA. The removal of any 
contaminating DNA was done following the protocol outlined above. 
 
2.9.2. Reverse Transcription 
The next step was to identify the optimal reverse transcription protocol for my 
investigation. Thus I conducted a literature review that pointed out that for this 
purpose the M-MLV H- RT enzyme would be the better choice since its 
complementary DNA (cDNA) synthesis rate is up to 40-fold greater than that of 
AMV. Furthermore, newly available theromostable RNAse H- RT maintains its 
activity up to 70oC, thus permitting increased specificity and efficiency of first 
primer annealing. Thus, due to its higher specificity and extensive used in the 
literature it was decided to employ this enzyme to produce my cDNA (Bustin, 
Benes et al. 2005). Subsequently I also evaluated the various options available 
for priming the reverse transcription reaction, primarily sequence specific 
primers, Oligo-dt and random hexameres. Target gene-specific primers work 
well in conjunction with elevated RT-reaction temperatures to eliminate 
spurious transcripts. The same reverse primer is used for subsequent PCR assay 
in conjunction with the corresponding gene-specific sense primer (forward 
primer). However, the use of gene specific primers limits the number of genes 
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that can be analysed per sample to the primer sets employed in the RT reaction. 
Furthermore it cannot be assumed that different reactions have the same cDNA 
synthesis efficiency, the result can be a high variability during multiple RT 
reactions.  
 
To circumvent the high inter-assay variations in RT, target gene unspecific 
primers e.g. random hexameres, ocatmeres or decameres can be used and a 
cDNA pool can be synthesized. Similarly poly-T oligonucleotides (Oligo-dt), 
consisting of 16-26 deoxythymidine residues can anneal to the polyadenylated 
3’ poly-A tail found in the large majority of mRNA. cDNA pools produced with 
unspecific primers can be split into a number of different target-specific kinetic 
PCR assays. This maximizes the number of genes that can be assayed from a 
single cDNA pool, derived from one small RNA sample (Bustin 2002; Bustin 
and Nolan 2004). Studies comparing these efficacy of the different priming 
methods have outlined that the best results were obtained with gene specific 
priming, with Oligo-dt priming ranking next and the random hexameres being 
the least efficient (Bustin, Benes et al. 2005).  
 
Since for my studies I did not want to restrict myself to a small number of 
genes, I decided to employ Oligo-dt as the primer of choice for the RT reaction. 
After deciding on the RT system to be employed, it was important to clean the 
RNA from any contaminating genomic DNA. This was achieved by incubating 
the extracted RNA solution with DNAse 1, where (20µl) RNA were treated with 
2U (1µl) of TURBO DNase 1 (Ambion, Austin, TX) and incubated for 30min at 
37°C to remove any contaminating genomic DNA. 4µl of DNase Inactivation 
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Reagent slurry (Ambion) was added, mixed thoroughly, and left at RT for 2min 
prior to centrifuging at 1250g for 2min. The RNA solution was then transferred 
to a new RNase-free tube. RNA was then ready for reverse transcription into 
cDNA using an Abgene thermal cycler. For each sample, 1µl of Oligo-dt (a 
poly-T strand annealing to the poly-A tails of the mRNA) 1µl 10mM dNTP 
Mix, and 11.8µl of RNA were first incubated at 65°C for 5min (to denature 
RNA secondary structure) and placed on ice for 2min (to allow primers to 
anneal). Tubes were then briefly centrifuged at 1250g for 30s and the other 
components for reverse transcription were added, including 4µl 5X first-strand 
buffer, 1µl 0.1M DTT, 1µl RNaseOUT (a recombinant RNase inhibitor), and 
1µl of Superscript™ III Reverse Transcriptase (200U/µl) (Invitrogen). Samples 
were gently mixed and incubated at 55°C for 1h (for cDNA extension) and then 
heated at 70°C for 15min to inactivate the enzyme and hence the reaction. 
 
2.9.3. cDNA Quantification 
cDNA was then quantified using a Nanodrop ND-1000 Spectrophotometer. 
With the sampling arm open, 1µl of sample was pipetted onto the lower 
measurement pedestal, the sampling arm was closed and spectral measurement 
made using the operating software on the PC; for cDNA quantification, the 
nucleic acid option was selected. When the measurement was complete, the 
sampling arm was opened and wiped gently from both the upper and lower 
pedestals using a soft tissue. The next sample was then measured and procedure 
repeated. The 260/280 ratio of the sample absorbance was used to assess the 
purity of the sample, a ratio of approximately 1.8 is generally accepted as ‘pure’ 
for DNA and a ratio of 2 generally accepted as pure for RNA. If the ratio is 
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lower, this indicates that protein/phenol or other contaminants are present that 
absorb near 280nm. The concentration of cDNA was measured in ng/µl from 
the absorbance at 260nm. cDNA was diluted to 40ng/µl in new tubes using 
molecular biology H20, ready for loading into 384-well plates for Real-Time 
PCR.   
 
2.9.4. Real-Time PCR 
The next step was to determine what type of detection chemistry I was to 
employ in my analysis, since this also influenced the primer design. Two 
general methods for the quantitative detection of the amplicon have become 
established: gene specific fluorescent probes or specific double strand (ds) DNA 
binding agents based on fluorescent energy transfer (FRET). The best-known 
probe based system is the ABI’s TaqMan, which makes use of the 5’-3’ 
exonuclease activity of Taq polymerase to quantitative target sequences in the 
samples. Probe hydrolysis separates fluorophore and quencher and results in an 
increased fluorescence signal referred to as ‘Foerster type energy transfer’. The 
alternative is a non-sequence specific fluorescent intercalating dsDNA binding 
dye such as SYBR Green 1 or POWER SYBR Green. For single PCR product 
reactions with well-designed primers, the SYBR Green chemistry has been 
shown to work extremely well, with spurious non-specific background only 
showing up in very late cycles. For my studied I decided to employ an 
intercalating dye: Power SYBR green. The SYBR Green reporter system 
consists of an asymmetrical cyanine dye, which binds to double-stranded DNA. 
The resulting DNA-dye-complex absorbs blue light (λmax = 488 nm) and emits 
green light (λmax = 522 nm). This decision was taken following reports in the 
literature where comparisons between labelled probes and SYBR green showed 
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that the two chemistries did produced similar outcomes when it came to 
dynamic range, sensitivity and selectivity of the signal produced as long as the 
primers employed for detection were selective and sensitive. Furthermore, 
SYBR Green detection was more precise and produced a more linear decay plot 
than the TaqMan probe detection. 
 
Subsequently it was important to identify a primer set of each gene under 
investigation: GAPDH, 18s, FPRL1 and Annexin A1, which also show an 
elevated sensitivity. The process for primer design involved first of all 
identifying a region for amplification, preferably one that is intron-spanning, 
since this would help in reducing interference by any genomic DNA that is 
found in the sample. Furthermore, each primer pair needs to have similar 
annealing temperature preferably close to 60oC since this will significantly 
reduce mismatch aligning and also the primer pair should not anneal against 
itself, thus producing primer-dimers. For this a number of online software 
programs were employed to identify potential primer pairs, amongst which 
BioEdit, Primer 3 (www.frodo.wi.mit.edi) and Biosearch Technology Primer 
design (biosearchtech.com)  
 
After choosing the primer sequences that satisfied the aforementioned criteria 
the next step was to determine which of the primer sets were sensitive enough to 
detect difference in cDNA copy numbers. This was done by preparing an 
efficiency plot that consisted of a 1:2 cDNA dilution series ranging from 
80ng/µl down to 0.3ng/µl. The efficiency of each primer pair was then 
calculated by plotting the cycle threshold (CT) (Figure 2.7) value for each of the 
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cDNA concentrations employed. The efficiency value was then obtained from 
the equation of the resulting slope where a value ranging between 1.8 and 2 
shows that the prime pair displays acceptable sensitivity to changes in cDNA 
copy number. 
Figure 2-9: Figure outlining a typical expression profile for a real tine PCR 
reaction. 
 
After several attempts I only succeeded in obtaining two primer sets with 
efficiency values falling between 1.8 and 2, those for GAPDH (Figure 2.8) and 
those for FPRL1 genes. Thus, I then conducted a literature search, which 
resulted in identifying a new primer source. This was the Qiagen Quantitec 
Primer Assay® system that consisted of pre-validated primer pairs which can 
also be used with the SYBR green detection system. For each of the genes 
mentioned above, upon purchasing each of these primer pairs I proceeded to 
validate them in my system by conducting an efficiency analysis, confirming 
that each of the primer sets was able to detect varying cDNA concentrations. 
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Figure 2-10: Figure outlining the efficiency plot obtained for the GAPDH gene. 
Representative of 3 distinct experiments. 
 
Thus after identifying the primer sequences to be employed in my study and 
producing cDNA from each of the patient and control sample under 
investigation I tested the relative levels of Annexin A1 and FPRL1 levels in 
these samples using the aforementioned Qiagen Quantitec Primer Assay®. The 
PCR reaction for determining the efficiency values for each of the primer pairs 
and subsequently for the detection of the relative gene expressions in the patient 
and control samples was performed using ABI Prism® 7900 Real Time PCR 
equipment. A mastermix was made for each gene specific primer, containing 
1µl primer, 5µl 2X POWER SYBR Green (ABi biosciences) and 2µl H2O; a 
final volume of 8µl was dispensed in each well and 2µl of diluted cDNA 
(100ng/µl) was added. Each sample was tested in triplicate for each of the four 
genes. The thermal profile consisted of 50°C for 2min, 95°C for 15min, then 40 
cycles of 94°C for 15s, 55°C for 30s and 72°C for 30s. Following which a 
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dissociation step was added, in order to determine if the PCR reaction was 
specific to the genes under investigation, with the following thermal profile: 
95°C for 15s, 60°C for 15s and 95°C for 15s. SYBR Green binds to newly 
synthesized double-stranded DNA, emitting fluorescence in direct proportion to 
the number of amplicons generated. A threshold line of fluorescence detected 
above background was set in the exponential phase of amplification, and the 
cycle number at which the samples reached this level was referred to as the 
cycle threshold value (CT), thus reflecting the relative abundance of the specific 
mRNA transcripts. The comparison between samples was performed using 
GAPDH and 18s ribosomal subunit as internal standards. REST MCS software 
was utilized for the calculation of the relative difference between the test 
groups. This software uses a mathematical model that is based on PCR 
efficiencies and the mean crossing point deviation between the sample and 
control group. Subsequently, the expression ratio results of the four investigated 
transcripts are tested for significance by a randomization test (Pfaffl, Horgan et 
al. 2002). 
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2.10. Isolation of Microparticles. 
2.10.1. From Purified Neutrophils 
To determine the functional role of microparticles in the inflammatory response 
these were isolated from both human and murine PMNs. Whereby after 
isolation of the PMNs from both species the cells were counted and re-
suspended at a concentration of 5x106 cells per ml (Gasser and Schifferli 2004). 
These were then incubated at 37oC for 20 min over an endothelial cell 
monolayer. In the case of the human PMNs the endothelial monolayer was a 
HUVEC monolayer, whilst the murine cells were preincubated over an 
endothelial monolayer isolated from WT lungs as described in section 2.13.1. 
The cells were then stimulated using fMLP, which aids in a specific priming of 
the PMNs, the concentrations employed varied between the human and the 
murine cells due to the varying sensitivity of the FPRL1 or its murine 
homologue to this ligand. In fact 1µM of fMLP was employed for the human 
cells and 10µM for the murine cells, in both cases the cells were incubated for a 
further 20 min at 37oC. Another difference in the murine experiments was that 
in this case microparticles were produced from both WT and Annexin A1 -/- 
mice, separately. Following the stimulation, the cells were centrifuged at 2000g 
for 10 min to remove any cells and debris and then the supernatant was 
centrifuged at 100,000g for 1 hr to obtain a microparticles pellet. Subsequently 
the resultant supernatant was removed and the pelleted microparticles were 
washed and re-suspended in PBS. 
 
In a separate set of experiments microparticles obtained for human PMNs 
without a pre-incubation over a HUVEC monolayer. In this case PMNs were 
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stimulated with µM fMLP for 20 min without preincubation with a HUVEC 
monolayer. After incubation with 1µM fMLP for 20 min at 37oC the cells were 
centrifuged at 2000g for 10 min and the microparticles isolated as detailed 
above. 
 
Microparticles were also generated by stimulating PMN in suspension with 
either fMLP (1µM), LXA4 (1nM) or AF2 (10µM) for 20 min at 37oC in RPMI. 
Following which the PMNs were removed and the microparticles extracted as 
outlined above. Furthermore in order to determine if there is an altered release 
of Annexin A1 in Wegner granulomatosis PMNs, the cells from these patients 
and aged matched healthy controls were extracted (as outlined in section 2.2) 
and stimulated for 20 min with 1µM of fMLP. The microparticles then extracted 
as outlined above and both the supernatant and microparticles were blotted for 
their Annexin A1 content as outlined above. 
 
2.10.2. From whole blood 
In order to determine the clinical relevance of Annexin A1 and FPRL1 positive 
microparticles in rheumatic diseases, blood was obtained from patients suffering 
from RA, GCA MPO and PR3 ANCA +ve patients along with healthy 
volunteers; this was done using the gradient centrifugation method outlined in 
section 2.2. In this protocol after layering the diluted whole blood over the 
double density Ficoll and centrifugation the plasma fraction was extracted. This 
was then spun at 4000g for 5 min to remove any contaminating platelets, 
aliquoted and stored at -80oC until required for the analysis of microparticle 
Annexin A1 and FPRL1 levels as described in section 2.4.2.  
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In a separate set of experiments blood was obtained from patients recruited to 
participate in a study to determined the efficacy of a 14 day prednisolone 
treatment on disease outcome in Rheumatoid arthritis in collaboration with Dr 
Stefen Kelly, Rheumatology Clinic, Mile End. In this case blood was take on 
days 0 (i.e. pre steroid treatment), 1, 7 and 14. The processed as previously 
described above. 
 
2.11. In-gel Digestion and LC/MS/MS analysis 
PMN microparticles were produced as outlined in section 2.5, after which 
~5x104 MP were loaded on to an 8% SDS gel run as described in section 2.5 
along with an Annexin A1 positive control. After the gel was run, this was cut 
in two and the proteins found on one half of the gel were transferred on to a 
PVDF membrane and probed against Annexin A1 as outlined in section 2.5. On 
the other hand the second half of the gel was stained using Coomassie Blue dye 
(containing 0.2% Coomassie Blue, 7.5% Acetic Acid and 50% Ethanol) for 1 
hour at room temperature and then the excess dye was removed by incubating 
the gel in destaining solution over night at room temperature on a plate rocker. 
Following which the band corresponding to the Annexin A1 band (at ~37kDa) 
was excised.  
 
The excised band was cut into small cubes using a scalpel blade; this was done 
in order to facilitate the further processing of the sample. In-gel reduction, 
alkylation and digestion with trypsin were then performed prior to subsequent 
analysis by mass spectrometry. Cysteine residues were reduced with DTT and 
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derivatized by treatment with iodoacetamide to form stable carbamidomethyl 
(CAM) derivatives.  Trypsin digestion was carried out overnight at room 
temperature after an initial 1hr incubation at 37oC.  
 
Peptides were extracted from the gel pieces by a series of acetonitrile and 
ammonium bicarbonate washes.  The extract was pooled and lyophilised.  Each 
sample was then re-suspended in 50mM ammonium bicarbonate and analysed 
by LC-MS/MS.  Chromatographic separations were performed using CapLC 
system (Waters corporation, UK).  Peptides were resolved by reversed phase 
chromatography on a 75 µm C18 PepMap column. A gradient of acetonitrile in 
0.05% formic acid was delivered to elute the peptides at a flow rate of 200 
nl/min. Peptides were ionised by electrospray ionisation using a Z-spray source 
fitted to a QTof-micro (Waters corporation, UK). The instrument was set to run 
in automated switching mode, selecting precursor ions based on their intensity, 
for sequencing by collision-induced fragmentation. The MS/MS analyses were 
conducted using collision energy profiles that were chosen based on the m/z and 
the charge state of the peptide. 
 
The mass spectral data was processed into peak lists (MS/MS data) and 
searched against the Swiss Prot and NCBI non-redundant database using 
Mascot software (Matrix Science, UK). Carbamidomethyl(C) and oxidation (M) 
were set as variable modifications within the searching parameters. A high level 
of confidence can be assigned to these protein identities because the results are 
based on exact matching of MS/MS data for multiple peptides from each 
protein. Identifications with a score of 30 or above were considered significant 
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2.12. Assessment of Reactive Oxygen Species (ROS) production 
by microparticles. 
Neutrophil derived microparticles were produced from healthy volunteers by 
stimulation of these cells with fMLP in the presence or absence of an 
endothelial monoloayer as detailed in section 2.10. These were then re-
suspended in HBSS counted (as outlined in section 2.10) and ~1x104 
microparticles were loaded into a 96 well plate in a total volume of 150µl HBSS 
containing 15mM of Lucigenin. The plate was then incubated at 37oC in the 
thermostable chamber of the luminometer (Wallac VICTOR2 1420 Multilabel 
Counter, Perkin Elmer Life Science, Boston, MA, USA) and allowed to 
stabilize for 15 min. 
 
After a baseline reading was established, cells were stimulated with 1µM fMLP 
or 16µM PMA. Changes in chemoluminescence were measured over a 30 min 
period.  Three separate experiments with triplicates for each test compound 
were performed. Microparticle generated superoxide was recorded as counts per 
sec (CPS). 
 
2′,7′-Dichlorofluorescin diacetate (DCFDA; Sigma) was also employed to 
determine ROS production by these microparticle populations. In this case the 
microparticles were co-incubated with 5 µM of DCFDA for 50mins at 37oC, 
they were washed and then re-suspended in PBC. Following which the 
microparticle ROS production was determined following PMA (16µM) 
stimulation in the FL1 channel of the flow-cytometer.  
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2.13. Animal experiments 
The Annexin A1 -/- mice were bread in house on a homogenous Balb/c 
background, whilst their age and sex-matched wild type (WT) controls were 
purchased from B&K Universal. Animals used for all experiments were fed 
laboratory chow and water ad libitum and were housed 6 to a cage under 
specific pathogen-free conditions. All experiments were performed with male 
animals (body weight ~ 22-25g) strictly following Home Office regulations 
(Guidance on the Operation of Animals, Scientific Procedures Act 1986).  
 
2.13.1. Murine Lung Endothelial Cell (MLEC) isolation.  
Primary mouse endothelial cells were isolated from the lungs of wild-type (WT) 
Bulb/c mice (Reynolds, Reynolds et al. 2004). Lungs were excised and kept in 
Ham’s F-12 media (Gibco, UK) on ice until isolation. Lungs were briefly rinsed 
in 70% ethanol, transferred to a Petri dish and chopped into small pieces using a 
scalpel blade. Tissue was digested with 1mg/ml collagenase type I-S (Gibco, 
UK) in PBS for 2h at 37°C. The digest was taken up in a syringe, passed 
through a 19-gauge needle 5 times and sieved through a 70µm-pore size cell 
strainer (BD Falcon, Bedford, MA). The cell suspension was then centrifuged at 
300g for 5min and re-suspended in 10ml of complete media (50:50 mix of 
Ham’s F-12:DMEM medium supplemented with 20% FCS, 20 µg/ml 
endothelial cell mitogen Biogenesis, Poole), 1µg/ml heparin, penicillin (100U) 
and streptomycin (100mg/ml)). All culture flasks/dishes were coated for 30min 
with 0.1% gelatine and 10µg/ml fibronectin in PBS prior to cell seeding. Cells 
were plated in a T75 flask and incubated in a humidified chamber in 5% CO2 at 
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37°C. After 24h, cells were washed 5 times with PBS to remove unbound cells 
and cultured for 2-4 days before purifying.  
 
Endothelial cells were purified by positive selection from contaminating 
fibroblasts using magnetic Dynabeads (Dynal Biotech, UK). The principal of 
this procedure is outlined in Figure 2-9 Cell culture media was removed from 
the flask and replaced with cold complete media and cells were put in the fridge 
for 20min. Media was then aspirated and cells were incubated with 3µg/ml of 
the primary Ab; rat anti-mouse CD102 (clone 3C4 (mIC2/4); BD Pharmingen) 
in PBS for 30min at 4°C. The PBS/Ab mix was removed, cells were rinsed once 
with PBS and then incubated with 10µl (approximately 4x106) sheep anti-rat 
IgG magnetic dynabeads in 3ml of PBS for 5min at 4°C. 
 
Flasks were rinsed 3 times with PBS to remove unbound beads, and then cells 
were detached using 1x trypsin (Sigma). Detached cells were transferred to a 
pre-coated T25 flask and positive cells were selected by placing the flask on a 
flat magnet and leaving for 5min. Contaminating cells were removed by 
aspiration, being careful not to disturb bead-bound cells. Flasks were rinsed and 
placed back on the magnet for 5min for two more rinse steps until only positive 
cells remained. 5ml of complete media was then added and cultures were grown 
to confluence. At least two positive sorts for ICAM-2–positive endothelial cells 
were performed before using in subsequent experiments in order to ensure a 
high purity endothelial culture. 
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Figure 2-11: Endothelial cell positive selection using magnetic Dynabeads. 
 
 
2.13.2. Bone Marrow Neutrophil Extraction and Purification 
Mice were killed by CO2 asphyxiation before each animal was sterilized by 
immersion in 70% ethanol. The femur of each leg was exposed and removed 
without crushing the bone. Briefly, this involved pulling back the skin from the 
ankle and then removing the muscle with fine pointed scissors. The lower art of 
the leg was then removed by cutting at the knee joint in order to facilitate easier 
access to the hip joint. The femur was removed with the ball joint intact, 
allowing both ends of the bone to the gently cut to expose the marrow without 
crushing the bone itself. Using a 2ml syringe with a 25 gauge needle attached, 
HBSS was flushed through both ends of the bone to remove the marrow. 
Complete removal was determined when the bone became translucent. The 
process was repeated for both femurs. The cells were then centrifuged at 500g 
for 7 minutes at 4oC before being re-suspended in PBS + 0.25% BSA for 
purification. Neutrophils were purified by a discontinuous Percoll gradient 
using the following protocol: 75% (7ml) of a 90% isotonic Percoll solution 
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diluted with PBS was gently overlaid with a 65% Percoll layer (7ml). A 55% 
(7ml) solution was then overlaid in a similar manner on to the 65% layer. The 
cell suspension (3ml) was then carefully overlaid onto the 55% layer. The 
gradient was subsequently centrifuged at 1500g for 30 minutes at 4oC. The cells 
at the cell/55% interface and the 55%/65% interface were removed to minimize 
contamination of the neutrophil layer at the interface between the 65%/75% 
layers (Figure 2-10). These cells were carefully removed, washed and 
differentially counted as previously described in section 2.2. The resultant yield 
was approximately 3.5x106-5x106 per mouse. Following the purification step, 
microparticles were produced from both the WT and Annexin A1 -/- mice as 
previously described in section 2.10. 
 
Figure 2-12: Neutrophil isolation from mouse bone marrow cells using a Percoll 
gradient. 
 
 
 
2.13.3. AirPouch Model of Inflammation 
Male Balb/c mice (24 to 26 g; B&K, Essex, UK) were used for all the following 
experiments. Dorsal subcutaneous (S.C.) air-pouches were prepared by injection 
of 2.5 ml of air on day 0 and day 3. Six days after the initial injection of air, 
mice received 10 ng of mouse IL-1β diluted in a volume of 500 µl of 0.5% 
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CMC (BDH, Dorset, UK) in PBS directly into the pouch. Control mice received 
the vehicle only. Four hours after IL-1 β administration mice were killed by 
exposure to CO2 and the pouches washed thoroughly with 2 ml of PBS 
containing 50 U/ml heparin. Total and differential leukocyte counts were 
performed after staining in Turk's solution (crystal violet 0.01 % in 3% acetic 
acid) by counting in an improved Neubauer haemocytometer and stained with 
Gr1 (clone rb6-8c5; eBioscience, Wembley, UK), by co-incubation of the cell 
suspension with the antibody for 30 min on ice following a 30 min blocking 
step with rat serum (Sigma, Poole, UK) and FC block (BD Pharmingen).After 
which the antigen expression was assessed on a FACSCalibur as previously 
outlined in section 2.4 and from which the number of PMN recovered from the 
pouch was then calculated. 
 
The effect of microparticles and specifically Annexin A1 as an inhibitor and/or 
antagonists in an inflammatory setting was assessed in two ways. First of all 
microparticles derived from human neutrophils were injected intra-veneously 
(i.v.) 10mins prior to IL1β  injection at the following 2 doses: 40x103 and 
90x103; more over hr-Annexin A1 was injected at 20ng per mouse as a positive 
control. Subsequently microparticles previously produced from the WT and 
Annexin A1 -/- mice, as outlined in section 2.10, were injected i.v. 10mins prior 
to IL1β injection at the following 2 doses: 40x103 and 70x103. 
 
In a distinct set of experiments after the airpouches were setup the mice were 
injected  i.v. 10mins prior to IL1β  injection with 50ng of Pep57, Pep59, Pep84 
(sequences illustrated in Table 1.3) or vehicle. After 4h blood was collected 
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from each group by cardiac puncture following which the cells migrated into the 
airpouch were recovered as outlined above. Blood cell counts were conducted 
by diluting the blood 1:10 in Turks solution; whilst the cell counts and Gr1 
staining on cells migrated into the airpouch were conducted as previously 
described in the section 2.4. 
 
2.14. Statistical Analysis 
Statistical Analysis was conducted using GraphPad Prism 4 computer software. 
Values are expressed as mean ± standard error of mean (SEM) of n experiments. 
Homogeneity of variances was first tested by Bartlett’s test to ensure that 
statistical comparison between groups would be valid. For parametric data when 
only two variables were being tested statistical differences were analysed by the 
Student’s t-test. When comparing multiple groups statistical significance was 
assessed using a one-way analysis of variance (ANOVA) analysis followed by a 
Dunnett’s post hoc test, with a P value ≤ 0.05 considered as significant.  In the 
case of densitometry data, values were either normalized against total protein 
loaded, against alpha tubulin or total ERK 1/2 and statistical analysis was 
performed using the Mann-Whitney U test for non-parametric data, P value ≤ 
0.05 were considered as significant. 
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3. Results 
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3.1. The Annexin A1 system and Rheumatic disease, is there a 
link? 
The cause of most types of rheumatic diseases remains unknown and, in many 
cases, it may vary depending on the type of rheumatic disease. However, it is 
believed that some if not all of the following factors may play a role in the 
development or aggravation of one or more types of rheumatic diseases: genetic 
predisposition and family history; lifestyle choices; trauma; infection; 
neurogenic disturbances; metabolic disturbances; excessive wear and tear along 
with stress on a joint(s); environmental trigger and the influence of certain 
hormones on the body. Increasing evidence is highlighting the role of auto-
antibodies in the propagation of at least a subset of rheumatic diseases where 
there can either reflect organ-specific or generalized autoreactivity. 
 
3.1.1. Role of the Annexin A1 system in Wegener’s Vasculitis. 
Endogenous anti-inflammatory mediators form a complex network triggered in 
the host to dampen cell activation and promote resolution of inflammation. 
Recent data points to the fact that a number of serine proteases expressed on 
human neutrophils (one such being proteinase 3; PR3), which has also been 
linked with Wegener granulomatosis) have the ability to cleave Annexin A1 and 
thus potentially render it inactive. Thus, we hypothesized that alterations in the 
Annexin A1 pathway in the vasculitis patients’ neutrophils could be, at least in 
part, responsible for the onset and development of this condition; either as a 
result of an enhanced cleavage of the Annexin A1 protein or in response to their 
activated phenotype (e.g. frustrated up-regulation). 
 
 131 
In collaboration with Prof B. Dasupta and Ms J Hollywood, Wegener 
granulomatosis patients were stratified in view of their plasma expression of 
anti-MPO or anti-PR3 ANCA. Blood was collected from age and sex matched 
healthy volunteers and Wegener patients between 9 and 10 AM, and processed 
within 2 hours. Gradient-purified neutrophils (PMN) were stained with specific 
monoclonal antibodies to monitor expression of Annexin A1, FPRL1 or FPR, as 
previously described in the methods, section 2.4. Annexin A1 levels in the 
neutrophil cytoplasm and plasma membranes were also gauged by western 
blotting; furthermore Annexin A1 and FPRL1 mRNA levels were analyzed by 
Real Time PCR in all patient sample groups. Subsequently, PMN reactivity was 
assessed by flowing the neutrophils over monolayers of human umbilical vein 
endothelial cells (HUVEC) for 8 min at 37°C, using 1 dyne/cm2 of shear. In 
some cases, human recombinant (hr) Annexin A1 (10 nM) was incubated with 
the neutrophils for 10 min prior to flow. 
 
Results obtained from the analysis of the flow-cytometric data points to a 
significant increase in blood neutrophil surface expression of Annexin A1 in the 
Wegner (both MPO and PR3 +ve) and GCA patients, with values of 8%, and 
13% increase in the number of Annexin A1 positive PMN, respectively (Figure 
3.1).  
 
A similar profile was observed for the expression of the Annexin A1 receptor, 
FPRL1, such that there was a significant increase in cell surface expression of 
this receptor on neutrophils from Wegener’s (MPO +ve: +16%; and PR3 +ve: 
+34) when compared to the healthy controls (Figure 3.3). Cell surface analysis 
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of the FPR family prototype receptor illustrated a significant increase in number 
of FPR +ve cells only in the PR3+ ANCA patients where there was an increased 
blood cell positivity of 21% (Figure 3.2). Finally, FACS analysis revealed an 
elevated PR3 membrane expression for both disease groups (Figure 3.4). 
 
Interestingly, in the Wegener patients there is also a possible difference in the 
mechanism by which the Annexin A1 protein is incorporated into the cell 
membrane as evidenced by the data generated following the washing of PMNs 
from these patients and healthy volunteers in an EDTA solution. In fact here we 
observed that this procedure was only able remove the Annexin A1 in the cells 
derived from healthy volunteers whilst the Annexin A1 levels were left 
unaltered or even enhanced in the Wegener patients. The increase in Annexin 
A1 levels following the EDTA wash in the MPO+ve ANCA patients is possibly 
due to the externalization of Annexin A1 found on the inner side of the plasma 
membrane as a result of the wash process cause by a reshuffling of the 
membrane components and thus the extrnalization of the Annexin A1 protein. 
This observation in conjunction with that made for the PMNs derived from PR3 
+ve patients in figure 3.1 would suggest that although in these two patient 
groups there is a deregulation in the Annexin A1 transport to the cell membrane 
the actual localisation and thus possibly the mechanism leading to this might be 
dissimilar. 
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Table 3-1: Table outlining the demographic parameters for the subjects 
employed for this study including treatment regimes. 
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Figure 3-1: Annexin A1 expression on control (CT) and Wegener granulomatosis 
patients pre and post EDTA wash. PMNs isolated form CT and Wegener patients’ 
whole blood were either washed twice with 1mM EDTA and stained or directly stained 
using an immunofluoroscent anti-Annexin A1 antibody, by incubation for 45 min at 4oC. 
The results in panel both panels (a) and (b) show that there is a statistically significant 
increase in Annexin A1 expression on both MPO ANCA and PR3 ANCA patients 
especially post EDTA wash. Data are mean ± SEM of 5 patients for the MPO ANCA 
group, 8 for the PR3 ANCA group and 12 for the CT group. *+ P<0.05 vs. CT group + 
P<0.05 vs. CT EDTA group * P<0.05 vs. untreated group.  
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Figure 3-2:  FPR expression on control (CT) and Wegener granulomatosis 
patients. PMNs isolated form Wegener patients’ whole blood were stained using an 
immunofluoroscent anti-FPR antibody, by incubation for 45 min at 4oC. These results 
show that there is a marked although not statistically significant decrease in FPR 
expression on MPO ANCA patients. On the other hand, there was a statistically 
significant increase in receptor expression on PR3 ANCA patients. This result is both 
reflected in the MFI values (a) and the % positive cells (b). Data are mean ± SEM of 5 
patients for the MPO ANCA group, 8 for the PR3 ANCA group and 12 for the CT group.  
* P<0.05 vs. CT group 
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Figure 3-3: FPRL1 expression on control (CT) and Wegener granulomatosis 
patients. PMNs isolated form Wegener patients’ whole blood were stained using an 
immunofluoroscent anti-FPRL1 antibody, by incubation for 45 min at 4oC. The results in 
panel (a) show that there is a marked although not statistically decrease in FPRL1 
expression on MPO ANCA patients whist on the other hand there was a statistically 
significant increase of the receptor on PR3 ANCA patients. On the other hand the 
although the results in panel (b) show that there was an increase FPRL1 receptor in the 
PR3 ANCA patients concordant with those in panel (a) the results for the MPO ANCA 
patients show that there is a statistically significant increase in the receptor as opposed 
to the trend observed in panel (a) Data are mean ± SEM of 5 patients for the MPO 
ANCA group, 8 for the PR3 ANCA group and 12 for the CT group. * P<0.05 vs. CT 
group 
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Figure 3-4: Membrane PR3 expression on control (CT) and Wegener 
granulomatosis patients. PMNs isolated form Wegener patients’ whole blood were 
stained using an immunofluoroscent anti-PR3 ANCA antibody, by incubation for 45 min 
at 4oC. The results in panel both panels (a) and (b) show that there is a statistically 
significant increase in PR3 expression on both MPO ANCA and PR3 ANCA patients, 
Data are mean ± SEM of 5 patients for the MPO ANCA group, 8 for the PR3 ANCA 
group and 12 for the CT group. * P<0.05 vs. CT group 
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The western blotting analysis highlights that whilst Annexin A1 levels in the 
cytoplasm of neutrophils derived from all the three groups of vasculitis patients 
was not significantly different from those seen in the healthy volunteers, the 
membrane pool of Annexin A1 was significantly higher (Figure 3.6). This 
observation corroborates the results obtained in the flow cytometric analysis 
described above. Even more interesting is the fact that the majority of this 
membrane pool is in fact found in the cleaved 33 kDa form (Figure 3.6a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: Membrane expression of Annexin A1 in PMNs from CT and 
Wegener vasculitis patients. PMNs were extracted from whole blood, after which 
the cells were lysed and the membrane fraction was separated by centrifugation 
and resuspension of the pellet in 1% TritonX. The membrane fraction was then 
blotted for the expression of Annexin A1 and densitometry was conducting 
comparing the Annexin A1 expression to β-actin. (a) representative blot of 3 
different patients per group. (b) densitometry of 8 individual samples per group. * 
P<0.05 vs. CT group. 
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Figure 3-6: Cytosolic expression of Annexin A1 in PMNs from CT and Wegener 
vasculitis patients. PMNs were extracted from whole blood, after which the cells were 
lysed and the membrane fraction was centrifuged the supernatant collected in a 
separate tube, yielding the cytosol fraction. This fraction was then blotted for the 
expression of Annexin A1 and densitometry was conducting comparing the Annexin A1 
expression to b-actin. (a) representative blot of 3 separate patients per group. (b) 
β-actin blot (c) densitometry of 8 individual samples per group. * P<0.05 vs. CT group. 
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Following the protein expression analysis we wanted to investigate if there was 
also an alteration at the genomic level of the Annexin A1 system. Real Time 
PCR analysis of mRNA extracted from the three vasculitis groups showed that 
there is no significant difference between the Annexin A1 levels in the Wegener 
groups and those found in healthy volunteers (Figure 3.8). On the other hand 
there was 1.5 and 6 fold increase in the FPRL1 mRNA for the MPO +ve ANCA 
patients over the healthy volunteers (Figure 3.49). Interestingly, the Wegener 
patients did not show altered mRNA levels when compared to the healthy 
volunteers (Figure 3.9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7: mRNA expression of Annexin A1 in Wegener granulomatosis patients 
versus CT in PMNs. mRNA was extracted from PMNs of CT and Wegener patients 
and then reverse transcribed, following reverse transcription the expression levels were 
analysed. The results show that there is no significant change in Annexin A1 
expression in both groups of Wegener granulomatosis. Results displayed as a 
representative blot of 6 different patients per group * P<0.05 vs. CT group. 
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Figure 3-8: mRNA expression of FPRL1 in Wegener granulomatosis patients 
versus CT in PMNs. mRNA was extracted from PMNs of CT and Wegener patients 
and then reverse transcribed, following reverse transcription the expression levels were 
analysed. The results showing that there is a slight but significant elevation in FPRL1 
mRNA levels in the MPO ANCA patients however no such elevation was observed in 
the PR3 ANCA patients. Results displayed as a representative blot of 6 different 
patients per group *P<0.05 vs. CT group. 
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After determining the antigen expression levels on these cells, I determined 
their level of reactivity by measuring the levels of interaction to an activated 
HUVEC monolayer in the flow chamber model. This analysis revealed that 
neutrophils derived from vasculitis patients were more reactive then control 
cells. More in particular, there was a higher number of cells firmly adhering to 
the endothelial monolayers. Wegener granulomatosis patients showed nearly a 
2.5 fold increase in the number of adherent neutrophils (Figure 3.10). 
Interestingly, there was no real difference in the number of rolling cells 
highlighting the possibility that the defect in this disease only effects one part of 
the leukocyte recruitment cascade. Even more striking was the observation that 
cell incubation with hr-Annexin A1 corrected this phenotype, bringing values of 
cell adhesion back to those measured with cells from the healthy controls 
(Figure 3.10). 
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Figure 3-9: Effect of Wegener Vasculitis on activation of PMN’s under flow, and 
the reversal of this effect through the administration of hr-Annexin A1. Confluent 
HUVEC monolayers were stimulated with TNF-a (10ng/ml) for 4 hours. Neutrophils 
isolated from CT patients and Wegener patients were incubated for 10 minutes at 37oC 
with or without 10nM hr-Annexin A1. Neutrophils (1x106/ml) were then perfused over 
the endothelial monolayers at a constant rate of 1 dyn/cm2, prior to quantifying the 
degree of PMN interaction with the HUVECs, both as PMN capture (a), adhesion (b) 
and rolling (c). The results depicted Results are plotted as mean + standard error of 3 
distinct experiments.  
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3.1.2. Role of Annexin A1 in Giant Cell Arteritis. 
Giant Cell Arteritis (GCA) is an inflammatory vascular disease, most commonly 
of the large (external carotid arteries) and medium arteries of the head; most 
common in the elderly. This can result in a wide variety of complications, 
including jaw pain, blurred vision, scalp sensitivity and headaches. Interestingly 
this disease is very responsive to glucocorticoid treatment alone, as opposed to 
Wegener granulomatosis, and thus we set out to explore where the basis of this 
difference in response could lie, by taking a close look the Annexin A1 system 
in these patients. 
 
The flow cytometric data showed that there was an elevated expression of all 
members of the Annexin A1 system on the GCA PMN when compared to the 
same cells from age matched healthy volunteers. In fact, there is an elevated 
expression of the FPR receptor in the disease state as shown by an elevated MFI 
value (Figure 3.11a), along with a trend to an elevated number of FPR positive 
cells (Figure 3.11b), which however did not reach statistical significance.  
 
An elevation in the Annexin A1 receptor, FPRL1 was also observed both in the 
quantity per cell, as observed through the increase in the MFI units (Figure 
3.12a), and in the number of cells expressing the receptor (Figure 3.12b). A 
similar result was also obtained for the Annexin A1 expression, where there was 
an approximate 3-fold increase in the MFI values (Figure 3.13a); the percent 
positive cells was also approximately a 3 fold increase in the GCA patients 
when compared to healthy volunteers (CT) (Figure 3.13a).  
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Interestingly an elevated PR3 expression was also observed in the GCA PMNs 
as detailed in Figure 3.14a and b, where we see a significant increase in both 
MFI and percent positive cells.  
 
 
 
 
Table 3-2: Table outlining the demographic parameters for the subjects 
employed for this study including treatment regimes.  
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Figure 3-10:  FPR expression on control (CT) and GCA patients. PMNs isolated 
form GCA patients’ whole blood were stained using an immunofluoroscent anti-FPR 
antibody, by incubation for 45 min at 4oC. These results show that there is a marked 
increase in FPR expression on GCA PMNs. This result is reflected in the MFI values 
(a) but not the % positive cells (b). Data are mean ± SEM of 8 patients for the GCA 
group and 12 for the CT group.  * P<0.05 vs. CT group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11:  FPRL1 expression on control (CT) and GCA patients. PMNs isolated 
form GCA patients’ whole blood were stained using an immunofluoroscent anti-FPRL1 
antibody, by incubation for 45 min at 4oC. These results show that there is a marked 
increase in FPRL1 expression on GCA PMNs. This result is both reflected in the MFI 
values (a) and the % positive cells (b). Data are mean ± SEM of 8 patients for the GCA 
group and 12 for the CT group.  * P<0.05 vs. CT group 
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Figure 3-12:  Annexin A1 expression on control (CT) and GCA patients. PMNs 
isolated form GCA patients’ whole blood were stained using an immunofluoroscent 
anti-Annexin A1 antibody, by incubation for 45 min at 4oC. These results show that 
there is a marked increase in Annexin A1 expression on GCA PMNs. This result is both 
reflected in the MFI values (a) and the % positive cells (b). Data are mean ± SEM of 8 
patients for the GCA group and 12 for the CT group.  * P<0.05 vs. CT group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13:  PR3 expression on control (CT) and GCA patients. PMNs isolated 
form GCA patients’ whole blood were stained using an immunofluoroscent anti-PR3 
antibody, by incubation for 45 min at 4oC. These results show that there is a marked 
increase in PR3 expression on GCA PMNs. This result is both reflected in the MFI 
values (a) and the % positive cells (b). Data are mean ± SEM of 8 patients for the GCA 
group and 12 for the CT group.  * P<0.05 vs. CT group 
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The western blotting analysis highlights that whilst Annexin A1 levels in the 
cytoplasm of neutrophils derived from both the healthy volunteers and GCA 
patients were not significantly different from those seen in the healthy 
volunteers (Figure 3.17), the membrane pool of Annexin A1 was significantly 
higher (Figure 3.16). This observation corroborates the results obtained in the 
flow cytometric analysis described above. Similarly to the analyses conducted 
with PMN taken from Wegener’s patients, the majority of this membrane pool 
is in fact found in the cleaved 33 kDa form (Figure 3.16). 
 
 
 
 
 
Figure 3-14: Membrane expression of Annexin A1 in PMNs from CT and GCA 
patients. PMNs were extracted from whole blood, after which the cells were lysed and 
the membrane fraction was separated by centrifugation and resuspension of the pellet 
in 1% TritonX. The membrane fraction was then blotted for the expression of Annexin 
A1 and densitometry was conducting comparing the Annexin A1 expression to β-actin. 
(a) representative blot of 3 different patients per group. (b) densitometry of 8 individual 
samples per group. * P<0.05 vs. CT group. 
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Figure 3-15: Cytosolic expression of Annexin A1 in PMNs from CT and GCA 
patients. PMNs were extracted from whole blood, after which the cells were lysed and 
the membrane fraction was centrifuged the supernatant collected in a separate tube, 
yielding the cytosol fraction. This fraction was then blotted for the expression of 
Annexin A1 and densitometry was conducting comparing the Annexin A1 expression to 
β-actin. (a) representative blot of 3 separate patients per group. (b) β-actin blot (c) 
densitometry of 8 individual samples per group. * P<0.05 vs. CT group. 
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Following the protein expression analysis I wanted to determine if the 
alterations observed above at the protein level for the Annexin A1 system were 
also present at the at the genomic level. Real-Time PCR analysis of mRNA 
extracted from PMN of the healthy volunteers and GCA patients groups showed 
remarkable changes, with a 10-fold increase in Annexin A1 mRNA (Figure 
3.18), over the control group whilst there was a 6-fold increase in the FPRL1 
mRNA (Figure 3.19). 
 
 
Figure 3-16: mRNA expression of Annexin 
A1 in GCA patients versus CT in PMNs. 
mRNA was extracted from PMNs of CT and 
Wegener patients and then reverse transcribed, 
following reverse transcription the expression 
levels were analysed. The results show that 
there is a significant upregulation of Annexin A1 
mRNA expression for the patients studies 
Results displayed as a representative blot of 6 
different patients per group * P<0.05 vs. CT 
group. 
 
 
 
 
Figure 3-17: mRNA expression of FPRL1 in 
GCA patients versus CT in PMNs. mRNA was 
extracted from PMNs of CT and Wegener 
patients and then reverse transcribed, following 
reverse transcription the expression levels were 
analysed. The results showing that there is a 
slight but significant elevation in FPRL1 mRNA 
levels in the GCA patients. Results displayed as 
a representative blot of 6 different patients per 
group *P<0.05 vs. CT group. 
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After determining the status of the Annexin A1 system at both the protein and 
the genomic level in GCA PMNs, the next step was to ascertain the level of 
reactivity that these cells posses in an in vitro system of leukocyte adhesion, the 
flow chamber model. In this model cells are flowed and a shear stress of 1 
dyne/cm2 over an activated HUVEC monolayer for 8 min prior to recording and 
then offline analysis of the leukocyte interaction, primarily capture-total cells, 
adherent and rolling cells to the endothelial monolayer. 
 
This analysis highlighted a higher level of reactivity of the PMN isolated from 
the GCA patients when compared to healthy volunteers. In fact, there is an 
increased number of cells captured over the endothelial monolayer which is 
mainly the result of an increased number of adherent cells, approximately 3 fold 
more (Figure 3.20) Interestingly, there was no real difference in the number of 
rolling cells highlighting the possibility that the defect in this disease affects one 
elements of the leukocyte recruitment cascade selectively. Further supporting 
the notion that there is a de-regulation in the Annexin A1 axis in these patients 
was the observation that upon incubation of the PMNs, both CT and those 
obtained from the GCA patients, with hr-Annexin A1 there was a striking 
reduction in the number of cells interacting with the endothelium, bringing the 
numbers of the GCA-derived cells down to those observed in the CT conditions 
(Figure 3.20) 
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Figure 3-18: Effect of GCA on PMN activation under flow, and the reversal of this 
effect through the administration of hr-Annexin A1 (Annexin A1). Confluent 
HUVEC monolayers were stimulated with TNF-a (10ng/ml) for 4 hours. Neutrophils 
isolated from CT patients and Wegener patients were incubated for 10 minutes at 37oC 
with or without 10nM hr-Annexin A1. Neutrophils (1x106/ml) were then perfused over 
the endothelial monolayers at a constant rate of 1 dyn/cm2, prior to quantifying the 
degree of PMN interaction with the HUVECs, both as PMN capture (a), adhesion (b) 
and rolling (c). The results depicted Results are plotted as mean + standard error of 3 
distinct experiments.  
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3.1.3. Understanding the influence of an acute glucocorticoid treatment on 
the Annexin  A1 system in patients with Rheumatoid Arthritis. 
 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that 
may affect many tissues and organs, but principally attacks the joints producing 
a inflammatory synovitis that often progresses to destruction of the articular 
cartilage and ankylosis of the joints (van den Berg, van Lent et al. 2007). RA 
can also produce diffuse inflammation in the lungs, pericardium, pleura, and 
sclera, and also nodular lesions, most common in subcutaneous tissue under the 
skin (Brent 2009). Although the cause of rheumatoid arthritis has been very 
pinpoint however the pivotal role played by the immune system in the onset and 
propagation of the disease is beyond discussion.  
 
About 1% of the world's population is afflicted by rheumatoid arthritis, women 
three times more often than men. Onset is most frequent in 40 to 50 years, but 
no age is immune. It can be a disabling and painful condition, which can lead to 
substantial loss of functioning and mobility. It is diagnosed chiefly on 
symptoms and signs, but also with blood tests (the gold standard being 
rheumatoid factor) and X-rays. 
 
Currently there is no cure for this disease thus the goal of treatment is mainly 
alleviation of the current symptoms, and prevention of future destruction of the 
joints, with the resulting handicap if the disease is left unchecked. These two 
goals may not always coincide: while pain relievers may achieve the first goal, 
they do not have any impact on the long-term consequences. For these reasons, 
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most authorities believe that RA should be treated by at least one specific anti-
rheumatic medication, also named Disease modifying anti-rheumatic drugs 
(DMARD), to which other medications and non-medical interventions can be 
added as needed. 
 
Glucocorticoid therapy has offered relief in the past, but its long-term effects, 
amongst which osteoporosis, have been deemed undesirable. However, 
cortisone injections can be valuable adjuncts to a long-term treatment plan, and 
using low dosages of daily glucocorticoid (e.g., prednisone or prednisolone, 5-
7.5 mg daily) can also have an important benefit if added to a proper specific 
anti-rheumatic treatment (Strand and Simon 2003). 
 
In my experiments I used blood samples taken from patients between 9 and 11 
am, on days 0 (i.e. prior to initiation of a daily dose of 15mg of prednisolone 
oraly), 1, 7 and 14. The blood was immediately processed and PMNs and 
PBMCs were isolated and stained using a number of immunofluoroscent 
antibodies. The purpose of the study was to determine the effects of an acute 
glucocorticoid therapy on the disease progression by monitoring cellular 
markers of activation and also to determine the effect of this therapy the on 
expression of elements of the Annexin A1 system during this treatment regime.  
 
The initial sets of data comparing the PMN (Figure 3.21) and monocyte (Figure 
3.22) populations in the blood versus the synovial fluid, which were identified 
in view of their scatter profile (i.e. on their physical properties such as 
granularity and size) as outlined in Figure 3.20 below, at day 0 prior to 
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glucocorticoid treatment, point to the fact that both subsets of cells display a 
more activated phenotype in the synovial compartments. Interestingly I could 
see a difference in the expression of the various members of the Annexin A1 
system between the two compartments: Annexin A1 was elevated in both 
cellular subsets, whilst FPR was only elevated for the monocyte group. 
Furthermore, even though not reaching statistical significance there is also a 
trend towards an elevated FPRL1 expression in the synovial over the blood 
compartment.  
 
 
 
Table 3-3: Table outlining the demographic parameters for the subjects 
employed for this study including treatment regimes.  
 
 
 
 
 
Figure 3-19: Representative 
dot plot of human blood 
leukocytes as employed for 
monitoring of antigen 
expression during this study. 
Granulocytes (purple), 
lymphocytes (green) and 
monocytes (light blue) are gated 
according to size and 
granularity.  
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Figure 3-20: Flow cytometric analysis of blood and synovial PMNs CD11b derived 
from Rheumatoid Arthritis (RA) patients prior to steroid treatment. PMNs isolated 
form RA patients’ whole blood and from synovial fluid following which they were stained 
using an immunofluoroscent antibodies by incubation for 45 min at 4oC. These results 
show that there is a marked decrease in CD62L expression in the synovial PMNs (a). 
There is also a decreased number of CD11b and CD62L expressing PMNs in the 
synovial fluid. (b). * P<0.05 vs. Blood PMN group (n=7 patients) 
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Figure 3-21: Flow cytometric analysis of blood and synovial Monocytes CD11b 
derived from Rheumatoid Arthritis (RA) patients prior to steroid treatment. 
Monocytes isolated form RA patients’ whole blood and from synovial fluid following 
which they were stained using an immunofluoroscent antibodies by incubation for 45 
min at 4oC. These results show that there is a marked decrease in CD11b expression 
in the synovial Monocytes (a). There is also an increased number of FPR and Annexin 
A1 expressing cells in the synovial fluid (b). * P<0.05 vs. Blood Monocyte group (n=7 
patients) 
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After comparing the difference in basal antigen expression between the synovial 
and blood compartment for the RA patients, the next step was to determine the 
effect of the treatment on the propagation of the disease and the potential 
associated changes the in Annexin A1 system.  
 
The results show that the 14-day treatment led to an increase in the number of 
cells circulating in the blood, a process of leukocytosis, which has been 
previously described in other studies looking at the effect of glucocorticoud 
administration in vivo (Figure 3.23) (Dale, Fauci et al. 1975; Fauci and Dale 
1975). Interestingly, although there was an increase in the circulating cell counts 
the flow cytometric analysis showed a reduction in CD11b expression on both 
cell types which was observed to return back to basal levels, this observation 
was also mirrored by the number of CD11b expressing cells, in both cell types 
after the 14 day treatment (Figure 3.24). Similarly a decrease in CD62L 
expression after the glucocorticoid treatment was measured, where both the 
CD62L expression per cell and the number of CD62L positive cells was 
decreased after the first day of treatment, this suggesting a deactivation of both 
cell types following glucocorticoid treatment and thus a possible shift of these 
cells to a more quiescent phenotype (Figure 3.25). 
 
Interestingly, in both cell types FPR expression is elevated, so that there is a 
significant increase in both abundance of the protein per cell and in the number 
of FPR positive cells (Figure 3.26). This increase is observed at the very 
beginning of the treatment and the returns back to basal levels towards the end 
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of the study, suggesting that any potential role that regulation of this receptor 
afforded by the treatment might only be important during the initial stages.  
 
Equally to FPR, FPRL1 cell surface expression is also de-regulated in both cell 
types, where we see both an increase in abundance of the receptor per cell and 
also an increase in the number of cells expressing the receptor in the PMN 
population, an upregulation that becomes more pronounced by day 14. On the 
other hand the abundance of the receptor per cell for the monocyte group seems 
only to increase after day 14, however similar to the PMNs there is an increase 
in the number of cells expressing the receptor from day 1 post treatment (Figure 
3.27).  
 
These observations might help provide an insight into the activity of insight into 
the activity of the glucocorticoids in reducing inflammation. Especially when 
one also looks at the Annexin A1 expression on these cells, where we see an 
increase in Annexin A1 levels on the surface of PMNs and monocytes as early 
as 1 day post treatment (Figure 3.28) which subsequently is reduced, showing 
that glucocorticoids have only a transient effect in the upregulation of surface 
Annexin A1 expression on these cells, at least in this condition. However, this 
transient increase could lead to the observed elevation in the FPRL1 levels 
previously described very most likely through an autologous feedback 
mechanism previously described by our lab. 
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Figure 3-22:  White blood profile during a 14-day steroid treatment. Results are 
Mean and SEM of n=7 patients. 
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Figure 3-23:  CD11b expression on monocytes and PMNs derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. Monocytes 
and PMNs isolated form RA patients’ blood were stained using an immunofluoroscent 
anti-CD11b antibody, by incubation for 45 min at 4oC. Results are Mean and SEM of 
n=7 patients;  * P<0.05 vs. Day 0 group, One way ANOVA. 
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Figure 3-24:  CD62L expression on monocytes and PMNs derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. Monocytes 
and PMNs isolated form RA patients’ blood were stained using an immunofluoroscent 
anti-CD62L antibody, by incubation for 45 min at 4oC. Results are Mean and SEM of 
n=7 patients;  * P<0.05 vs. Day 0 group, One way ANOVA. 
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Figure 3-25:  FPR expression on monocytes and PMNs derived from Rheumatoid 
Arthritis (RA) patients during a 14-day steroid treatment. Monocytes and PMNs 
isolated form RA patients’ whole blood were stained using an immunofluoroscent anti-
FPR antibody, by incubation for 45 min at 4oC. Results are Mean and SEM of n=7 
patients;  * P<0.05 vs. Day 0 group, One way ANOVA. 
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Figure 3-26:  FPRL1 expression on monocytes and PMNs derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. Monocytes 
and PMNs isolated form RA patients’ whole blood were stained using an 
immunofluoroscent anti-FPRL1 antibody, by incubation for 45 min at 4oC. Results are 
Mean and SEM of n=7 patients;  * P<0.05 vs. Day 0 group, One way ANOVA 
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Figure 3-27:  Annexin A1 expression in on monocytes and PMNs derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. Monocytes 
and PMNs isolated form RA patients’ whole blood were stained using an 
immunofluoroscent anti-Annexin A1 antibody, by incubation for 45 min at 4oC. Results 
are Mean and SEM of n=7 patients;  * P<0.05 vs. Day 0 group, One way ANOVA. 
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3.2. Annexin A1 in microparticles and its potential role as 
biomarker.  
3.2.1. Exploring a novel mechanism for Annexin A1 release 
3.2.1.1. Extraction and determination of Annexin A1 presence 
in PMN-derived microparticles 
In order to fulfil the aim of this part of the project, it was important to establish 
a microparticle extraction technique along with a method to determine the 
production of microparticles. After extraction using a pre-establish technique 
detailed in the Methods section, the forward and side scatter parameters of the 
flow cytometer were set using 1 µM beads, once the instrument was calibrated 
the microparticle containing solution was analysed using the flow cytometer 
(Figure 3-29).  
 
This initial determination was only based on the forward and side scatter 
parameters, therefore size and granularity, along with comparison to the 
calibration beads. Using these parameters it was established that the population 
under analysis had similar characteristics to those published for neutrphil 
microparticles. In order to confirm whether this population was in fact 
composed of microparticles, staining was performed where first these 
microparticles were co-incubated with Annexin V, to detect phosphatidylserine 
(PS) serine exposed on the outer surface of these microstructures (Figure 3-
30a). This marker is employed since in the process of microparticle production, 
phosphatidylserine is exposed on the outer surface of the cell membrane 
following membrane flip-flop. Furthermore, so as to establish the cellular origin 
of these microparticles, immunohistochemical staining for CD62L, a PMN 
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specific antigen, was conducted the result of which confirmed these structures 
to be neutrophil derived (Figure 3-30b). 
 
 
 
Figure 3-28: Determining the presence of 
Microparticles following instrument 
calibration. Following the calibration by 
1µm beads (in red) microparticles (M.P.) 
were flowed through the flow cytometer to 
confirm their presence based on their 
physical properties, since the literature 
defines these entities as having a size 
ranging between 1.5µm and 0.2µm. 
 
 
 
 
 
 
 
Figure 3-29: FACS analysis on microparticles derived from adherent PMN. Flow 
cytometry analysis of adherent PMN (to HUVEC monolayers)-derived microparticles, 
with acquisition of 5-10,000 events per sample. a) Histograms demonstrating detection 
of Phosphatidylserine L-selectin b) CD62L Data are representative from ≥3 
independent microparticle preparations.  
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After confirming that the microstructures isolated from the PMN supernatant 
were in fact PMN derived microparticles it was now important to establish the 
presence of Annexin A1 in these microparticles. For this purpose PMN 
microparticles were isolated and immediately lysed in lysis buffer following 
which they were loaded on to a 10% polyacrylimide gel, after electrophoresis 
and transfer the blot was probed against Annexin A1 which showed the 
presence for the first time of this protein in PMN derived microparticles (Figure 
3-31). This result was then confirmed using another analytic tool, mass 
spectrometry, where the 37kDa band corresponding to the Annexin A1 band 
was excised from the polyacrylamide gel previously stained with Coomassie 
blue and analysed as highlighted in the previous section (Figure 3.32). Once the 
peptide sequences identified from this band were analysed the presence of 
Annexin A1 was confirmed.  
 
After confirming the presence of Annexin A1 in these microstructures I wanted 
to determine if this protein was located on the extracellular surface of these 
structures. For this purpose, I employed flow cytometric analysis, staining 
microparticles with both anti-CD62L (as a positive control) and anti-Annexin 
A1 antibodies (Figure 3.33 b and c). The result of this analysis showed that 
Annexin A1 is present on the outer surface of microparticles and is expressed on 
their surface. Thus all three experimental methods confirmed the presence of 
Annexin A1 on PMN derived microparticles, all, or at least a significant pool, 
being on their membrane. Furthermore, I observed that membrane Annexin A1 
bound in a calcium dependent manner, since upon washing the microparticles 
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with a 1µM EDTA solution removed over 95% of the Anneixn A1 found a the 
surface of these microstructures as verified through the flowcytometric analysis 
depicted in Figure 3.36. 
 
In order to determine if there were any contaminating microparticles derived 
from other cell sources, PMN-derived microparticles were also stained with anti 
P-selectin and anti CD14, to identify platelet and monocyte sources, 
respectively Figure 3.34 (b and c).  
 
An important control, for this part of my study, was to stain microparticles 
obtained from non-stimulated PMN. Firstly, it was interesting to note that even 
in this very mild, or null, culturing condition, I could find microparticles; these 
could be identified by CD62L and phosphatidylserine expression (Figure 3-35 b 
and c). Of interest, these microparticles were not immuno-reactive for the anti- 
Annexin A1 antibody (Figure 3-35 d). 
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Figure 3-30: Western Blot showing the presence of 
Annexin A1 in PMN derived microparticles. Following 
microparticle extraction, western blot analysis was conducted 
comparing human recombinant Annexin A1 (0.1 ng) to extracts 
from ~60x103 microparticles. Following gel electrophoresis and 
transfer the blot was probed with an anti-Annexin A1 antibody, 
showing the presence of Annexin A1 in the microparticles 
(arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31: LC/MS/MS analysis of the 37kDa immunoreactive band. Following gel 
electrophoresis the gel was Coomassie stained and the 37kDa immunoreactive band 
was excised and digested. The resulting peptides were analysed against the SwissProt 
database and Annexin A1 resulted as the most abundant protein in this band. 
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Figure 3-32: FACS analysis on microparticles derived from adherent PMN. Flow 
cytometry analysis of adherent PMN (to HUVEC monolayers)-derived microparticles, 
with acquisition of 5-10,000 events per sample. A) Dot-plot showing the heterogeneity 
in microparticle sizes (a); Histograms demonstrating detection of L-selectin (CD62L) 
(b), Annexin A1 (c) Data are representative from ≥3 independent microparticle 
preparations.  
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Figure 3-33: FACS analysis on microparticles derived from adherent PMN. Flow 
cytometry analysis of adherent PMN (to HUVEC monolayers)-derived microparticles, 
with acquisition of 5-10,000 events per sample. A) Dot-plot showing the heterogeneity 
in microparticle sizes (a); Histograms demonstrating detection of P-selectin (CD62P) 
(b), CD14 (c) Data are representative from ≥3 independent microparticle preparations.  
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Figure 3-34: Staining for microparticles derived from unstimulated PMNs. 
Following extraction the microparticles were stained by incubation with for 30 minutes 
at room temperature with FITC conjugated Annexin V and an immunofluoroscent anti-
CD62L antibody. The positive shift when compared to the isotype control for both 
CD62L (b) and phosphatidylserine (c) confirms the presence of PMN derived 
microparticles, whilst figure (d) outlines the absence of Annexin A1 in this microparticle 
population  
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Figure 3-35: Flow-cytometric analysis of Annexin A1 +ve M.P following EDTA 
wash. Following the ultracentrifugation step, microparticles (M.P.) were either washed 
with 1mM EDTA or just PBC, following this wash step, these M.P. were ultracentrifuged 
resuspended in PBC and incubated with either an anti-Annexin A1 ab or an isotype 
control. The figure (a) represents the PBC washed M.P. whilst figure (b) the M.P. 
washed with the EDTA following which the M.P. Annexin A1 expression Annexin A1 
expression was quantified by flow-cytometry, table (c) is a summary of the MFI values 
obtained in 3 independent microparticle preparations, with results expressed as mean 
and SEM. 
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3.2.2. The in vitro anti-inflammatory role on Annexin A1 in PMN derived 
microparticles   
 
After showing presence of Annexin A1 in PMN derived microparticles, the next 
step was to determine if they might be of any biological relevance. Since hr-
Annexin A1 is known to elicit inhibitory and anti-adhesion effects, I tested these 
microparticles in an adhesion assay. This was done by co-incubating 
microparticles with recipient PMNs for 10 min and then flowing the mixture of 
cells and microvesicles over an activated HUVEC monolayer. These results 
showed that in fact Annexin A1 +ve microparticles do possess anti-
inflammatory properties since whether pre-incubated with the HUVECs or with 
the PMN, the number of cells recruited to the endothelium was significantly 
reduced. In particular, incubation of these microstructures with PMN reduced 
significantly both their extent of rolling and adhesion (Figure 3-37). 
 
To elucidate the role of Annexin A1 on the observed inhibition of leukocyte 
recruitment underflow, neutrilising monoclonal antibodies against either the 
Annexin A1 protein or its receptor were employed, applying them in the 
microparticle/PMN incubation phase. The results show that by blocking either 
component of the Annexin A1 pathway, the anti-inflammatory effects exerted 
by these microparticles was reverted, with values of cell recruitment returning 
to control levels (Figure 3-40). Interestingly incubation of the 
microparticles/PMNs with either neutrilising antibody was only able to reverse 
part of the recruitment cascade, that is adhesion. In fact these microparticles 
were still observed to inhibit PMN rolling over the activated endothelial 
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monolayer suggesting that an alternative pathway might be at least in part also 
responsible for the observed reduction in the number of rolloing cells.  
 
I finally wanted to determine whether the mode of production of these 
microparticles was important in the conferring the observed anti-inflammatory 
properties to these structure and whether there were other components on these 
microparticle which could also confer anti-inflammatory properties. The results 
point out that only microparticles produced by co-incubating PMNs over a 
HUVEC monolayer possessed inhibitory properties, whereas microparticles 
harvested from un-stimulated PMN were without any evident effect. As the 
latter type of microparticles are Annexin A1 –ve, these results strongly suggest 
that presence of Annexin A1 on these microparticles is responsible for some of 
the observed effects (Figure 3-42).   
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Figure 3-36: Characterization of PMN derived M.P. prior to use in flow chamber. 
M.P. were stained with an anti-Annexin A1 (a) and anti-CD62L (b) both of which 
confirmed the presence of PMN derived Annexin A1 positive microparticles. The table 
(c) provides a summary of the MFI values obtained in 3 independent microparticle 
preparations, with results expressed as mean and SEM 
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Figure 3-37: Annexin A1 rich microparticles inhibit PMN/HUVEC interaction under 
flow. PMN were incubated with microparticles, microparticles + anti-FPRL1 neutralizing 
antibody, Microparticles + anti-Annexin A1 or microparticles + Isotype CT prior to flow 
over TNF-α stimulated  (10 ng/ml, 4 h) HUVEC. PMN-endothelium interactions were 
quantified off-line. (a) Number of PMN captured. (b) Number of firmly adherent PMN. 
(c) Number of rolling PMN. Data are presented as mean ± SEM of 4 independent 
experiments. * = P<0.05 vs. control group, One way ANOVA. 
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Figure 3-38: Characterization of PMN derived M.P. prior to use in flow chamber. 
M.P. were stained with an anti-Annexin A1 (a) and anti-CD62L (b) both of which 
confirmed the presence of PMN derived Annexin A1 positive microparticles. The table 
(c) provides a summary of the MFI values obtained in 3 independent microparticle 
preparations, with results expressed as mean and SEM. 
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Figure 3-39: Role for Annexin A1 in the inhibitory property of PMN-derived 
microparticles. PMNs (5x106) were incubated with microparticles (between 30 and 
50x103) for 10 min at 37°C.  In some tubes, isotype control Ab, or neutralizing anti-
Annexin A1 or anti-ALX mAb were also added. PMN (5x106) were then flowed for 8 min 
at 1 dyne/cm2, prior to quantifying the degree of PMN interaction with the HUVECs, 
both as PMN capture (a), rolling (b) and adhesion (c). Data are mean ± SEM of from 4 
to 5 independent experiments (with distinct microparticles, PMN and HUVEC 
preparations); P<0.05 vs. microparticles treated group, data analysed using One way 
ANOVA 
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Figure 3-40: Characterization of PMN derived M.P. prior to use in flow chamber. 
M.P. from resting and adherent PMN were stained with an anti-Annexin A1 and anti-
CD62L the latter confirmed the presence of PMN derive M.P. (b, and d), whilst the 
former stain showed that Annexin A1 was only found on the M.P. derived from 
adherent PMNs (c) with the M.P. derived from resting PMN showing no shift in the 
staining (a). The table (e) provides a summary of the MFI values obtained from in 3 
independent microparticle preparations, with results expressed as mean and SEM. 
 
 
 182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-41: Confirming that only microparticle from fMLP stimulated PMN 
possess inhibitory properties. PMNs (5x106) were incubated with M.P. (between 30 
and 50x103) for 10 min at 37°C.  In some tubes PMNs were incubated with 
microparticles obtained from non-stimulated PMN that had been incubated for 20mins 
at 37oC or with microparticles obtained from fMLP stimulated PMN. PMN (5x106) were 
then flowed for 8 min at 1 dyne/cm2, prior to quantifying the degree of PMN interaction 
with the HUVECs, both as PMN capture (a), adhesion (b) and rolling (c). Data are 
mean ± SEM of from 5 independent experiments (with distinct M.P PMN and HUVEC 
preparations); P<0.05 vs. M.P. treated group, data analysed using one way ANOVA. 
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3.2.3. The in vivo anti-inflammatory role on Annexin A1 in PMN derived 
microparticles 
A way to extend the inhibitory actions of PMN derived microparticles in the 
flow camber assay was to determine if this observation would also hold true in 
an in vivo setting. I set out to determine this by testing these microparticles into 
a pre-clinical model of PMN recruitment, the mouse air-pouch model. 
 
I injected two doses of microparticles which resulted in a decreased in GR1+ve 
cell recruitment to the site of inflammation (Figure 3-43). Therefore, the anti-
inflammatory actions reported in vitro are also translatable to the in vivo 
scenario. However, this observation does not conclusively determine the role 
that Annexin A1 might be playing in these conditions. In order to address this 
question, neutrophils were extracted from murine bone marrows of both WT 
and Annexin A1 -/- animals following which the microparticles were produced 
by co-incubation of these cells over a mouse endothelial layer and stimulation 
with fMLP. Following production and extraction, microparticles were stained 
with Annexin V and anti-CD62L in order to confirm the presence and origin 
(Figure 3-44). Their anti-inflammatory properties were then tested in the murine 
air-pouch model. As observed for human derived microparticles, there was a 
dose dependent reduction in the number of GR1+ve cells recruited to the site of 
inflammation for the WT microparticles whilst, on the other hand, this effect 
was lost when the animals were injected with similar doses of the Annexin A1 -
/- PMN-derived microparticles (Figure 3-45). These observations further 
underscore the anti-inflammatory role played by the Annexin A1 found on PMN 
derived microparticles.  
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Figure 3-42: Anti-inflammatory effects of human PMN-derived microparticles. 
Mice received 200 µl i.v. of saline or two doses of human PMN-derived ectosomes, or 
human recombinant Annexin  A1 (20 µg; positive control), immediately before the local 
injection of mouse IL-1ß into 6-day-old airpouches. The extent of cell migration was 
determined 4 h later, following airpouch washing and staining of migrated cells with Gr1 
marker. Data are mean ± SEM of 5 mice per group. *= P<0.05 vs. vehicle group, 
statistical analysis was conducted by one way ANOVA. 
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Figure 3-43: Positive identification of the murine PMN-derived microparticles. 
Using flow cytometric techniques the microparticles were stained with anti-CD62L and 
Annexin V, where for both the WT and the Annexin A1 -/- PMN derived microparticles 
there was a strong positive signal. Table (b) summarises the MFI values obtained for 
each animal group (n=5 mice per group), data is expressed as a mean and SEM. 
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Figure 3-44: Anti-inflammatory effects of murine PMN-derived microparticles. 
Mice received 200 µl i.v. of saline or two doses of WT, or Annexin  A1 -/- microparticles, 
immediately before the local injection of mouse IL-1ß into 6-day-old airpouches. The 
extent of cell migration was determined 4 h later, following airpouch washing and 
staining of migrated cells with Gr1 marker. Data are mean ± SEM of 5 mice per group. 
*P<0.05 vs. vehicle group, data was analysed using one way ANOVA. 
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3.2.4. Reactive Oxygen Species production by human PMN-derived 
Microparticles. 
As discussed in chapter 1.3 microparticles have been described to possess both 
pro and anti-inflammatory functions, which can vary depending on the cells of 
origin or even the stimulus applied to the cell for their generation. For instance, 
as highlighted above, Annexin A1 loaded PMN-derived microparticles possess 
anti-inflammatory functions; however, PMN derived microparticles have also 
been described as having a pro-inflammatory role. Thus, I set out to determine 
what lead to this dichotomy. One of the approaches I took was to change the 
stimulus provided, and then determining if these microparticles were capable of 
producing ROS.  
 
Following incubation of PMNs either in suspension or over a HUVEC 
monolayer, microparticles were isolated and analysed using a flow cytometer, 
where it was observed that a distinct, larger population emerged in those 
samples obtained from PMNs stimulated in suspension (Figure 3-46a). This 
subset of microstructures was confirmed to be microparticles through the 
analysis of the antigen expression, which showed that they were both CD62L 
and were PS (Figure 3-47a) positive, whilst being CD62P negative (Figure 3-
47b). 
ROS production was assessed by employing a simple technique, where the 
microparticles were loaded in lucigenin and then stimulated with a direct 
synthetic NADPH oxidase activator we could detect the presence of ROS 
(Figure 3-48). Interestingly this ROS production was not observed when I used 
microparticles obtained from PMNs adherent to a HUVEC monolayer (Figure 
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3-48), this suggesting a stimulus specific response to the microparticle 
production and possibly content. 
In order to establish whether in fact the larger microparticle population was 
responsible for the ROS production this population was isolated employing 
FACS techniques. Following isolation the ability of the two populations gated 
below as R1 and R2 to produce ROS was assessed employing a DCFDA assay 
that confirmed that the larger microparticle population (R2) was in fact able to 
produce ROS (Figure 3-49b) whilst the population gated in R1 was unable to 
produce these chemical entities (Figure 3-49c). 
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Figure 3-45: Analysis of the microparticle populations produced by differential 
stimulation using flow cytometry. PMN were incubated either in suspension (a) over 
a HUVEC monolayer (b) for 20 min, then stimulated for 20 min with 1µM fMLP. The 
analysis of the populations produced a new microparticle population in the PMNs 
stimulated in suspension highlighted in box R2. Scatterplots are representative of 5 
independent microparticle preparations. 
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Figure 3-46: Flow cytometric determination of FPRL1 in ROS producing PMN 
derived microparticles. The microparticles were stained with immunofluoroscent anti-
CD62L, anti-FPRL1 (a) and anti-CD62P (b) antibodies. The microparticle CD62L, 
CD62P and FPRL1 expression was quantified by flow cytometry. Histograms are 
representative of 5 distinct experiments.  
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Table 3-4: Table outlining the abundance of the different microparticle 
populations produced upon differential stimulation. Results are presented as mean 
and SEM percentages out of the total population and are representative of 6 distinct 
preparations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-47: Reactive Oxygen Species Production by PMN derived microparticles 
The potential for ROS production was analysed by co-incubation of the two sets of 
microparticles i.e. microparticles produced by direct stimulation (  ) or following co-
incubation over a HUVEC monolayer (  ). This showed that only the latter set of 
microparticles were able to produce ROS. Data are mean ± SEM of 5 distinct 
preparations. 
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Figure 3-48: Reactive Oxygen Species analysis using the DCFDA assay. Following 
microparticle isolation, these microstructures were incubated in DCFDA for 20 min at 
room temperature following which they were stimulated with PMA and the ROS 
production was determined in the FL1 channel. Figures (b) and (c) show that only the 
larger microparticle gated in R2 was able to produce ROS. Histograms are 
representative of 3 distinct preparations. 
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Table 3-5 Quantification results for Reactive Oxygen Species determination in 
PMN derived microparticles. The MFI values confirm that only the R2 population has 
the ability to produce reactive oxygen species in this assay. The results are a summary 
of 3 distinct preparations. Data is expressed as mean and SEM. 
 
 
Table 3-6 Table summarising the MFI values for the 3 distinct M.P. preparations. 
The data shown above highlights the fact that in each of these conditions PMN derived 
M.P. were not contaminated by other M.P. present from platelets (CD62P) or 
monocytes (CD14). Furthermore the M.P. obtained from resting PMN did not have any 
Annexin A1 as did the larger M.P. (R2) obtained from stimulated PMN in suspension. 
However all the M.P. populations expressed the FPRL receptor. Data is expressed as 
mean and SEM 
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3.2.5. Stimulus specific expression of the Annexin A1 system in M.P. 
Previously conducted studies have shown that microparticles from one cell type 
can be heterogeneous expressing different antigens on their surface. 
Furthermore opposing roles for microparticles derived from a specific cell type, 
such as the PMN, have been described. I have previously described that 
microparticles obtained from PMNs in suspension have the ability to produce 
ROS, whilst those PMN adhesion to a HUVEC monolayer do not. This 
prompted us to explore if different stimuli can influence expression of Annexin 
A1 in PMN derived microparticles.  
 
The flow-cytometric analysis confirmed previously outlined results that fMLP 
stimulated microparticles express Annexin A1 on their outer surface, 
furthermore it also showed that LxA4 and AF2 stimulation produce 
microparticles which contain similar levels of Annexin A1 (Figure 3-50). On 
the other hand, there is a stark difference in FPRL1 expression between the 
various treatments, where in all three cases the expression was above that 
observed in the control unstimulated levels. This data also shows that the 
microparticles obtained following LxA4 stimulation are richer in the receptor 
that the other three sources whilst AF2 stimulation produced a higher 
percentage of microparticles containing this receptor (Figure 3-50).   
 
Interestingly western blotting analysis revealed that the majority of the Annexin 
A1 detected in the incubation medium was in fact contained in the 
microparticles with very low levels of this protein being detected in the 
concentrated microparticle depleted supernatant (Figure 3-51).  
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Figure 3-49: Flow cytometric determination of Annexin A1, FPRL1, and CD62L 
PMN derived M.P. M.P. were produced by coincubation of PMN with fMLP, LxA4, AF2 
or from CT PMN. The M.P. were the stained with anti-Annexin A1, anti-FPRL1 or anti-
CD62L ab followed by a 2o ab. The M.P. were also incubated with an isotype control 
and a straight secondary control. The microparticle antigen expression was quantified 
by flow cytometry. Data are mean ± SEM of 3 independent preparations. *P<0.05 vs. 
vehicle group, data was analysed using one way ANOVA. 
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Figure 3-50: Western Blot analysis of M.P. rich supernatant After cell stimulation 
the cells were centrifuged and the supernatant was loaded on to a 10 % gel.  Following 
gel electrophoresis and transfer the blot was probed with an anti-Annexin A1 antibody, 
showing the presence of Annexin A1 in the microparticles. (a) representative blot 
showing the presence of Annexin A1 in the PMN supernatant (b) densitometry results 
for the microparticles blots (n=3 distinct preparations). Data represented as mean and 
SEM and analysed using one way ANOVA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 197 
 
 
 
Figure 3-51: Western Blot analysis of microparticles depleted supernatant. 
Following microparticles extraction, the supernatant from each condition was 
concentrated down from 2ml to 40 µl using 10kDa cut-off centrifugation columns. The 
concentrated supernatant was loaded in on to 10% gel. Following gel electrophoresis 
and transfer the blot was probed with an anti-Annexin A1 antibody, showing the 
presence of Annexin A1 in the microparticles. (a) a representative blot showing minimal 
Annexin A1 presence in the microparticles supernatant for all 4 conditions with the 
fMLP condition showing a slightly elevated Annexin  1 presence; (b) densitometry 
results for the microparticles blots (n=3 distinct preparations). Data presented as mean 
and SEM and analysed using one way ANOVA.  
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3.2.6. Determining the role of the Annexin A1 and FPRL1 positive M.P. in 
Rheumatic Diseases 
 
Alterations of microparticle populations in the plasma of patients suffering from 
a number of rheumatic diseases have been reported in the literature. In light of 
my observations that Annexin A1 positive microparticles play an important role 
in the resolution of inflammation and that both Annexin A1 and FPRL1 levels 
can be altered, in a stimulation dependent manner, I decided to explore if there 
were any differences in their expression in three rheumatic conditions RA, 
Wegener Vasculitis (MPO and PR3 +ve ANCA) and GCA. 
 
Flow-cytometric analysis highlighted a significant reduction in the Annexin A1 
positive microparticles in all 3 conditions, with the largest decrease being in the 
PR3+ve ANCA patients where we see 15% reduction  (Figure 3-53).  
On the other hand in all the conditions studied there was an elevated number of 
FPRL1 positive microparticles with the Wegener Patients displaying the largest 
increase (Figure 3-53).  
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Figure 3-52: Flow cytometric determination of Annexin A1 and FPRL1 +ve M.P. in 
plasma from patients suffering from Rheumatic diseases. Plasma was obtained 
from patients suffering from RA, Wegener granulomatosis (MPO +ve and PR3 +ve) and 
GCA by differential centrifugation. This plasma was then incubated with 10 antibodies 
against Annexin A1 and FPRL1 and then a 2o ab that was FITC conjugated. The 
microparticle antigen expression was quantified by flow cytometry. Data are mean ± 
SEM of 8 patients per group. *P<0.05 vs. CT group. Data analysed using one way 
ANOVA. 
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3.2.7. Exploring the potential of monitoring microparticle populations as 
biomarkers during disease treatment in Rheumatoid Arthritis. 
Microparticles have over the last few years gained in importance as biomarkers 
of disease where elevated levels of specific subsets of microparticles have been 
linked with a number of systemic conditions, such as atherosclerosis and RA 
(Erdbruegger, Grossheim et al. 2008; Umekita, Hidaka et al. 2009). However 
little data is available on the effect of therapeutic treatment on these 
microparticle populations. Therefore I took advantage of the RA study 
employing prednisolone treatment to investigate whether I could detect changes 
in the microparticle profile. 
 
Blood was collected from RA patients in collaboration with Dr. Stephen Kelly 
between 9 and 11am and the plasma was immediately separated to avoid 
contamination by further cellular activation. The plasma was centrifuged again 
to remove any contaminating platelets and stained using immunofluoroscent 
antibodies against a number of antigens described in the literature to correspond 
to the cell of origin of the microparticles. Furthermore, the level of expression 
of Annexin A1 and FPRL1 on these microparticles was also determined.  
 
The results I produced indicate that there is a significant reduction in the PMN 
(CD62L positive) (Figure 3.54), platelet (CD62P positive) (Figure 3.55) and 
monocyte (CD14 positive) (Figure 3.57) derived microparticle population upon 
a two week glucocorticoid treatment in these patients. On the other hand, an 
increase in endothelial (CD54 positive) (Figure 3.56) derived microparticles, 
both in the MFI and percentage positive events. Even more interestingly, there 
was a decrease in the number of FPRL1 (Figure 3.58) positive microparticles, 
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mirrored by an increase in Annexin A1 (Figure 3.59) positive microparticles, 
suggesting that distinct effects of the prednisolone treatment.  
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Figure 3-53:  CD62L expression on plasma microparticles derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. 
Microparticles were isolated and stained by incubation with immunofluoroscent anti-
CD62L antibody, by incubation for 60 min at 4oC. These results show that there is a 
marked decrease in CD62L positive microparticles over the 14-day treatment as 
highlighted by both a reduction in MFI units (a) and number of CD62L positive 
microparticles (b). * P<0.05 vs. Day 0 group (n=7 patients). Data presented as mean 
and SEM and analysed by one way ANOVA. 
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Figure 3-54:  CD62P expression on plasma microparticles derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. 
Microparticles were isolated and stained by incubation with immunofluoroscent anti-
CD62P antibody, by incubation for 60 min at 4oC. These results show that there is a 
marked decrease in CD62P positive microparticles over the 14-day treatment as 
highlighted by both a reduction in MFI units (a) and number of CD62L positive 
microparticles (b). * P<0.05 vs. Day 0 group (n=7 patients). Data presented as mean 
and SEM and analysed by one way ANOVA. 
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Figure 3-55:  CD54 expression on plasma microparticles derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. 
Microparticles were isolated and stained by incubation with immunofluoroscent anti-
CD54 antibody, by incubation for 60 min at 4oC. These results show that there is a 
marked increase in CD54 positive microparticles over the 14-day treatment as 
highlighted by both a reduction in MFI units (a) and number of CD54 positive 
microparticles (b). * P<0.05 vs. Day 0 group (n=7 patients). Data presented as mean 
and SEM and analysed by one way ANOVA. 
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Figure 3-56:  CD14 expression in on plasma microparticles derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. 
Microparticles were isolated and stained by incubation with immunofluoroscent anti-
CD14 antibody, by incubation for 60 min at 4oC. These results show that there is a 
marked decrease in CD14 positive microparticles over the 14-day treatment as 
highlighted by both a reduction in MFI units (a) and number of CD14 positive 
microparticles (b). * P<0.05 vs. Day 0 group (n=7 patients). Data presented as mean 
and SEM and analysed by one way ANOVA. 
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Figure 3-57:  FPRL1 expression on plasma microparticles derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. 
Microparticles were isolated and stained by incubation with immunofluoroscent anti- 
FPRL1 antibody, by incubation for 60 min at 4oC. These results show that there is a 
marked decrease in FPRL1 positive microparticles over the 14-day treatment as 
highlighted by both a reduction in MFI units (a) and number of FPRL1 positive 
microparticles (b). * P<0.05 vs. Day 0 group (n=7 patients). Data presented as mean 
and SEM and analysed by one way ANOVA. 
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Figure 3-58:  Annexin A1 expression in on plasma microparticles derived from 
Rheumatoid Arthritis (RA) patients during a 14-day steroid treatment. 
Microparticles were isolated and stained by incubation with immunofluoroscent anti- 
Annexin A1 antibody, by incubation for 60 min at 4oC. These results show that there is 
a marked increase in Annexin A1 positive microparticles over the 14-day treatment as 
highlighted by both a reduction in MFI units (a) and number of Annexin A1 positive 
microparticles (b). * P<0.05 vs. Day 0 group (n=7 patients). Data presented as mean 
and SEM and analysed by one way ANOVA. 
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3.3. Development of novel Ac2-26 derived peptides  
In the quest to assess the potency of the novel Ac2-26 derived peptides a 
number of properties were assessed in order to determine their potential as anti-
inflammatory drugs. Previous studies conducted in our group and by others has 
show the Ac2-26 peptide has the ability to bind three of the FPR family 
members, namely FPR, FPRL1 and FPRL2 leading to the down stream 
activation of p-ERK, however only the former two receptors have been shown 
to be important in conveying its anti-inflammatory properties. Therefore, in 
order to assess the activity of the novel peptides it was deemed important to 
evaluate their potential for activating these two receptors. For this purpose three 
transfected HEK cell lines were employed. These cell lines were transfected 
with either an empty vector and termed HEK-CMV, a vector over expressing 
FPR, and thus termed HEK-FPR, or a vector over expressing the FPRL1 gene 
and consequently termed HEK-FPRL1. Before embarking on experiments with 
the novel Annexin A1 peptides I checked whether the cellines in culture were 
expressing the expected receptors. As outlined in Figure 3.60 all the HEK-FPR 
and the HEK-FPRL1 cell expressed the FPR and FPRL1 receptors respectively, 
with the latter cell line showing a strong receptor expression whilst there seems 
to be a weaker staining for the FPR receptor. The latter result can be explained 
in the light of the fact that the FPR antibody possesses lower affinity to the 
receptor. The second important conclusion that could be deduced from this data 
was the lack of cross contamination between the cell lines containing the 
receptors; furthermore, the HEK-CMV cell line was devoid of the two 
receptors. 
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Figure 3-59: Flow cytometric analysis of the three transfected HEK cell lines. The 
three transfected HEK cell lines, (a) HEK-CMV, (b) HEK FPR and (c) HEK-FPRL1 
immunofluoroscently stained with 1o abs against FPR, FPRL1 or an isotype control, 
followed by a 2o FITC conjugated ab. The results show that in the CMV cell line, neither 
of the two receptors is expressed, whilst there is an expression of the FPR receptor in 
the HEK-FPR cells and FPRL1 in the HEK-FPRL1 cell line.   
 
Anti-FPRL1 
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Table 3-7 Summary of the flow cytometric analysis conducted on the HEK cell 
lines. The MFI units outlined above confirm that the CMV cell line does not contain any 
of the two receptors whilst there is no cross contamination between the other two cell-
lines (n=3 distinct experiments). Data presented as mean and SEM (PMT value=548). 
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After the generation of this basic yet fundamental data I was ready to use these 
cell lines for testing the novel peptide sequences obtained from Unigene. The 
starting point was to use the p-ERK assay for screening the agonistic activity to 
the FPRL1 receptors of these novel peptides. Firstly I compared two sources of 
the Ac2-26 peptide in order to determine if there was a difference in their ability 
activate the FPLR1 receptor and thus determine which would be more 
appropriate to use as positive control. As depicted in Figure 3.61, the Ac2-26 
obtained from Cambridge Research Biochemicals (CRB) was more effective at 
activating p-ERK then the peptide supplied by Unigene. Therefore it was 
decided that the CRB peptide was to be employed in subsequent 
experimentation.  
 
Figure 3.60: Western blotting analysis comparing the activation potency of p-
ERK by the two Ac2-26 peptides. The HEK-FPRL1 cells were co-incubated for 8mins 
with the respective peptides, or just DMSO and then transferred to the -80oC. The cells 
were then lysed using a lysis solution and 100ng of total protein were loaded on to a 
10% polyrylamide gel. Following electrophoresis, transfer and blocking the membrane 
was first probed with an anti p-ERK anti-body and then stripped and reprobed with and 
anti t ERK anti-body. Whilst the t-ERK blot shows equal amounts of ERK in all the 
samples, the CRB peptide was the one that activated p-ERK. (a) a representative blot 
(b) densitometry results highlighting the ratio between the p–ERK and t-ERK bands. 
Data presented as mean and SEM of 3 distinct experiments with one way ANOVA 
employed for statistical analysis.(*= P<0.05 vs. CT) 
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The next step was to identify which of the novel peptides activated the p-ERK 
through the FPRL1 receptor, similarly to the parent peptide. The western blot 
analysis pointed out that Pep57, Pep59 and Pep84 were the more potent ERK 
activators (Figure 3-62).  
 
However, in order to confirm which of the five Ac2-26 derived peptides showed 
the highest potential for further analysis another set of experiments was 
conducted. In this assay the capability of these amino acid sequences to reduce 
the PMN interaction to an activated HUVEC monolayer was assessed and 
compared to the inhibitory properties of the parent Ac2-26 peptide. Pep57 and 
Pep84 were observed to display inhibitory properties similar to those observed 
in the parent Ac2-26 peptide confirming the p-ERK data (Figure 3-63). 
Interestingly Pep59, which also showed a very high p-ERK activation potential, 
did not display any inhibitory properties whilst, on the other hand, Pep60 which 
was unable to phosphorylate ERK, displayed potent inhibitory properties similar 
to those displayed by the parent Ac2-26 peptide.  
 
 
 
 
 
 
 
 
 
 213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-61: Western blotting analysis comparing the activation potency of novel 
Annexin A1 n-terminally derived peptides. The HEK-FPRL1 cells were co-incubated 
with 10 µM of the novel Ac2-26 peptides for 8mins following which the cell were lysed 
and resuspended in cell lysis solution. Then 100ng of total protein were loaded on to 
10% polyacrylamide gel. Following electrophoresis, transfer and blocking the 
membrane was first probed with an anti p-ERK antibody and then stripped and 
reprobed with and anti total ERK antibody. Whilst the t-ERK blot shows equal amounts 
of ERK in all the samples the p-ERK activated was observed to be highest with Pep57, 
59 and 84, similar to the activation caused by the parent Ac2-26 and less then the 
second control, the W-peptide. (a) representative blots for p-ERK and t-ERK (b) 
densitometry results relating the p-ERK to the t-ERK levels. Data presented as mean 
and SEM of 3 distinct experiments with one way ANOVA employed for statistical 
analysis.(*= P<0.05 vs. CT) 
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Figure 3-62: Flow chamber analysis determining the inhibitory potency of the 
novel Ac2-26 peptides. PMNs (5x106) were incubated with 10µM of the various 
peptides for 10 min at 37°C. The PMNs were then flowed for 8 min at 1 dyne/cm2, prior 
to quantifying the degree of PMN interaction with the HUVECs, both as PMN capture 
(a), adhesion (b) and rolling (c). The results highlights the fact that only Pep57, 60 and 
84 display inhibitory properties in this assay. Data are mean ± SEM of 3 independent 
experiments (with distinct PMN and HUVEC preparations); * = P<0.05 vs. CT group, 
data analysed using one way ANOVA. 
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Following the results obtained in the initial experiments I concluded that out of 
a panel of 5 peptides only Pep57 (Figure 3-64) and Pep84 (Figure 3-65) 
displayed properties similar to those observed for Ac2-26 under the same 
conditions. Thus I extended the investigation on these two peptides whereby 
both Pep57 and Pep84 were observed to activate ERK even at concentrations as 
low as 0.1nM. This activity was also observed in the flow chamber model where 
both peptides significantly reduced the number of cells interacting with the 
endothelium down to a concentration of 0.01nM (Figure 3-70).  
 
The flow chamber analysis also showed there are a number of distinct 
differences between the two peptides, the first one is that Pep84 (Figure 3-71) 
produced a dose response inhibition in the number of PMNs interacting with the 
endothelium. On the other hand Pep57 showed similar potency throughout the 
entire concentration range (Figure 3-70). The second difference is that Pep84 
was observed to inhibit rolling more significantly that adhesion as was observed 
for the parent peptide. On the other hand Pep57 was observed to have a higher 
effect on adhesion over rolling. 
 
The ability of these two peptides to activate ERK through the FPR receptor was 
also assessed. The results highlight that even in this case the two peptides have 
the ability to activate ERK at concentrations as low as 0.1nM (Figure 3-66; 3-
67) even though this seems to be to a somewhat lower extent as that observed 
through FPRL1. Importantly no ERK activation was observed in the HEK-CMV 
(Figure 3-68; 3-69) highlighting that ERK phosphorylation observed in the 
other two cell lines were consequent to sensitization of either receptor.  
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Figure 3-63: Western blotting analysis of the Pep57 dose response highlighting 
its p-ERK activation potency through the FPRL1 receptor. The HEK-FPRL1 cells 
were co-incubated with the varying concentrations of Pep57 for 8mins following which 
the cell were lysed and resuspended in cell lysis solution. Then 100ng of total protein 
were loaded on to 10% polyacrylamide gel. Following electrophoresis, transfer and 
blocking the membrane was first probed with an anti p-ERK antibody and then stripped 
and reprobed with and anti total ERK antibody. The t-ERK blot shows equal amounts of 
ERK in all the samples. The p-ERK blot also shows a significant activation above basal 
level for all the Pep57 concentrations employed showing a high affinity of this peptide 
to the FPRL1 receptor (a) representative blots for -ERK and t-ERK (b) densitometry 
results relating the p-ERK to the t-ERK levels Data presented as mean and SEM of 3 
distinct experiments with one way ANOVA employed for statistical analysis.(*= P<0.05 
vs. CT). Data analysis was conducted using one way ANOVA. 
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Figure 3-64: Western blotting analysis of the Pep84 dose response highlighting 
its p-ERK activation potency through the FPRL1 receptor. The HEK-FPRL1 cells 
were co-incubated with the varying concentrations of Pep84 for 8mins following which 
the cell were lysed and resuspended in cell lysis solution. Then 100ng of total protein 
were loaded on to 10% polyacrylamide gel. Following electrophoresis, transfer and 
blocking the membrane was first probed with an anti p-ERK antibody and then stripped 
and reprobed with and anti total ERK antibody. The t-ERK blot shows equal amounts of 
ERK in all the samples. The p-ERK blot also shows a significant activation above basal 
level for all the Pep84 concentrations employed showing a high affinity of this peptide 
to the FPRL1 receptor. (a) representative blots for -ERK and t-ERK (b) densitometry 
results relating the p-ERK to the t-ERK levels. Data presented as mean and SEM of 3 
distinct experiments with one way ANOVA employed for statistical analysis.(*= P<0.05 
vs. CT). Data analysis was conducted using one way ANOVA. 
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Figure 3-65: Western blotting analysis of the Pep57 dose response highlighting 
its p-ERK activation potency through the FPR receptor. The HEK-FPR cells were 
co-incubated with the varying concentrations of Pep57 for 8mins following which the 
cell were lysed and resuspended in cell lysis solution. Then 100ng of total protein were 
loaded on to 10% polyacrylamide gel. Following electrophoresis, transfer and blocking 
the membrane was first probed with an anti p-ERK antibody and then stripped and 
reprobed with and anti total ERK antibody. The t-ERK blot shows equal amounts of 
ERK in all the samples. The p-ERK blot also shows a significant activation above basal 
level for all the Pep57 concentrations employed showing a high affinity of this peptide 
to the FPR receptor. (a) representative blots for -ERK and t-ERK (b) densitometry 
results relating the p-ERK to the t-ERK levels. Data presented as mean and SEM of 3 
distinct experiments with one way ANOVA employed for statistical analysis.(*= P<0.05 
vs. CT). Data analysis was conducted using one way ANOVA. 
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Figure 3-66: Western blotting analysis of the Pep84 dose response highlighting 
its p-ERK activation potency through the FPR receptor. The HEK-FPR cells were 
co-incubated with the varying concentrations of Pep84 for 8mins following which the 
cell were lysed and resuspended in cell lysis solution. Then 100ng of total protein were 
loaded on to 10% polyacrylamide gel. Following electrophoresis, transfer and blocking 
the membrane was first probed with an anti p-ERK antibody and then stripped and 
reprobed with and anti total ERK antibody. The t-ERK blot shows equal amounts of 
ERK in all the samples. The p-ERK blot also shows a significant activation above basal 
level for all the Pep84 concentrations employed showing a high affinity of this peptide 
to the FPR receptor. (a) representative blots for -ERK and t-ERK (b) densitometry 
results relating the p-ERK to the t-ERK levels. Data presented as mean and SEM of 3 
distinct experiments with one way ANOVA employed for statistical analysis.(*= P<0.05 
vs. CT). Data analysis was conducted using one way ANOVA. 
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Figure 3-67: Western blotting analysis determine if p-ERK activation by Pep57 is 
being activated by other receptors apart from the FPR family in the HEK cells. 
The HEK-CMV cells were co-incubated with the varying concentrations of Pep57 for 
8mins following which the cell were lysed and resuspended in cell lysis solution. Then 
100ng of total protein were loaded on to 10% polyacrylamide gel. Following 
electrophoresis, transfer and blocking the membrane was first probed with an anti p-
ERK antibody and then stripped and reprobed with and anti total ERK antibody. The t-
ERK blot shows equal amounts of ERK in all the samples. However no p-ERK signal 
was observed confirming that the p-ERK activation observed for Pep57 was solely 
through the FPR family receptors (representative of 3 indep. exp). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-68: Western blotting analysis determine if p-ERK activation by Pep84 is 
being activated by other receptors apart from the FPR family in the HEK cells. 
The HEK-CMV cells were co-incubated with the varying concentrations of Pep84 for 
8mins following which the cell were lysed and resuspended in cell lysis solution. Then 
100ng of total protein were loaded on to 10% polyacrylamide gel. Following 
electrophoresis, transfer and blocking the membrane was first probed with an anti p-
ERK antibody and then stripped and reprobed with and anti total ERK antibody. The t-
ERK blot shows equal amounts of ERK in all the samples. However no p-ERK signal 
was observed confirming that the p-ERK activation observed for Pep84 was solely 
through the FPR family receptors (representative of 3 indep. exp). 
 
 221 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-69: Flow chamber analysis determining the inhibitory potency of Pep84. 
PMNs (5x106) were incubated with 10µM of the peptide for 10 min at 37°C. The PMNs 
were then flowed for 8 min at 1 dyne/cm2, prior to quantifying the degree of PMN 
interaction with the HUVECs, both as PMN capture (a), adhesion (b) and rolling (c). 
The results highlight the fact that only Pep84 has a dose dependent inhibitory effect on 
PMN recruitment to the activated endothelial cells. Data are mean ± SEM of 3 
independent experiments (with distinct PMN and HUVEC preparations); P<0.05 vs. CT 
group. Data analysed using one way ANOVA. 
 222 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-70: Flow chamber analysis determining the inhibitory potency of Pep57 
PMNs (5x106) were incubated with 10µM of the peptide for 10 min at 37°C. The PMNs 
were then flowed for 8 min at 1 dyne/cm2, prior to quantifying the degree of PMN 
interaction with the HUVECs, both as PMN capture (a), adhesion (b) and rolling (c). 
The results highlight the fact that Pep57 does not have the a classical dose response 
inhibitory effect on PMN recruitment to the activated endothelial cells. Data are mean ± 
SEM of 3 independent experiments (with distinct PMN and HUVEC preparations); 
P<0.05 vs. CT group. Data analysed using one way ANOVA. 
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I then proceeded to determine the affinity of these novel peptides to the FPRL1 
receptor by performing radioligand binding assays. Firstly I determined the 
concentration of tracer and cold peptide to employ. Basing myself on previously 
conducted analysis I employed a concentration range between 82pM and 
0.82fM and a cold peptide concentration of 1µM. These results highlight that 
the optimal concentration of tracer to be employed is of 82pM (Figure 3-72). 
Next step was to determine the optimal cold peptide concentration to be 
employed, where three concentrations were employed, 01, 1 and 10µM. This 
determined that the optimal concentration of cold peptide to be employed for 
this set of experiments was of 10µM (Figure 3-73). Following, which the 
binding affinities of Pep57 (Figure 3-74a) and Pep84 (Figure 3-74b) to the 
FPRL1 was assessed, this showed that these peptides have a similar binding 
affinity with an IC50 of approximately 3µM. On the other hand the binding 
affinity for Pep84 to the FPR receptors was determined to be of about 6µM 
(Figure 3-75a) whilst that for Pep57 could not be determined as observed in 
Figure 3-75b. 
 
 
 
 
 
 
 
 
 
 224 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-71: Determining the optimal concentration of tracer to be employed in 
Radioligand Binding assay. Following the resuspension of the HEK-FPRL1 cells at a 
concentration of 1x106 cells were incubated with 10µM of cold peptide and various 
concentrations of tracer. The highest concentration of tracer is the one that shows a 
significant difference between Total and nonspecific binding (NSB). Data are mean ± 
SEM of 3 independent experiments. * = P<0.05 vs. CT group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-72: Determining the optimal concentration of cold peptide to be 
employed in Radioligand Binding assay. Following the resuspension of the HEK-
FPRL1 cells at a concentration of 1x106 cells were incubated with 7pM of cold peptide 
and 10, 1 or 0.1µM of cold peptide. In this set of experiments the highest concentration 
of cold peptide was shown to be the most effective at displacing the tracer from the 
FPRL1 receptor. Data are mean ± SEM of 3 independent experiments * = P<0.05 vs. 
CT group 
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Figure 3-73: Radioligand binding assays determining the affinity of Pep84 and 
Pep57 to the FPRL1 receptor. HEK-FPRL1 cells were incubated on ice with varying 
concentrations of Pep84 (a), Pep57 (b) and 82pM of 125I labelled W-peptide for 1h at 
4oC, following which the cells were collected over a filter paper and washed to remove 
any unbound tracer. The counts were then measured on a gamma counter 
(SB=specific binding where the cells were incubated with tracer only). The results 
outline that both peptides exhibit similar affinities for the FPRL1 receptor. Data are 
mean ± SEM of 3 independent experiments. Analysis was conducted using a non-linear 
regression. 
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Figure 3-74: Radioligand binding assays determining the affinity of Pep84 and 
Pep57 to the FPR receptor. HEK-FPR cells were incubated on ice with varying 
concentrations of Pep84 (a), Pep57 (b) and 82pM of 125I labelled W-peptide for 1h at 
4oC, following which the cells were collected over a filter paper and washed to remove 
any unbound tracer. The counts were then measured on a gamma counter 
(SB=specific binding where the cells were incubated with tracer only). The results 
outline that Pep84 has an approximately 10 fold less affinity to the FPR as to the 
FPRL1. On the other hand Pep57 seems to maximally displace the tracer even to at 
the lower concentrations thus not providing a classical dose response. Data are mean 
± SEM of 3 independent experiments. 
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After determining that both Pep57 and Pep84 displayed inhibitory properties in 
vitro the next step was to determine if these peptides were active in vivo. For 
this purpose preclinical model of inflammation was employed where it was 
observed that Pep84 displayed a higher anti-inflammatory effect then Pep57 in 
vivo (Pep59 was employed as a negative control) (Figure 3-76). The anti-
inflammatory effect was further confirmed through the blood cell counts, where 
it was observed that there was no reduction in circulating neutrophil counts 
(Figure 3.77), confirming that the reduction in cell recruitment into the airpouch 
was in fact due to an inhibition of cell recruitment rather then a toxic effect on 
the circulating cells.  
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Figure 3-75: Anti-inflammatory effects of three novel Ac2-26 derived peptides. 
Mice received 200µl i.v. of saline+DMSO or a dose of 50µg per animal of one of the 
three Ac2-26 derived peptides, immediately before the local injection of mouse IL-1ß 
into 6-day-old airpouches. The extent of cell migration was determined 4 h later, 
following airpouch washing and staining of migrated cells with Gr1 marker. When cells 
were counted Pep57 and 84 were observed to display anti-inflammatory properties, 
with Pep57 losing this observed effect when the GR1+ve cells were taken into account. 
Data are mean ± SEM of 5 mice per group. *P<0.05 vs. vehicle group. Data was 
analysed using one way ANOVA 
 
 
 
 
 
 229 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-76: The effects the novel Ac2-26 derived peptides on blood leukocyte 
populations. Blood was taken via cardiac puncture from anesthetised mice, 4h after 
peptide and IL1β immediately prior to culling and washing the pouch. A differential cell 
count for PMN (a) and PBMC (b) was conducted where it was observed that there were 
no statistical significant changes in cell counts upon treatment except for the Pep84 
treated group where the PMN populations were observed to be elevated. Data are 
mean ± SEM of 5 mice per group. *P<0.05 vs. vehicle group. Data was analysed using 
one way ANOVA 
 
 
 
 
 230 
In order to shed novel insights into potential mechanisms of activation, I 
explored the possibility that FPRL1 receptor internalization could be differently 
modulated by established and novel agonists. Moreover, FPRL1 internalisation 
would represent another way to demonstrate agonistic activity by these peptides. 
From this analysis in the HEK-FPRL1 cells, it emerged that the over all profile 
for the 3 peptides was similar, where there was an initial down-regulation, and 
possibly internalization, with levels being repristinated two hours by the 2 hour 
time point. Thus, highlighting that following the initial signalling the receptor is 
generally internalized, with over the first 30 minutes, following which the 
process starts being reversed and the receptor returned to the cell surface Figure 
3-78.  
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Figure 3-77: Flow cytometric analysis on FPRL1 expression on HEK-FPRL1 cells 
following co incubation with peptide Ac2-26, Pep57 or Pep 84. HEK-FPRL1 cells 
were co incubated for various time points with either Pep 84 (a) Pep57 (b) or Ac2-26 (c) 
following which the cells’ metabolism was stopped and the cells stained using an anti-
FPRL1 1o ab followed by a 1o ab. Results outline that all 3 peptides cause initial 
internalization of the receptor, which then recycles back to the cell surface. Data are 
mean ± SEM of 3 independent experiments (with distinct PMN and HUVEC 
preparations); P<0.05 vs. CT group. Data was analysed using one way ANOVA 
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4. Discussion 
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4.1. The Annexin A1 circuit and Rheumatic disease, is there a 
link? 
 
4.1.1. Evidence for a dysregulated Annexin A1 pathway Wegener 
Granulomatosis and Giant Cell Arteritis 
The cause of most rheumatic diseases remains unknown and in many cases may 
vary depending on the type of disease. Increasing evidence highlights the role of 
auto-antibodies in the propagation of at least a subset of such diseases where 
they can either reflect organ-specific or generalized auto-reactivity (Roitt, 
Hutchings et al. 1992). Glucocorticoids have proved over the years (Combe 
2007; Morand 2007), to be an effective treatment for many of these rheumatic 
conditions with some of these conditions, such as Giant Cell Arteritis (GCA,) 
being more responsive to this treatment regime (Wang, Hu et al. 2008).  
 
As described in Chapter 1, Annexin A1 was initially identified as a 
glucocorticoid inducible protein with the ability to downregulate phospholipase 
A2 (PLA2) and thus arachidonic acid synthesis (Cirino, Peers et al. 1989). Since 
then studies conducted by a number of laboratories have shown that this protein, 
at least in part, exerts its anti-inflammatory effects by regulating cell 
recruitment to the site of inflammation (Errasfa, Rothhut et al. 1985; Perretti 
and Flower 1993; Lim, Solito et al. 1998; Hayhoe, Kamal et al. 2006).  
Subsequent studies, have highlighted that the anti-inflammatory effects of 
Annexin A1 extend beyond inhibition of cell recruitment to the site of the 
inflammatory insult. In fact, various works have shown that this protein also has 
 234 
an influence on the crucial pro-resolving process of apoptosis: exogenous 
administration of Annexin A1 can promote cell apoptosis (see below). 
Moreover, addition of the Annexin A1 mimetic peptide Ac2-26 to macrophages 
increments the rate of phagocytosis of apoptotic PMN (Maderna, Yona et al. 
2005), an effect which is coupled to TGF-β1 release and to changes in F-actin 
reorganization suggesting that this peptide primes the macrophages to a more 
phagocytic phenotype leading to the enhanced rate of phagocytosis. This effect 
reproduces genuine actions of endogenous Annexin A1 as highlighted by the 
incubation of naive human monocyte derived macrophages in the presence of 
conditioned medium, produced following a 5 day culture of macrophages in the 
presence of dexamethasone, which enhanced their ability to engulf apoptotic 
PMNs. Furthermore this effect was blocked any of the following treatments: an 
Annexin A1 blocking antibody, by immunodepletion of the supernatants, or by 
the formyl peptide receptor family antagonist Boc1. It can be concluded that the 
final effect observed upon Annexin A1 administration may vary depending on 
the target cell (Goulding, Euzger et al. 1998; Scannell, Flanagan et al. 2007).  
 
The treatment of PMNs with human recombinant Annexin A1 leads to increased 
PMN apoptosis through a BAD dependent pathway (Solito, Kamal et al. 2003). 
On the other hand, a diametrically opposite effect is reported on prostate cancer 
cells and monocytes where Annexin A1 has been shown to exert a protective 
effect by reducing the rate of apoptosis induced by etoposide and TNF-α 
respectively (Carollo, Parente et al. 1998; Solito, de Coupade et al. 2001).  
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Coupled by the fact that glucocorticoids play such an important role as disease 
modifying drugs in rheumatic conditions, and that both endogenous and 
exogenous Annexin A1 have been shown to possess very strong 
immunomodulatory actions, it was deemed important to investigate if there was 
a deregulation in the Annexin A1 pathway. Furthermore, proof of a deregulated 
Annexin A1 pathway could provide a pharmacological target for the 
development of safer treatments, thus eliminating the problems linked with 
prolonged glucocorticoid administration. 
 
The analyses I conducted on patients suffering from either Wegener 
granulomatosis or GCA provide the first direct body of evidence that there is in 
fact an underlying deregulation in the Annexin A1 pathway in these conditions. 
Initial flow-cytometric analysis illustrated elevated Annexin A1 levels on the 
cell membranes of patients suffering from either disease. This observation was 
further corroborated by Western blotting analysis, where in both patient groups 
Annexin A1 levels in the membrane pool of PMNs, were elevated when 
compared to the levels found in healthy volunteers. Conversely, real time PCR 
analysis showed an up-regulation in mRNA levels for Annexin A1 in the GCA 
group only. This observation suggests that although at the protein level the 
deregulation in Annexin A1 protein levels seems to be similar for both the 
Wegener and GCA conditions, the underlying mechanism leading to this 
deregulation might be different. This is even more interesting in the light of fact 
that both patient groups were receiving similar glucoroticoid treatment regimes, 
furthermore it is a well accepted fact that GCA patients respond much better to 
this treatment regime then Wegener patients (Dasgupta, Hutchings et al. 2006; 
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Subrahmanyan and Dasgupta 2006; Dasgupta and Hassan 2007) further 
underlining the importance of the Annexin A1 pathway in the treatment of this 
condition.  
 
The observed elevation in membrane Annexin A1 levels seems to be in contrast 
with the current literature, where Annexin A1 has been shown to play a tonic 
inhibitory role on leukocyte recruitment; blocking the signalling of Annexin A1 
by neutralizing antibodies to its receptor FPRL1 increases interactions between 
PMN and the activated endothelial cells in vitro (Hayhoe, Kamal et al. 2006). 
However, the Western blotting analysis sheds light on this apparent 
contradiction, as in conjunction to an elevation of the full length (37kDa) 
protein on the cell membrane of PMNs from the patient groups a second, 
smaller band of 33kDa corresponding to the N-terminal cleaved form of 
Annexin A1 was observed.  
 
The 13 members of the Annexin superfamily show a high degree of structural 
homology, with each including four (or 8 in the case of ANXA6) repeated units 
of approximately 70 amino acids within the core and C-terminal regions; these 
units are believed to confer the Ca2+ and phospholipid binding properties of the 
proteins. On the other hand the N-terminal region of each family member is 
unique and thus is considered to confer the biological specificity to the 
individual proteins. Therefore cleavage of the N-terminal region, as observed in 
the membrane pools of these patients, might void Annexin A1 of its unique 
functions, providing a plausible explanation for the observations made: higher 
Annexin A1 in inflamed PMN (Gerke and Moss 2002; Rescher and Gerke 
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2004). The emerging model I wish to propose is that the activation status of the 
patients’ PMN determined membrane localization of intracellular Annexin A1, 
perhaps in an attempt to counteract the aberrant stimulation, yet the protein is 
largely cleaved hence inactive. 
 
Consistent with this, the flow-cytometric analysis conducted on neutrophils 
obtained from these patients, showed elevated proteinase 3 (PR3) expression on 
the cell surface, an observation that provides us with a possible mechanism for 
Annexin A1 cleavage in the cell membrane compartment. PR3 is a proteinase 
that has been linked with the development of Wegener granulomatosis (Witko-
Sarsat, Lesavre et al. 1999). The analysis of PR3 membrane expression on 
circulating resting neutrophils revealed the existence of two distinct subsets of 
neutrophils, one expressing membrane PR3 (mPR3+) and the other devoid of 
mPR3 (mPR3-). The proportion of these two subsets is a stable feature of a 
given subject, not related to age or gender. It was shown that the distribution of 
the mPR3+ neutrophil subset among healthy individuals corresponds to three 
discrete phenotypes, mPR3low, mPR3inter, and mPR3high, present in 9, 36, and 
55% of the healthy individuals respectively (Witko-Sarsat, Lesavre et al. 1999). 
Furthermore, the frequency of the mPR3high phenotype is strikingly higher in 
patients with ANCA-related vasculitis than in the healthy control population. 
The proportion of mPR3+ neutrophils in a given patient is remarkably stable 
during follow-up studies and is not influenced by relapses or by therapy, in spite 
of variations in ANCA titers (Witko-Sarsat, Lesavre et al. 1999). Furthermore, 
the mPR3+/total neutrophil ratio is not modified after in vitro activation of 
patients' neutrophils. This suggests the possibility that a high proportion of 
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membrane PR3+ neutrophils might be a more general risk factor for 
autoimmune responses (Kantari, Pederzoli-Ribeil et al. 2007). Interestingly, the 
Wegener granulomatosis patients were not the only group presenting with 
elevated PR3 levels, in fact the flow cytometric analysis conducted on 
neutrophils from GCA patients revealed that the PR3 levels on these cells were 
also elevated to similar levels as those observed for the Wegener granulomatosis 
patients. 
 
Work done by Vong et al (2007) showed that this proteinase enzyme has the 
ability to cleave Annexin A1 at 3 distinct loci on the N-terminal portion of the 
protein thus leading to its inactivation. As a result, it could be hypothesized that 
the translocation of Annexin A1 on to the cell membrane possibly following the 
activation of the cells by the ANCA antibodies exposes this protein to cleavage 
by PR3 and other serine proteases present on the cell membrane consequently 
leading to its inactivation. 
 
Flow chamber analyses further confirm this hypothesis since a significantly 
higher number of adherent PMNs were observed for all three patient groups 
when compared to aged matched healthy volunteers, suggesting that these cells 
are in fact activated and thus providing the driving stimulus for the translocation 
of Annexin A1 to the cell surface (Perretti, Croxtall et al. 1996). Nonetheless, 
Annexin A1 is anti-adhesive in this assay (Hayhoe et al., 2006), yet the fact that 
the large majority of the protein is cleaved fits well with the higher PMN 
reactivity (quantified as adhesion to HUVEC) I measured. 
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It must also be noted that elevated mPR3 levels do not reflect an overt over-
activation of neutrophils since Wegener granulomatosis patients were shown to 
present normal levels of CD62L or of CD11b on their circulating PMN 
(Kantari, Pederzoli-Ribeil et al. 2007). However, in this study the Authors did 
not evaluate the levels of CD11b in its active conformation, which in turn has 
been shown to be involved in the process of firm adhesion (Montoya, 
Luscinskas et al. 1997). Moreover the superfusion of ANCA IgG over rolling 
cells in an in vitro flow chamber model resulted in conversion to stationary 
adhesion accompanied by shape change, a process shown to be CD11b 
mediated (Radford, Luu et al. 2001), leaving open the possibility that peculiar, 
yet relevant, mode(s) of activations could be experienced by these cells in vivo. 
This could provide a possible explanation for the discrepancy in observations 
between the current study and that by Kantari and colleagues (2007), since an 
elevation in active CD11b would lead to an increase in PMN firm adhesion, as I 
have observed in the flow chamber analysis. PMN adhesion in this model relies 
on CD11a and CD11b so that blockade by specific antibodies directed to either 
CD11a/CD18 (LFA-1, a ICAM-1 counter-receptor), CD11b/CD18 (Mo-1), or 
CD18 (common β2-integrin) also blocked greater than 90% of PMN 
transmigration (Luscinskas, Cybulsky et al. 1991). Interestingly, there was no 
observed difference in the number of neutrophils recorded rolling over the 
activated endothelial monolayer in my assays; this would be in line with 
previously published data which show no changes in CD62L levels in Wegener 
PMNs (Kantari, Pederzoli-Ribeil et al. 2007).  
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A further deregulation in the Annexin A1 pathway was observed when levels of 
the Annexin A1 receptor, FPRL1, and its prototype receptor FPR, were 
assessed.  The FPR family of receptors forms part of the GPCR superfamily of 
receptors. Formyl peptide receptors (FPRs) are a small group of seven-
transmembrane domain, G protein-coupled receptors that are expressed mainly 
by mammalian phagocytic leukocytes and are known to be important in host 
defense and inflammation (Ye, Boulay et al. 2009).  
 
The FPR receptor was originally identified by cloning the high affinity-binding 
site for fMLP on the surface of PMNs from a differentiated human myeloid 
leukaemia-cell (HL-60) cDNA library (Boulay, Tardif et al. 1990). Subsequent 
work led to the isolation of two additional human genes with high sequence 
homology (Murphy, Ozcelik et al. 1992) clustered with the prototype FPR on 
chromosome 19.3.3; these genes encode the GPCRs FPR-Like 1 (FPRL1) and 
FPR Like-2 (FPRL2) (Ye, Boulay et al. 2009).  
 
Studies have demonstrated that Annexin A1 binds specifically to the FPRL1 
(Perretti, Chiang et al. 2002) whilst its N-terminal peptides (Annexin A1 
peptido-mimetics) are able to bind and activate - at concentrations in the low 
micromolar range - all three members of the FPR family (Ernst, Lange et al. 
2004). Moreover, recent data showed that this protein and its peptides exert the 
majority of their anti-inflammatory actions through the FPRL1 (Hayhoe, Kamal 
et al. 2006). In fact, it was demonstrated, through the use of competitive binding 
assays, that both Annexin A1 and the N-terminal derived peptides Ac2-26 and 
Ac2-12 competed for specific [3H]LXA4,  with the full length protein showing a 
 241 
higher affinity (~30 fold) towards displacement of tracer from FPRL1, than the 
shorter N-terminal derived peptides (Perretti, Chiang et al. 2002; Hayhoe, 
Kamal et al. 2006). The direct interaction between Annexin A1 and FPRL1 was 
further substantiated via immunoprecipitation of both the proteins from 
activated human polymorphonuclear (PMN) cell lysates (Perretti, Chiang et al. 
2002). 
 
Flow cytometric analysis of neutrophils extracted from the three patient groups 
showed an elevated expression of both the FPR and FPRL1 on their cell surface. 
The rationale behind this observation is not as clear as that for the Annexin A1 
protein, however this enhanced expression could be a result of cell priming 
which would once again lead to the translocation of the receptor from the 
cytoplasm to the cell surface. In line with this hypothesis studies conducted on 
human PMNs have pointed out that both FPR and FPRL1 share a very similar 
sub-cellular localization: they are found in cytoplasmic vesicles (primarily 
gelatinase granules but also secretory vesicles), so that mild activation of PMNs 
would lead to their mobilization resulting in an increased cell membrane 
expression (Sengelov, Boulay et al. 1994; Bylund, Karlsson et al. 2002). Of 
interest, a great proportion (~60-70%) of intracellular Annexin A1 in the 
neutrophil, is contained in gelatinase granules (Perretti, Christian et al. 2000), 
leading me to hypothesise that ligand and receptor might be in close vicinity 
also inside the cell; however, externalization onto the cell surface will be 
associated with Annexin A1 change of structure, with exposure of the N-
terminus (Rosengarth and Luecke 2003), a conformational change provoked by 
the presence of high concentration of Ca2+ (Gerke, Creutz et al. 2005) 
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A process of controlled degranulation – as proposed by Borregard (Borregaard 
and Cowland 1997) - would not fully explain the observed increase in cell 
surface expression of these receptors, since analysis of FPRL1 mRNA levels 
highlighted a significant up-regulation in the gene expression in both MPO 
ANCA and GCA patient groups. A model whereby the initial increase in 
receptor levels could occur through a non-genomic pathway leading to an initial 
hyper-activation of the cells, which would become a sustained phenotype 
through up-regulation of gene transcription, could be put forward. What could 
control FPRL1 gene transcription is scarcely known, though below I will 
discuss the link between this receptor and glucocorticoids. There are no 
published studies on the FPRL1 promoter, neither in terms of identification of 
the right sequence(s) hence even less in terms of factors that would modulate it.  
 
The aim of my study was to determine if the Annexin A1 system was 
deregulated in these conditions and thus provide a new pharmacological target 
to treat these conditions. The first aim was achieved as outlined by the 
discussion above. The next step was to determine if pharmacological treatment 
with hr-Annexin A1 could prove to be a potential treatment for these conditions.  
 
The flow chamber analysis confirmed that pharmacological treatment of PMNs 
from the different patient groups with hr-Annexin A1 was able to reverse their 
activated profile, initially observed through an increased level of adhesion of 
these cells to the activated endothelium, when compared to healthy control cells. 
This modulation in fact confirms that Annexin A1, and possibly its N-terminal 
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derivatives, could be an attractive alternative to glucocorticoid treatment in 
these conditions, restoring a status demonstrated by a basal degree of PMN 
activation.  
 
4.1.2. Modulation of the Annexin A1 system upon glucocorticoid 
administration in Rheumatoid Arthritis   
 
RA is a chronic systemic inflammatory disorder that may affect many tissues 
and organs, but principally attacks the joints producing inflammatory synovitis 
that often progresses to destruction of the articular cartilage and ankylosis of the 
joints. RA can also produce diffuse inflammation in the lungs, pericardium, 
pleura, and sclera, and also nodular lesions, most common in subcutaneous 
tissue under the skin (Scott and Steer 2007). Although the cause of rheumatoid 
arthritis has been very hard to pinpoint the pivotal role played by the immune 
system in the onset and propagation of the disease is beyond discussion. 
  
Currently there is no cure for this disease thus the goal of treatment is mainly to 
alleviate the symptoms, preventing the future destruction of the joints with the 
resulting handicap if the disease is left unchecked. These two goals may not 
always coincide: while pain relievers may achieve the first goal, they do not 
have any impact on the long-term consequences (Walker-Bone and Farrow 
2007). For these reasons, most authorities believe that the majority of RA 
patients should be treated by at least one specific anti-rheumatic medication, 
also named Disease modifying anti-rheumatic drugs (DMARD), to which other 
medications and non-medical interventions can be added as needed (Dougados, 
Combe et al. 1999; Sizova 2008; Braun and Rau 2009). 
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Understanding the influence of an acute glucocorticoid treatment on the 
Annexin A1 pathway in patients with Rheumatoid Arthritis (RA) is a topic only 
partially investigated in the past with most of the efforts being concentrated on 
cells found in the synovial compartments. Work conducted by Sampey and 
colleagues (2000) showed that there is reduced detection of Annexin A1 binding 
sites on fibroblast-like synoviocytes obtained from RA patients when compared 
to age and sex matched cells from osteoarthritis (OA) patients. Furthermore, 
dexamethasone treatment of these cells in vitro showed a modulation of 
Annexin A1 expression, with an increase in protein translocation to the cell 
membrane and mRNA expression (Morand, Hall et al. 2006). On the other hand 
in a study monitoring Annexin A1 induction following the administration of 
hydrocortisone it was reported that the acute administration of 100-mg of the 
steroid was unable to induce Annexin A1 production in monocytes extracted 
from RA patients when compared to those obtained from healthy controls 
(Morand, Jefferiss et al. 1994). Interestingly raised levels of auto-antibodies to 
Annexin A1 have also been reported in the plasma of patients suffering from 
Systemic Lupus Erythematosus (SLE) levels which in turn were observed to be 
associated with active inflammatory disease but were independent of 
corticosteroid treatment. Conversely, in patients suffering from RA the levels of 
anti-Annexin A1 antibodies, were low in for those patients which had not 
received any glucocorticoid treatment, however subsequent to chronic 
glucocorticoid administration these levels were observed to elevate, suggesting 
the that treatment in this case is responsible for the elevation of these auto-
antibody levels (Goulding, Podgorski et al. 1989) 
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Glucocorticoid therapy offers relief, but its long-term side effects, such as 
osteoporosis and hypertension, are deemed undesirable. Nonetheless, steroid 
injections can be valuable adjuncts to a long-term treatment plan, and using low 
dosages of daily glucocorticoid can also have an important benefit if added to a 
proper specific anti-rheumatic treatment (Da Silva, Jacobs et al. 2006). In order 
to determine the effect of acute prednisolone treatment (15mg daily), would 
have on the expression profile of the Annexin A1 system in both PMNs and 
monocytes, blood samples were taken from patients between 9 and 11 am, on 
day 0 (i.e. prior to initiation of a daily dose of 15mg of prednisolone), and then 
day 1, 7 and 14. The blood was immediately processed, PMNs and PBMC’s 
were isolated and stained using a number of immunofluorescent antibodies 
against L-selectin (CD62L) and CD11b (as markers of activation); (Smith 1993) 
and FPR, FPRL1 and Annexin A1. 
 
CD62L is a highly glycosylated protein of 95-105 kDa (on PMN) containing 
lectin, epidermal growth factor (EGF) like, and multiple short consensus repeat 
(SCR) domains. It is constitutively expressed on almost all leukocytes, 
including neutrophils, monocytes, NK cells and lymphocytes. The prominent 
surface localization of CD62L, which is clustered on the tips of leukocyte 
microvilli, is thought to facilitate its cellular interaction under flow. CD62L has 
been shown to bind several ligands on high endothelial venules (HEV) 
including mucosal addressin cell adhesion molecule-1 (MAdCAM-1), 
glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1) and 
haematopoietic progenitor cell antigen-1 (HPCA-1; CD34) (Tedder, Penta et al. 
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1990), whilst it has been shown to bind PSGL1 on HUVECs (Paschall and 
Lawrence 2008). The CD62L ligands so far identified share similarities to sLx 
and sLa and all are sialylated, fucosylated and sulphated (Hiraoka, Petryniak et 
al. 1999).  This molecule plays a vital role in neutrophil recruitment, with 
impaired responses in CD62L null mice in a number of models.  
 
CD62L is rapidly shed from PMN surface upon activation, a process that leaves 
the proteolytically cleaved extracellular portion of the molecule still retaining 
the functional lectin and EGF domains, present in the plasma (Smalley and Ley 
2005). This soluble form of CD62L (sCD62L) retains functional activity by 
inhibiting PMN recruitment to the activated endothelium. A number of studies 
have attempted to identify the molecule(s) responsible for this cleavage process. 
CD62L sheddase was the first protein identified: this is a cell surface 
metalloproteinase that is resistant to common protease inhibitors including 
tissue inhibitor of metalloproteinase (TIMP) (Preece, Murphy et al. 1996). 
Studies have identified CD165b, a disintegrin and metalloproteinase (ADAM-
17) protein that sheds TNF-α from the cell surface, and hence is otherwise 
known as TNF-α converting enzyme (TACE), as an enzyme capable of cleaving 
CD62L from the surface of thymocytes (Walcheck, Alexander et al. 2003).  
However more recent evidence has show that, in the absence of ADAM17, such 
as in ADAM17 null mice, ADAM10 is able to cleave CD62L from the surface 
of mouse embryonic fibroblasts; the same holds true for CHO cells where the 
disintegrin is silenced (Le Gall, Bobe et al. 2009). Interestingly, the process of 
CD62L shedding is elicited by molecules that are both pro-inflammatory, such 
as PAF and fMLP (Filep, Zouki et al. 1999; Asimakopoulos, Taylor et al. 2000) 
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and anti-inflammatory, including Ac2-26 (Hayhoe, Kamal et al. 2006) and 
NSAIDs (Gomez-Gaviro, Dominguez-Jimenez et al. 2000; Aktas, Pozgajova et 
al. 2005).  
 
A number of studies have attempted to shed light onto the biological 
significance of CD62L shedding. Walcheck and colleagues (1996) have shown 
that inhibiting CD62L shedding results in a decrease in PMN rolling and an 
increased PMN accumulation in an in vitro flow adhesion assay. Furthermore 
by using a MECA-79 antigen (the peripheral node addressin carbohydrate 
epitope found on CD62L ligands) as an adhesion substrate in the flow chamber 
assay, it was concluded that CD62L shedding represented a de-adhesive event 
in PMN rolling, thereby decreasing leukocyte accumulation at sites of 
inflammation. However more recent results, from another flow chamber study, 
provided conflicting results, showing no evidence for a regulatory role of 
CD62L shedding on neutrophil recruitment to an activated HUVEC monolayer 
(Allport, Ding et al. 1997). This later result can be explained in the light of the 
observations made by Hafezi-Moghadam and colleagues (1999) who showed 
that the expected reduction in rolling velocity after blocking of CD62L does not 
occur when CD62E is also expressed, suggesting the existence of at least some 
degree of redundancy in this system. In vivo data produced using the mouse 
cremaster model have shown that in this model there is in fact a decrease in 
rolling velocity and an increase in the number of rolling leukocytes per unit time 
after CD62L blockade using a hydroxamic acid-based metalloprotinease (KD-
IX-73-4) (Hafezi-Moghadam and Ley 1999), confirming the initial observations 
made by Walcheck and colleagues (1996).  
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On these bases, (Hafezi-Moghadam, Thomas et al. 2001) and colleagues (2001) 
have proposed two mechanisms for the involvement of CD62L in leukocyte 
recruitment. Firstly the observed decrease in rolling velocity observed upon 
blockade of CD62L shedding increases the time that the leukocyte is exposed to 
the activated endothelium which in turn increases the likelihood that the 
leukocyte is activated thus increasing the likelihood of a successful arrest. 
Furthermore this process also leads to an increase in the contact time of the 
leukocyte with the endothelium, since CD62L blockade reduces the degree of 
jerkiness of the rolling (fewer microjumps along the endothelial surface) thus 
leading to an elevated contact time with the endothelium. Moreover they 
suggest that CD62L acts as a signalling molecule activating the Ras pathway via 
src-like tyrosine kinases and the small G-protein Rac, leading to integrin 
activation, binding to ICAM-1 and subsequent adhesion (Brenner, Gulbins et al. 
1996; Brenner, Weinmann et al. 1997). Thus blockade of CD62L shedding also 
leads to enhanced signalling and thus an elevated integrin activation, which can 
be expected to lead to an elevated ‘stickiness’ of these cells. 
 
The implications of CD62L shedding can be viewed in two opposing ways: this 
process could either mediate the detachment of the leukocytes from the 
activated endothelial surface or on the other hand promote transmigration 
through the endothelium. A number of studies have tried to addressed the 
modulation of CD62L expression in disease, where CD62L expression on 
peripheral blood monocytes and granulocytes in patients on continuous 
ambulatory peritoneal dialysis (Dadfar, Lundahl et al. 2004), and those suffering 
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from asthma (Jahnova, Horvathova et al. 1998) sickle cells disease (Lard, Mul 
et al. 1999) and Cohen syndrome (Olivieri, Lombardi et al. 1998), was observed 
to be significantly lower when compared to those found in healthy volunteers. 
Interestingly, the CD62L levels in patients suffering from asthma were 
significantly elevated following disodium chromoglycate treatment (Jahnova, 
Horvathova et al. 1998). On the other hand, when CD62L levels were measured 
in peripheral blood PMNs in patients suffering from cystic fibrosis (Russell, 
McRedmond et al. 1998), chronic obstructive pulmonary disease (COPD) 
(Noguera, Busquets et al. 1998), Kawasaki disease (Kobayashi, Kimura et al. 
2007) and SLE (Molad, Buyon et al. 1994) no significant differences were 
observed compared to levels measured in healthy volunteers. Conflicting results 
were also obtained when CD62L levels were monitored in PMNs derived from 
Wegener granulomatosis patients. In fact whilst Muller and colleagues (1998) 
did not report any significant differences but Riecken and colleagues (1994) 
observed an elevated CD62L expression in the patient derived cells when 
compared to healthy volunteers, a discrepancy, which was, attributed to the 
different PMN extraction methods. Thus, although conflicting data exists, so to 
not confirm CD62L expression as a universal marker of cell activation in 
systemic disease, very little data is available on the effect of treatment, in 
particular glucocorticoid treatment, on the modulation of CD62L expression in 
RA. Moreover, as highlighted above, since CD62L is important in mediating 
leukocyte recruitment to the site of inflammation it was deemed important to 
determine the impact of a glucocorticoid treatment regime on the expression of 
this surface antigen.  
 
 250 
Analysis of antigen expression on PMN and monocytes during the 
glucocorticoid treatment regimen highlighted the anti-inflammatory properties 
of an acute glucocorticoid dosing, and provided an insight into the mechanism 
governing these effects in rheumatoid arthritis. The first protein observed to be 
modulated following the initiation of treatment is Annexin A1, so that cell 
membrane levels of the protein are significantly elevated above control (Day 0) 
levels after the first day of treatment. This observation comes as no surprise 
since the relationship glucocorticoids—> Annexin A1 is well established. 
Recent work demonstrates that short-term application of glucocorticoids to cells 
induces externalization of Annexin A1 from the cytosolic pool through a non-
genomic mechanism (Yazid, Solito et al. 2009); longer treatments of cells, in 
this case HL60 cells, was shown to up-regulate the Annexin A1 gene leading to 
a more sustained higher degree of protein expression (Sawmynaden and Perretti 
2006). 
 
Cell surface expression of the Annexin A1 receptor (FPRL1) on PMN and 
monocytes was also rapidly modulated after Day 1. This, I believe this is the 
first study that has monitored FPRL1 (and FPR) modulation on these cell types 
following clinical administration of glucocorticoids to RA patients. The process 
leading to the observed up-regulation in membrane expression of this receptor is 
probably parallel to that observed for Annexin A1 whereby upon cellular 
activation, following binding of the glucocorticoid to its intra-cellular receptor, 
there is a mobilization/translocation of the receptor from intracellular 
compartments, as discussed above. Subsequently the observed sustained up-
regulation would result from de novo synthesis, an effect that has been 
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previously described in HL60 and monocytes cells upon incubation with 
glucocorticoids (Sawmynaden and Perretti 2006). In fact in this study it was 
observed that in both HL60 cells and monocytes, glucocorticoid treatment led to 
an initial up-regulation in FPRL1 mRNA followed by protein expression as 
soon as 2h post treatment, with a second peak at 24 h post treatment. I would 
think that the initial peak results from cellular activation, as described above, a 
process that would occur concomitantly to the mobilization of Annexin A1 to 
the cell membrane. Once the Annexin A1 protein is on the cell membrane it can 
bind to its receptor leading to de novo synthesis of its receptor; though not fully 
reported in any study as yet, I would not be surprised if a positive loop Annexin 
A1/FPRL1 will soon be described. Further support to this model derives from 
the observations made in Annexin A1 -/- animals, whereby the Fpr2 (the murine 
equivalent of human FPRL1) levels were decreased in a model of colitis when 
compared to wild type littermate controls (Babbin, Laukoetter et al. 2008), 
supporting the notion of a potential role for Annexin A1 in regulating FPRL1 
(or Fpr2 in this case) expression under patho-physiological conditions.  
 
Levels of expression of FPR, the prototype of this family of receptors, were also 
modified upon glucocorticoid treatment. In line with changes for Annexin A1, 
the degree of expression of FPR peaked 24h (Day 1) after the initiation of 
treatment. Such a regulation has already been reported in a recent study 
conducted with primary monocytes in vitro where fluticasone was observed to 
markedly up-regulate FPR expression and function. Furthermore treatment of an 
osteosarcoma cell line (Saos-2) also resulted in up-regulation of this receptor, 
but only at the mRNA level (Giner, Mancini et al. 2007). 
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However, the link between Annexin A1 and FPR is not as clear as for FPRL1, 
as no direct binding affinity has been shown between the FPR and full length 
Annexin A1. I have discussed in the Introduction section that peptide Ac2-26 
binds to and activates - to a different extent - all three members of the FPR 
family FPR, FPRL1 and FPRL2 (Rescher, Danielczyk et al. 2002; Ernst, Lange 
et al. 2004; Karlsson, Fu et al. 2005), A note of caution, here, is due though: 
these analyses have always been conducted with transfected cell line, hence 
with artificial levels of expression of these GCPRs.   
 
The binding of the FPR to this and other Annexin A1 N-terminal derived 
peptides, suggests that glucocorticoid treatment might lead to the production of 
these peptides, perhaps downstream the over-production of Annexin A1. The 
release of these peptides, possibly at the site of inflammation, could in turn lead 
to deactivation of both PMNs and monocytes through a process involving 
CD62L shedding, as shown by Hayhoe and colleagues (2006). Altogether, this 
could be a second mechanism up-regulated by acute glucocorticoid treatment, 
which is responsible for the mediation of their anti-inflammatory properties 
through the Annexin A1 pathway. 
  
The observed modulation of the Annexin A1 pathway is seen to coincide with a 
reduction in CD62L expression on both the PMN and monocyte cell surfaces, 
thus suggesting that this circuit might be responsible for the ‘de-priming’ of 
these cells during this treatment regime. In fact, it has long been established that 
Annexin A1 is endowed with anti-inflammatory properties leading to reduction 
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in the extent of PMN recruitment in a number of in vitro and in vivo (Errasfa, 
Rothhut et al. 1985; Cirino, Peers et al. 1989; Lim, Solito et al. 1998; D'Amico, 
Di Filippo et al. 2000; Gavins, Dalli et al. 2007) models. This process might 
occur, at least in part, through CD62L shedding; for instance, co-incubation of 
the monocytic cell line U-937 with either dexamethasone or hr-Annexin A1 in 
vitro leads to CD62L shedding (de Coupade, Solito et al. 2003). Furthermore, 
immuno-precipitation and binding assays supported the suggestion that this 
effect could be mediated by an interaction between externalized Annexin A1 
and CD62L. Such interaction involved the N-terminal domain of Annexin A1 
and was calcium-dependent (de Coupade, Solito et al. 2003). Thus, I wish to 
propose that the observed reduction in CD62L expression might be a 
consequence of a reduction in the activation profile of the cell following 
treatment with the glucocorticoid 
 
The second leukocyte adhesion molecule I monitored in this study was CD11b, 
a heterodimeric integrin composed of integrin alpha M (ITGAM) subunits.  It 
has been shown to form a heterodimer with CD18 and is found on both 
granulocytes and monocytes, but not lymphocytes. This molecule has been 
shown to be involved primarily with the leukocyte firm adhesion process, 
involved in sustaining the adhesion initiated by the interaction of CD11a/CD18 
with ICAM-1 on the endothelium (Hentzen, Neelamegham et al. 2000). 
Experiments conducted in CD11b deficient mice further confirmed this role, as 
displayed by a significantly impaired neutrophil adhesion to fibrinogen coated-
plastic discs implanted into the mouse peritoneal cavity when compared with 
wild type mice.  Furthermore, CD11b deficient neutrophils display defective 
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degranulation and complement-mediated phagocytosis, thus suggesting that 
CD11b/CD18 mediated stabilization of adhesive bonds is due, at least in part, to 
its involvement in the process of neutrophil activation (Lu, Smith et al. 1997).  
 
The results obtained for the CD11b staining also suggest that there is a decrease 
in the activation profile of both PMNs and monocytes at day 1 post treatment, 
further suggesting that the Annexin A1 pathway, and in particular the Annexin 
A1 itself, could be mediating these effects. This observation is corroborated by 
a number of in vivo studies where CD11b protein, but not mRNA, levels were 
down-regulated in eosinophils post-glucocorticoid treatment (Lim, Flower et al. 
2000), an effect that was, at least in part, mediated by Annexin A1 (Das, Lim et 
al. 1997). 
 
Interestingly, the CD11b levels return back to basal levels at Day 7 remaining 
stable until the end of the study, suggesting that white blood cells return to their 
basal status. However, these observations are not conclusive since it is not 
merely the presence of the integrin that is important but, as I said above, the 
degree of activation of this protein. This is a point, which will need to be 
considered when designing future studies in order to determine if there is in fact 
a reduction in the active conformation of the CD11b antigen upon 
glucocorticoid treatment.  
 
A further added value for this translational study was to monitor the levels of 
expression of these proteins on synovial cells and compare them to those seen in 
the blood pool to determine how the Annexin A1 system is modulated in this 
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condition, upon extravasation of these cells into the synovium. Comparison of 
the blood vs. synovial cell populations highlighted that both synovial PMN and 
PBMC, population had reduced CD62L and CD11b cell membrane levels, 
possibly suggesting a less activated profile than those found in the blood 
compartment.  
 
A reduction in CD62L expression also goes hand in hand with the changes of 
this protein described in the PMN extravasation process (Finn, Strobel et al. 
1994; Liu, Kishimoto et al. 1998). Cellular activation along with the 
transmigration process could also be responsible for the elevated Annexin A1 
expression on the cell membranes of these cells, since it has been demonstrated 
in a number of studies that PMN activation and adhesion leads to the 
translocation of gelatinase granules containing Annexin A1, causing the 
increased localization of the protein in the membrane compartment. Moreover, 
studies in a mouse peritonitis model showed up-regulation of Annexin A1 gene 
promoter activity (measured with a LacZ gene reporter assay) in PMN 
extravasated into the mesenteric tissue as early as 4h post zymosan injection, 
with protein levels increasing soon after and being still elevated at the 24h time-
point (Damazo, Yona et al. 2006).  
 
This result suggests that following the initial up-regulation elicited by the 
extravasation process through granule mobilization, de novo synthesis is 
possibly elicited either by an autocrine/paractine effect or through priming by 
the pro-inflammatory environment found in the synovium. Furthermore I could 
also measure elevated FPR and FPRL1 levels in the synovial monocyte 
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subgroup, as compared to matched blood cells, an observation that could be 
explained again by cellular activation resulting from the transmigration process.  
I would repeat, though, that I am aware the CD11b levels measured here do not 
reflect the activated status of the cell since only the total antigen population was 
analysed, as opposed to the levels of active CD11b proportion. Thus, overall 
this analysis in RA patients subjected to glucocorticoid treatment suggests a 
strong modulation of elements of the Annexin A1 pathway upon cellular 
transmigration into the synovium; I believe this is the first study in man to 
report so. 
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4.2. The biological functions of Annexin A1 in PMN derived 
microparticles 
 
4.2.1. The anti-inflammatory action of Annexin A1 in PMN-derived 
microparticles  
Microparticles, which were first described by Wolf in 1967, are membrane-
derived vesicles produced by a number of cells as a result of activation or 
apoptosis. Originally described as platelet dust, they have been shown to 
possess pro-thrombotic properties. Since their discovery they have been 
implicated in a number of processes, including cardiovascular function and 
inflammation. However, to date very few microparticle components have been 
shown to be directly responsible for these effects, amongst these we find 
receptors such CCR5 and CXCL7. These receptors have been reported to be 
responsible for the increase in susceptibility of cells to infection by some strains 
of the HIV virus (Mack, Kleinschmidt et al. 2000).  
 
Interestingly, microparticles have also been attributed a role in the 
reduction/prevention of inflammation; specifically, PMN-derived microparticles 
were shown to exert an inhibitory effect on human monocyte derived 
macrophages, leading to the downregulation of TNF-α and IL8 production when 
these cells were incubated with these microvesicles and LPS (Gasser and 
Schifferli 2004). This interesting knowledge prompted the following question: 
can Annexin A1, a homeostatic pro-resolving protein that is abundantly 
expressed in PMNs, be mediating this inhibitory effect of microparticles?  
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As a result of the investigations I conducted it can be concluded that Annexin 
A1 is at least in part responsible for the anti-inflammatory role attributed to 
PMN-derived microparticles.  
 
As previously highlighted, the mechanism leading to the incorporation of the 
Annexin A1 protein is governed by the adhesion of the PMNs to the endothelial 
cells, a process that leads to the translocation of the Annexin A1 protein from 
inside the cytoplasm to the plasma membrane (Perretti, Croxtall et al. 1996).  
However, even though a number of studies have tried to address the mechanism 
by which Annexin A1 is translocated to the cell membrane, no data is available 
as to the process by which this protein is exported outside the cell and recovered 
from supernatants. Thus, my study started by addressing the question whether 
PMN-derived microparticles contained Annexin A1 and if so, whether this 
protein could be responsible for the time dependent dampening effect on PMN 
recruitment to an activated endothelial monolayer in vitro and, ideally, to the 
site of inflammation in vivo.  
 
The results I produced provide us with a potential mechanism by which these 
microstructures, released into the circulation and rich in Annexin A1, could lead 
to their accumulation and subsequent inactivation of other PMNs, as observed 
by the reduction in cell recruitment to the activated HUVEC monolayer in vitro. 
This will in turn lead to the inhibition of cell recruitment to the site of 
inflammation as observed in vivo upon administration of Annexin A1+ve PMN 
microparticles, where there was a significant reduction in the number of cells 
that extravasated to the mouse air-pouch. This effect was primarily Annexin A1 
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dependent since microparticles produced from Annexin A1 -/- neutrophils failed 
to inhibit PMN recruitment into the mouse airpouch.  
 
It is also possible that Annexin A1+ve PMN-derived microparticles might alter 
the phenotype of endothelial cells, a model perhaps more likely to occur in vivo, 
where longer time-points were applied (4 h) compared to the short time of the 
flow chamber assay (10 min). Importantly, microparticle components derived 
from activated/apoptotic human cells have been shown to alter EC phenotype. 
In a recent study, Agouni and colleagues (2007) demonstrated that 
micropartcles containing sonic hedgehog (a morphogen involved in 
embryogenesis but also shown modulate angiogenesis under ischaemic 
conditions) could modulate ECs phenotype. These microparticles were 
produced from activated/apoptotic T lymphocyte and once incubated with ECs 
augmented expression and phosphorylation of enzymes related to the NO 
pathway resulting in increased release of NO from these cells. Furthermore the 
administration of these microparticles in vivo reverted endothelial dysfunction 
following ischeamia reperfusion injury by modulating the release of NO 
(Agouni, Mostefai et al. 2007). 
 
The hypothesis I put forward above, that microparticles might affect PMN 
responsiveness of recipient PMN, is indirectly supported by studies conducted 
in patients suffering from septic shock (Fujimi, Ogura et al. 2003): PMNs 
derived from these patients are unresponsive to further stimulation. Although 
these studies did not investigate the presence of Annexin A1+ve microparticles 
in these patients, from the data generated in my study I can speculated that these 
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PMN microparticles could contain Annexin A1; in turn, this protein will interact 
with its receptor leading to desensitization of other GPCR, and the overall 
outcome would be desensitization of the target cells. In any case, I am aware 
this model can only explain part of the effects of PMN-derived microparticles, 
so it may be only a transient effect; in fact when PMNs were obtained from the 
same patients after several days of the initial insult it was observed that the cells 
were then hyper-reactive (Fujimi, Ogura et al. 2003).  
 
4.2.2. Reactive oxygen species production by PMN-derived microparticles 
Infection by bacteria and other foreign organisms leads to the build up of an 
inflammatory response. One of the response mechanisms of PMNs and other 
inflammatory cells to infection is the production of reactive oxygen species. 
This response plays a very important role within the innate immune system 
since it is crucial for the destruction of inflammatory agents. Therefore, the 
further understanding of this type of response is of fundamental importance, 
especially in addressing problems related to septic shock. Thus, initially I set 
out to determine whether PMN-derived microparticles were able to generate 
ROS. Upon stimulation with phorbol 12-myristate 13-acetate (PMA) it was 
observed that microparticles are in fact able to produce ROS, a process, which is 
normally related to the onset of inflammation. At this point the question of how 
can the same PMN-derived microparticles fulfill both a pro- and anti-
inflammatory role came naturally. The answer to this, I believe and propose, lies 
in their mode of production, where in fact ROS producing microparticles were 
obtained though direct stimulation of the PMNs with a high concentration of 
fMLP, mimicking perhaps the close encounter of the PMN with the infective 
agent, whilst microparticles observed to convey the anti-inflammatory effect 
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reported above (produced by co-incubation of the PMNs with a HUVEC 
monolayer) were unable to produce ROS even upon subsequent stimulation 
with PMA. This observation further supports the knowledge that microparticles 
are not produced through passive processes but are stimulus dependent hence 
heterogeneous in their content and possibly function(s). Stressing this point 
further is the fact that the microparticles shown to be responsible for the 
production of ROS are larger than those observed to contain Annexin A1, 
possibly as a result of the incorporation of the ROS producing machinery, which 
is know to be formed by relatively large proteins. Amongst these proteins we 
find NADPH oxidases, originally thought to be a single enzyme but now know 
to be a large family of enzymes dedicated to the production of ROS play a 
major role in their production, although other complexes such as xanthine 
oxidase, glucose oxidase and enzymes involved in arachidonic acid metabolism 
probably also contribute here (Morgan, Kim et al. 2008; Dowling and Simmons 
2009). Moreover flow cytometric analysis of ROS generating microvesicles 
show that they are devoid of Annexin A1, further outlining their pro-
inflammatory role.  
 
Collectively, these observations support the hypothesis that protein 
incorporation into microparticles is a tightly regulated process resulting from a 
complex sequence of events and stimuli. Thus, in the context of pathological 
conditions like sepsis where ROS production is thought to play a central role in 
the aetiology of cell dysfunction and tissue damage (Everton Andrades, Ritter et 
al. 2009), understanding the mechanisms leading to the production of these 
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microstructures in the vasculature could provide an insight into this very 
complex, and still elusive, pathological condition. 
 
Interestingly, ROS-producing microparticles were observed to contain the 
Annexin A1 receptor FPRL1. This result suggests that the modulatory role of 
these microstructures in vivo could be two fold.  Firstly as pro-inflammatory 
agents through the production of ROS, aiding in the destruction of the infectious 
agent. Secondly, they could play a delayed anti-inflammatory role through the 
incorporation of the FPRL1 receptor onto ‘naive’ cells, that is to say cells that 
do not normally express the receptor at a given time point, thus rendering these 
cells responsive to the anti-inflammatory actions of Annexin A1 (or other 
ligands, e.g. Lipoxin A4), leading to the proposed time dampening effect 
referred to above. Clearly future studies can address this specific point 
determining, for instance, the components of ROS-producing microparticles, the 
ability to transfer elements of the Annexin A1 pathway in recipient cells, and so 
forth; in any case, I think that my initial data have just opened the lid onto a 
completely new area of biology, the cell-to-cell cross talk in inflammation. 
 
4.2.3. The potential for use of of Annexin A1 positive PMN-derived 
microparticles as biomarkers of treatment and disease 
Another important aspect that my research has indicated is whether Annexin 
A1+ve PMN derived microparticles could be used as biomarkers of disease. The 
use (and need) of disease biomarkers is growing, with a steady stream of 
products and assays being brought out by the pharmaceutical industry. Some of 
these assist in diagnosis, others provide a means of monitoring the state of 
disease progression and the effectiveness of therapeutic options. Identification 
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of robust disease biomarkers to provide unequivocal disease diagnosis, ideally 
also easy to quantify, is becoming the prime focus of a large body of research.  
 
Having established that Annexin A1 positive microparticles play an important 
role in the regulation of cell recruitment both in vitro and in vivo in a preclinical 
model of cell recruitment, it was deemed important to determine if these 
microparticles were also detectable in the plasma of healthy volunteers and then 
in patients suffering from a number of diseases where PMN-derived 
microparticle populations have been shown to be significantly elevated. For this 
purpose, I measured levels of Annexin A1 and FPRL1+ve microparticles in the 
plasma of patients suffering from rheumatoid arthritis and vasculitis, 
specifically GCA and Wegener granulomatosis. Captivatingly, observations 
made from these analyses showed a reduction in the number of Annexin A1+ve 
microparticles and an increase in the FPRL1+ve microparticles in these disease 
conditions. This observation further confirms the hypothesis of a deregulation in 
the Annexin A1 pathway in pathology, coupling alterations at the cellular level 
with ‘defects’ in specific microparticle levels. 
 
The biological significance of the observed deregulation in the Annexin A1 axis 
is not clear however one can speculate that the reduction in Annexin A1+ve 
microparticles could at least in part explain the hyper-reactive profile of PMNs 
and monocytes obtained from these patients. Furthermore the increase in the 
number of FPRL1+ve microparticles could either occur through chance 
incorporation, since it has been shown that this receptor is normally located in 
lipid rich regions of the cell membrane known as lipid rafts (Tuluc, Meshki et 
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al. 2003), the same regions which have been indicated to be the site of 
microparticle production (Horstman, Jy et al. 2004). Thus activation of the 
parent cell, with the subsequent increase in microparticle production, could lead 
to an increased presence of the receptor in the plasma of these patients. 
However this hypothesis is in sharp contrast to the mounting body of evidence 
that protein incorporation into micropaticles is governed by a tightly regulated 
process (Horstman, Jy et al. 2004; Hugel, Martinez et al. 2005). An alternative 
hypothesis, more in line with the current literature, is that the observed increase 
FPRL1 levels are a compensatory mechanism to the reduction in Annexin 
A1+ve microparticles. An attempt by the cells to re-establish homeostasis in 
these disease conditions by elevating the levels of the receptor in the absence, or 
reduction, of the ligand, is an interesting hypothesis which obviously needs 
further robust testing, but which would be very exciting if confirmed since it 
would give a better insight into the processes responsible for the reestablishment 
of homeostasis. 
 
I wish to note that changes in microparticle levels, in a specific cell source 
manner, have been recently reported, adding inflammatory pathological 
conditions to the series of studies that have investigated, by and large, 
cardiovascular diseases (e.g. atherosclerosis). As an example, elevated levels of 
PMN and platelet-derived microparticles have been reported in the acute phase 
of vasculitis and dialysis-induced inflammation, where it was suggested that 
their elevated levels could be important in the modulation of the coagulation 
and inflammatory processes (Daniel, Fakhouri et al. 2006). 
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Can Annexin A1+ve PMN derived microparticles be used as biomarkers of 
treatment effectiveness?  After establishing the presence of Annexin A1+ve 
microparticles in these inflammatory disease states, and the fact that there is a 
sensible alteration in Annexin A1 content in microparticles obtained from 
patients suffering from a number of chronic inflammatory conditions, the next 
question that came to mind was if microparticle populations are modulated 
during treatment, and whether they could be used as a measure of treatment 
efficacy. For this purpose I took advantage on a clinical trial conducted by our 
Musculo-skeletal Clinical Academic Unit (led by Professor Pitzalis) measuring 
microparticle levels in the plasma of patients suffering from RA, both pre- and 
post-steroid treatment. The results showed a striking modulation in 
microparticle populations with a general decrease in the number of 
microparticles found in the plasma of these patients, where a reduction in 
CD62L, CD62P and CD14+ve microparticles was measured. Interestingly, the 
incremented plasma levels of these microparticles was similar to that observed 
in a number of systemic pathologies including arthrosclerosis (Leroyer, Isobe et 
al. 2007) and sepsis (Mostefai, Meziani et al. 2008). Following the regimen of 
glucocorticoid treatment of the RA patients, cell-specific microparticle returned 
to levels similar to those observed in healthy volunteers (Mostefai, Meziani et 
al. 2008), as also highlighted in the results section above). My data indicates 
that this process might be concordant with the anti-inflammatory properties of 
glucocorticoids. However, more interestingly, administration of 15 mg 
prednisolone daily had an influence on both Annexin A1 and FPRL1+ve 
microparticles over the course of a 14-day treatment. I wish to note, though, that 
these changes were significant by day 14, so they may reflect not necessarily 
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modulation of white blood cell activation, but could also be reflective of 
changes within the peripheral blood leukocyte populations. 
 
Studies conducted by Dale and colleagues (1975) have shown that an oral dose 
of prednisolone (even as low 5mg) is able to elicit bone marrow PMN egress 
into the blood stream with a significant rise in the number of circulating cells as 
early as 2h post administration. A second study looking at the effect of 
glucocorticoid administration on lymphocyte recruitment showed that following 
a single intra-veneous hydrocortisone administration lymphocyte recruitment 
into the blood peaked 28h post administration, following which the lymphocyte 
levels returned to basal after 48h. There are no controlled studies, to my 
knowledge that have monitored peripheral blood cells upon glucocorticoid 
treatment for 1 or 2 weeks. 
 
Altogether, I favour the hypothesis that the changes provoked by glucocorticoid 
treatment administered to the RA patients derive from a ‘deactivating’ effect, 
rather than qualitative and/or quantitative changes in white blood cell types. 
Importantly, monitoring Annexin A1+ve (and FPRL1+ve) microparticles could 
be used as an indication of treatment efficiency. In support of this, although the 
treatment was observed to increase the number of circulating leukocytes, there 
wasn’t an increase in the number of CD62L positive and CD14 positive 
microparticles; so, cells present in the circulation following the initiation of 
glucocorticoid treatment have a more quiescent profile, and this is in line with 
the cell surface expression of CD11b and CD62L discussed above.  
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Altogether, I think that these observations are exciting and could provide a way 
of easily monitoring the effectiveness of glucocorticoid, and possibly other 
treatments, in this and other inflammatory disease conditions.  
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4.3. Developing and testing of Novel Ac2-26 peptides 
Members of the annexin family of proteins are characterized by a highly 
conserved core region, responsible for the annexins distinctive Ca2+ and 
phospholipid binding properties, and an N-terminal segment unique to each 
annexin, with this portion of the protein being responsible for the individual 
function of each member of the annexin family (Gerke and Moss 2002). For this 
reason a number of Annexin A1 N-terminally derived peptides have been 
developed over the years that were shown to mimic the anti-inflammatory 
actions of the full-length protein in several models of inflammation both in vitro 
and in vivo, albeit at higher molar concentrations than those employed for the 
parent protein (Relton, Strijbos et al. 1991; Lim, Solito et al. 1998; Perretti, 
Chiang et al. 2002; Hayhoe, Kamal et al. 2006).  
 
More recent studies conducted in our lab have identified a number of cleavage 
sites susceptible to protinease 3  (PR3) in the N-terminal portion of the Annexin 
A1 protein (Vong, D'Acquisto et al. 2007). Thus, following the rationale 
whereby cleavage of the N-terminal portion of the full-length protein by this 
serine proteinase would lead to the loss of its anti-inflammatory properties, it 
was hypothesized that the same enzyme could also cleave the N-terminally 
derived peptides rendering them inactive. Thus basing ourselves on one of the 
more extensively studied N-terminal derived peptide, the Ac-2-26, in 
collaboration with Unigene Corp. we substituted two cleavage sites, the alanine 
at position 11 and the valine at position 22 (Vong, D'Acquisto et al. 2007) with 
a number of amino acids. The amino acids employed in these substitutions were 
selected based on the impact that their inclusion would produce on the three 
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dimensional properties of the polypeptide. In this sense amino acid χ (Peptide 
59) and amino acid δ (Peptide 60) are charged amino acids thus their inclusion 
would most likely alter the three dimensional properties of the polypeptide 
especially at position 11 which might lead to the breakdown of the alpha-helix 
found in this portion of the protein. The inclusion of amino acid β (Peptide 83), 
which in contrast to the previous two amino acids is not charged is also likely to 
lead to the breakdown of the alpha helix due to the steric hindrance produced by 
the hydrocarbon side chain found on this amino acid. Finally two non-charged, 
non-bulky amino acids were also employed in the synthesis of the novel N-
terminally derived amino acids, these were amino acid α (Peptide 84) and amino 
acid ε (Peptide 57). In this case the substitution of the alanine and valine amino 
acids with either amino acid α or amino acid ε is not expected to cause any 
significant changes in the 3 dimensional properties of the peptide (Note: clearly, 
I cannot disclose the precise sequences of these novel Ac2-26 derivatives in 
view of our commitment with Unigene Corp (furthermore, I am in the dark 
here); however, the indications given above are sufficient to allow me elaborate 
on the changes acted upon the Ac2-26 sequence and trying to relate them to 
biological function). 
 
In the quest to determine the potency of the novel Ac2-26 derived peptides a 
number of properties were assessed in order to determine their potential as anti-
inflammatory drugs. Previous studies conducted in our group, and by others, 
have shown that peptide Ac2-26 binds to the two FPR receptors expressed by 
PMN, namely FPR and FPRL1 (Walther, Riehemann et al. 2000; Ernst, Lange 
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et al. 2004; Hayhoe, Kamal et al. 2006). The classical ligand of the FPR family 
of GPCRs is the pro-inflammatory chemoattractant fMLP.  
 
The binding of agonist to the FPR receptor leads to a conformational change 
allowing the interaction of the C-terminal portion of the receptor with the Gi 
protein family, a process shown to be pertussis toxin sensitive. This interaction 
leads to the exchange of guanosine diphosphate (GDP) with guanosine 
triphosphate (GTP) on the α-subunit and dissociation of the βγ−subunits from 
the G protein heterotrimer (Selvatici, Falzarano et al. 2006; Gripentrog and 
Miettinen 2008). This leads to the activation of several signalling pathways and, 
in human neutrophils, the Gi βγ−subunits leads to the activation of 
phospholipase Cβ (PLCβ) (Camps, Carozzi et al. 1992), resulting in the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtIns(4,5)P2), with the 
generation of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) as 
second messengers (Berridge 1993). DAG subsequently leads to the activation 
of various PI3K isoforms amongst which phosphoinositide 3-kinase (PI3K); the 
γ isoform of PI3K is also activated by Gi proteins (Stephens, Ellson et al. 2002) 
and causes actin polymerization and activation of integrins involved in 
neutrophil migration, although in this respect it is still not clear whether this 
FPRL1 signalling is positive or negative towards migration. IP3 mediates the 
rapid release of Ca2+ from intracellular stores, which precedes the longer lasting 
influx of extracellular Ca2+ (Berridge 1993; Davies-Cox, Laffafian et al. 2001). 
In addition other intracellular effectors including small GTP binding proteins of 
the Rho family, the mitogen activated protein kinase (MAPK) cascade, tyrosine 
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kinases and protein phosphatases can also be activated by ligand binding to FPR 
(Niggli 2003).  
 
The exact signalling pathway for the Ac2-26 peptide is not yet fully understood 
however a number of studies have shown that its binding to the FPR family of 
receptors leads to an increase in intracellular Ca2+ fluxes, as observed for fMLP 
(Ernst, Lange et al. 2004). Furthermore, the incubation of cells with the Ac2-26 
peptide was shown to down-regulate subsequent cellular responses to fMLP, 
including generation of respiratory burst by the desensitization of the receptor 
(Walther, Riehemann et al. 2000).  
 
To assess the activity of the novel peptides, I initially determined their ability to 
bind to and activate the FPR family of receptors, specifically FPR and FPRL1. 
For this purpose three transfected HEK cell lines were employed. These cell 
lines were transfected with either an empty vector and termed HEK-CMV, a 
vector over expressing FPR and thus termed HEK-FPR or a vector over 
expressing the FPRL1 gene and consequently termed HEK-FPRL1 (Hayhoe, 
Kamal et al. 2006). One drawback of using this cell line was that activation of 
the receptor lead to only a marginal phosphorylation of the extracellular signal-
regulated kinases (ERK) 1 and 2, which made it more difficult to determine the 
ability of the peptides to activate the receptor, however this problem was 
overcome by loading a high amount of protein (~120µg) onto the SDS gel, 
which made the detection of the phospho-ERK 1/2 possible by western blotting.  
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The results obtained from the initial screening using these cell-lines showed that 
peptides 57, 59 and 84 had the highest ability to activate ERK 1/2 through the 
FPRL1 receptor to levels similar to those observed for the parent Ac2-26 
peptide. Furthermore the assessment of the novel N-terminal derived peptides 
showed that peptide 57 and 84 were also able to inhibit PMN interaction with an 
activated endothelium, similar to that observed for Ac2-26 (Hayhoe, Kamal et 
al. 2006). Interestingly peptide 59, which has the ability to activate ERK 1/2 to a 
similar level as the other three peptides, did not display any anti-adhesive 
property in the flow chamber assay! Therefore, either ERK phosphorylation is 
only one of the possible downstream signalling events evoked by FPRL1 
activation, or this outcome is dissociated from the effects monitored with the 
flow chamber assay (I discuss this point further below). 
 
Furthermore peptide 60, which did not show any activity in the p-ERK assay 
when using FPRL1-HEK cells, also displayed anti-inflammatory properties. 
This result could be due to the observed inhibitory effects transduced by 
receptor/s other then the FPRL1, possibly the FPR, however this hypothesis 
merits further investigation since I did not explore the ability of this peptide to 
interact and activate the FPR receptor due to time constraints.  Alternatively, 
peptide 60 might incite distinct intracellular signaling, in any case, this 
observation is interesting in itself since it suggests that the amino acid 
substitutions conducted in the synthesis of this peptide could have created an 
FPR specific agonist. 
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Studies conducted in our lab have shown that the Ac2-26 can bind to both the 
FPR and FPRL1 receptors with a similar affinity and that its inhibitory effects 
are mediated through both receptors (Hayhoe, Kamal et al. 2006). Thus in line 
with the aim to determine which from the newly synthesized peptides displayed 
anti-inflammatory properties similar to those reported for the parent Ac2-26 
peptide, I decided to proceed with my analyses focusing on peptides 57 and 84, 
since these two peptides best mimicked the properties of the parent peptide.  
 
Subsequent analysis of the binding affinities for these two peptides showed that 
they have similar binding affinities to the FPRL1 receptor (3.34µM and 3.37µM 
for peptides 84 and 57 respectively), which is also similar to that reported for 
Ac2-26 (1.8µM) (Hayhoe, Kamal et al. 2006). On the other hand the binding 
affinity to the FPR receptor for peptide 84 (6µM) was two orders of magnitude 
lower than that observed for the FPRL1 receptor and 6 orders less then that 
reported for the parent peptide (1.4µM) (Hayhoe, Kamal et al. 2006). 
Furthermore, peptide 57 did not seem to bind in a classical manner to the FPR 
receptor since no classical dose response was observed however the peptide was 
still able to activate ERK.  
 
These results highlight that peptide 84 is in fact the one that shares the highest 
degree of similarity, at least in the experimental assays I conducted, with the 
native peptide Ac2-26. However, this data is in contrast to the p-ERK data 
which shows that peptide 57 is able to bind and activate the receptor to a similar 
extent as peptide 84, suggesting that although not showing a classical binding 
pattern to the FPR, it is still biologically active through this receptor. It is 
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plausible that other downstream signaling events are important, and activated, 
by Ac2-26 and its novel derivatives; moreover, different degree of activity can 
be present with respect to these ‘un-identified’ signaling responses.  I wish to 
note that LXA4, another agonist at FPRL1, activates and recruits SHP-2 (SH2 
domain-containing tyrosine phosphatase-2) within a lipid raft microdomain, 
which in turn leads to the dephosphorylation of PDGFRβ diminishing its 
mitogenic activities (Mitchell, O'Meara et al. 2007). Furthermore, LXA4 has 
also been reported to lead to the dephosphorylation of MYH9, a nonmuscle 
myosin H chain (NMMHC) class IIA protein, which is involved in cytoskeleton 
rearrangement, a process that was observed to lead to an increase in 
phagocyotsis of apoptotic leukocytes, an observation also reported for the Ac2-
26 peptide (Maderna, Yona et al. 2005; Reville, Crean et al. 2006). A Real-time 
PCR analysis conducted on samples obtained from a animal model of anti–
glomerular basement membrane (GBM) glomerulonephritis, where the animals 
were treated with (15-epi-16-(FPhO)-LXA-Me) or vehicle alone showed that 
treatment with the stable lipoxin analogue lead to the down regulation of a 
number of genes amongst which: Interferon regulatory factor 1 (IRF1), 
proteosome subunit, beta type 9 (PSMβ9), T cell–specific GTPase (TGTP), and 
IFN-γ–induced GTPase (IGTP) (Ohse, Ota et al. 2004). In light of the diverse 
effects that can be elicited through the FPRL1 receptor by LXA4 I can now see 
how my analyses have been quite basic, aiming at establishing, predominantly, 
whether these new peptides were endowed with agonistic activity at FPRL1 
(and by comparison, FPR). More importantly, my focus was by and large on the 
biological properties of these peptides. 
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The inhibitory potential was also assessed for both peptides by conducting a full 
concentration response analysis in the flow chamber assay. This analysis 
demonstrated that both peptides showed inhibitory properties down to 0.01 nM, 
with peptide 84 displaying a classical dose dependent response, whilst peptide 
57 retained a similar level of activity down to the lowest concentration tested. 
An explanation for the observed difference in the ability of the two peptides to 
inhibit PMN recruitment could be possibly related to a different mode of 
activation of the FPR and FPRL1. In any case, it is clear that much more work 
is necessary for these issues to be unravelled to a degree of scientific 
satisfaction.  
 
Finally when the inhibitory properties of peptides 57 and 84 were assessed in 
vivo in a preclinical model of PMN recruitment, both inhibited PMN 
recruitment into the air-pouch inflamed with IL-1β. However, this observed 
reduction reached statistical significance only for peptide 84. Again, more 
experiments are required. An important observation I made, though, is that 
peptide 84 effect genuinely resulted from inhibition of cell recruitment into the 
air-pouch and was not secondary to a non-specific toxic effect exerted, for 
instance, on blood cell profiles. This apparent discrepancy between the results 
obtained from the in vitro assay and those obtained in vivo especially for peptide 
57, could be due to the a difference in the ability of this peptide to activate the 
murine FPR family of receptors, which have been reported to show a reduced 
affinity to classical ligands such as fMLP. Moreover, could be influenced by 
pharmacokinetics issues, which clearly are not explored at all at these early 
stages of development. 
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In conclusion, peptide 84 with the α substitution seems to maintain most of the 
anti-inflammatory properties of the parent Ac2-26. Further work will determine 
if this new peptide is resistant to cleavage thus resulting in a better 
pharmacodynamic profile. In any case, I am happy to have contributed to put in 
motion a ‘pharmaceutical project’ that could take advantage from over 20 years 
of research on Annexin A1 and PMN recruitment in inflammation, possibly 
exploiting this wealth of knowledge for novel therapeutic development. 
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5. Conclusion 
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Studies published following the successful cloning of lipocortin-1 and its 
subsequent renaming to Annexin A1 have provided us with convincing 
evidence that Annexin A1 is a homeostatic endogenous anti-inflammatory 
mediator of the innate immune system.  Although the link between the Annexin 
A1 pathway and inflammatory conditions is far from clear, the current study has 
for the first time provided evidence for a deregulation of this circuit in 
rheumatic conditions. In particular, I observed that there were elevated levels of 
cleaved Annexin A1 on the cell membranes of PMNs extracted from both 
Wegner granulomatisis and GCA patients. Furthermore both FPR and FPRL1 
levels were elevated on PMNs and monocytes extracted from these patients. 
Over and above, my data have provided evidence in support of monitoring 
specific elements of the Annexin A1 pathway as potential biomarker of disease 
as well as to determine the efficacy of drug treatment upon effective disease 
management.  
 
In line with this, the data obtained from flow chamber analysis on PMNs from 
vasculitis patients has evidenced that the addition of exogenous Annexin A1 
was able to reduce leukocyte-endothelial interactions bringing them back to 
similar levels as those observed with control PMNs. Furthermore evidence was 
also provided implying Annexin A1 as a mediator of the anti-inflammatory 
effects observed in RA patients upon acute glucocorticoid treatment.  
 
Furthermore this treatment was also observed to modulate the levels of Annexin 
A1 and FPRL1 positive microparticles in the plasma of these patients.  This was 
another captivating outcome of my studies, hence the correlation, for the first 
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time, of Annexin A1 in PMN derived microparticles with their anti-
inflammatory properties.   
 
These microstructures inhibited cellular recruitment to an activated endothelial 
monolayer in vitro and reduced the reduction of cell recruitment into the mouse 
airpouch in vivo. Annexin A1 lacks a signal peptide but nonetheless is 
abundantly released from activated PMN. Thus these novel data indicate that 
Annexin A1 can be released from activated PMN via the ‘microparticle 
pathway’, hence multiple ways of mobilizing the protein from this cell type 
might exist. Annexin A1 is not unique in employing this mechanism of release, 
in fact the FPRL1 was also observed to be contained in these microparticles. 
Collectively, these observations allow me to hyptohesise novel biological 
functions, so that the receptor contained in the microparticles might have a role 
in the time-dependent regulation of cell recruitment, though the exact dynamics 
governing these processes were not investigated during this study fueling scope 
for future studies.  
 
The current notion is that microparticles are not just a by-product of cellular 
activation, but distinct entities produced through a highly regulated process. An 
observation which was in part confirmed by data produced during this study 
whereby differential stimulation of PMNs in suspension produced 
microparticles which in contrast to those produced upon co-incubation over an 
endothelial monolayer were able to produce reactive oxygen species. This 
ability was subsequently attributed to a distinct subset of the microparticle 
population, moreover this subset of the microparticle population was also 
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observed to be Annexin A1 negative.  
 
A number of studies have highlighted altered microparticle populations in a 
number of systemic diseases, an observation that I corroborated here for patients 
suffering from Wegner granulomatosis, GCA and Rheumatoid arthritis. 
However, the published studies have monitored the degree of microparticles 
generated from the different cell sources (e.g. CD62L+ve or CD14+ve, for 
PMN and monocytes, respectively).  My analyses have evolved around the 
determination of the levels of Annexin A1 or its receptor on these 
microstructures, identifying a deregulation in the number of Annexin A1 and 
FPRL1 positive microparticles in these inflammatory diseases, suggesting a 
further “mode of alteration” of the Annexin A1 pathway. Interestingly an acute 
glucocorticoid treatment had profound effects on this subset of microparticles, 
further corroborating the observation that these microstructures may not be just 
mere by-products of activation. The observed modulation of microparticle 
populations in disease, and upon therapeutic management, might suggest that 
different microparticle subsets could be useful indicators or biomarkers. 
 
The development of safe and effective drugs is the ultimate quest of current 
major drug discovery programs. Peptides derived from the N-terminal portion of 
the Annexin A1 have been show to retain the anti-inflammatory properties of 
the parent protein in several in vivo models. The in vitro and in vivo analysis 
conducted on the 5 new Annexin A1 N-terminal derived peptides pointed to 
peptides 57 and 84 as two potential candidates for use as anti-inflammatory 
drugs.  
 281 
 
Interestingly in both these peptides the amino acid groups used to modify the 
parent Ac2-26 peptide were neither charged nor bulky suggesting that the three 
dimensional properties of these peptides, especially the alanine located in the 
initial alpha helical portion of the peptide, determine the level and extent of 
binding to the FPR family of receptors, in order to mediate their anti-
inflammatory effects. Another interesting observation was that whilst peptide 59 
was able to activate ERK to a similar extent to peptides 57 and 84, it did not 
display any anti-inflammatory properties as observed through both in vitro and 
in vitro analyses. On the other hand peptide 60 did not activate ERK through the 
FPRL1 receptor however it still displayed very strong inhibitory properties as 
determined by the flow chamber assay. It seems to me I can suggest that that 
ERK phosphorylation through FPRL1 is not discriminatory for mediating the 
anti-inflammatory effects of these peptides.  
 
To reiterate and conclude, my results further advanced our understanding of the 
role of the Annexin A1 and other elements of this circuit (FPRL-1) in disease, 
providing for the first time a strong indication for a link between Annexin A1 
and a number of rheumatic conditions. Furthermore, this study has also 
provided, for the first time, evidence suggesting that the anti-inflammatory 
actions of glucocorticoids in rheumatoid arthritis are associated with changes in 
the Annexin A1 pathway. Moreover this pathway is also important in mediating 
the anti-inflammatory properties of PMN derived microparticles and it is 
deregulated in the rheumatic conditions studied, a deregulation which seems to 
be reversed upon an acute glucocorticoid treatment. It is plausible that novel 
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Annexin A1 derived peptides could retain some of the anti-inflammatory 
actions of glucocorticoids and be developed as novel therapeutic tools, possibly 
effective in controlling the degree of leukocyte activation in the vasculature. 
Only the future will tell us if this possibility will become real! 
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